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Summary 
The human body contains hundreds of cell types, which are specialized to form various 
tissues and organs with a particular function. The communication between these cells is a key 
aspect of any multi-cellular biological system and is mediated by specialized signal transduction 
cascades. Such cascades generally begin by binding of extracellular ligands such as 
neurotransmitters, growth factors or cytokines to a specific cell surface receptor, or by the 
activation of an intracellular sensor. Its signal is propagated, regulated, and amplified by other 
proteins, often via protein phosphorylation. Ultimately, a final effector molecule -- itself 
regulated by phosphorylation -- binds to conserved elements in many promoters to control a 
variety of processes. Although the cell responds to a plethora of signals and environmental 
conditions in many different ways, there is only a small set of signal transduction cascades, each 
conserved among many different cell types.  
These highly conserved signaling pathways open the possibility to study human inter-
individual differences in neurologically and physiologically relevant processes using accessible 
primary tissues, i.e. skin fibroblasts. The idea of using skin as a proxy for what happens in the 
brain is not as farfetched as it seems. For example, many studies showed that not only the 
neurons of the central clock in the brain but also many peripheral tissues possess circadian 
clocks. The circadian signaling pathway is one crucial transduction pathway, which is 
responsible for the production and maintenance of daily rhythms in physiology, mood and 
cognition. Therefore, this high level of homology in signal transduction pathways provides a 
possibility to study human differences at a cellular level in peripheral tissues.  
The circadian properties (e.g. Circadian period, phase or amplitude) of human beings differ 
widely in the population and several studies showed that the daily behavior has a significant 
genetic component. On the top of this, recent investigations showed that the in vitro circadian 
period length of human skin fibroblasts measured through a lentiviral reporter system correlates 
with the human physiological period length and is in turn directly predictive of human diurnal 
behavior. All these findings suggested that signaling outputs obtained from the human primary 
fibroblasts could in the future serve as an excellent system to determine the genetic basis of 
human inter-individual differences, and formed the basis of my PhD project.  
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The first part of this thesis focuses on the study of inter-individual differences of human 
circadian properties. The primary aim of this study was to establish a technology which would 
facilitate the expression quantitative trait mapping of genetic loci that influence circadian 
behavior within the human population. Our laboratory uses a lentivirus cell-based reporter 
construct containing mouse Bmal1 promoter, the firefly luciferase coding region and the Bmal1 
3’UTR, flanked by the long terminal repeats. Immortalized lymphoblastoid cell lines as well as 
human umbilical cord fibroblasts derived from the healthy individuals, represent sufficient cell 
libraries required for the linkage and/or association mapping of a causative genetic modifier. To 
our big disappointment, lymphoblastoid cells revealed almost no circadian oscillations and 
although umbilical cord fibroblasts seem to have a modest circadian rhythmicity, the amplitude 
of these rhythms was extremely low and quickly damping.  
Besides the circadian signaling pathway, other non-circadian transduction cascades are key 
regulators of the multilevel cellular communication responsible for many essential biological 
processes. Technologies similar to those developed to study the human circadian rhythms 
variation could be equally applied to these non-circadian signaling cascades. Therefore, the 
second part of the thesis deals with a development of lentivirus – based technologies that allow 
determination of human inter-individual variation in gene expression of major signal 
transduction pathways. By using this system, surprisingly large inter-individual differences in the 
expression pattern of CREB, Elk1 and CHOP signaling pathways have been discovered. The 
existence of these variations was confirmed by genome-wide gene expression analysis, 
uncovering differences in transcription from genes known to be activated by these pathways. 
Moreover, at least on the cellular level these differences have functional relevance because they 
also translate into differences in cellular toxicity and efficacy of pathway-specific drugs.  To 
demonstrate the broader physiological relevance of these findings, I was able to correlate 
reporter-detected inter-individual differences in human fibroblast CREB signaling with actual 
suppression of the hormone melatonin by light in the same human subjects, a process known to 
be CREB-dependent from rodent studies. 
The third and last part of the thesis describes the broader impact of the developed 
technologies. Independent proliferation, avoidance of apoptosis and unlimited replicative 
potential -- the hallmarks of tumorigenesis -- are signatures for altered functions of signal 
transduction cascades. Many studies have already shown that balance and integration among 
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these signals varies among different tumors. Knowledge about their signaling cascade function 
could serve as an important marker for successful medication. Therefore, I applied our novel 
lentiviral reporter system to trace the behavior of signaling pathways within growing tumors in 
living mice. An interesting kinetic pattern, with possible in vivo activation of some signaling 
pathways during tumor progression was obtained. As cancer development is an extremely 
complex process involving multilevel communication between many cells, understanding the 
basis of altered signal transduction might help to improve existing drug treatment strategies and 
bring more insights into the variability of cancer pathogenesis among human populations.  
 
At a cellular level, nearly all drugs act upon regulatory proteins of signaling cascades that 
transmit information from the cell surface in order to elicit cytoplasmic or nuclear changes.  
Therefore, the widespread problem of inter-individual variations in responses to many classes of 
drugs actually begins here: due to genetic variation, the expression or structure of signaling 
cascade proteins can differ from one person to another.  Understanding the cellular determinants 
of these differences is a fundamental question for pharmacology, and is the basis of 
“personalized medicine.” In the course of my thesis work, I have developed a novel high-
throughput technology that is capable of measuring differences in the output of several signaling 
cascades between human subjects. This system could now be applied in the testing of many 
pharmaceutical compounds directly in human primary fibroblasts derived from multiple 
individuals. Understanding patterns of gene expression variation among human individuals will 
provide powerful insights into the molecular basis of phenotypic variation and interpretation of 
differences in the expression patterns in disease. 
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Zusammenfassung 
Der menschliche Körper besteht aus hunderten verschiedener Zelltypen, die Gewebe und 
Organe mit spezifischen Funktionen bilden. In einem solchen multizellulären System ist die 
Verständigung zwischen den Zellen von zentraler Bedeutung und erfolgt mittels spezialisierter 
Signaltransduktionskaskaden. Im allgemeinen beginnen diese Sinalwege wenn Neurotransmitter, 
Wachstumsfaktoren oder Zytokine an spezifische Rezeptoren auf der Zelloberfläche binden oder 
intrazelluläre Sensoren aktiviert werden. Dieses Signal wird dann von anderen Proteinen – oft 
durch Phosphorylierung derselben – weitergeleitet, reguliert und verstärkt. Schliesslich bindet 
am anderen Ende der Kaskade ein Effektormolekül, selbst durch Phosphorylierungsänderungen 
reguliert, an konservierte Motive im Promotorbereich zahlreicher Gene und kontrolliert so 
diverse Prozesse. Im Vergleich zu der grossen Anzahl verschiedener Signale und Umweltreize 
auf die die Zelle in jeweils spezifischer Weise reagieren muss, gibt es nur wenige 
Signaltransduktionskaskaden, die dazu benötigt werden. Hinzu kommt, dass diese Kaskaden 
auch zwischen verschiedenen Zelltypen keine wesentliche Unterschiede aufzeigen  
Hier bietet sich die Chance diese prinzipielle Ähnlichkeit zwischen verschiedenen Zelltypen 
auszunutzen, um interindividuelle Unterschiede neurologisch und physiologisch relevanter 
Prozesse beim Menschen in leicht zugänglichen Hautzellen beziehungsweise Fibroblasten zu 
untersuchen. Die Strategie, die Haut als Model für Vorgänge im Gehirn zu benutzen, hat sich 
schon in anderem Kontext als erfolgreich erwiesen. Beispielsweise haben schon viele Studien 
gezeigt, dass nicht nur die Neuronen der zentralen zirkadianen Uhr im Gehirn die Zeit messen 
können, sondern auch viele periphere Gewebe die gleiche Eigenschaft haben. Dieser zirkadiane 
Signalweg generiert die 24-Stunden Rhythmen der menschlichen Physiologie und Psychologie. 
Das hohe Mass an Übereinstimmung der zellulären Signaltransduktionswegen ermöglicht es, 
inter-individuelle Unterschiede zwischen Menschen auf zellulärer Ebene in peripheren Geweben 
zu untersuchen. 
Die Eigenschaften der zirkadianen Uhr des Menschen (beispielsweise Periodenlänge, 
Phasenlage oder Amplitude) unterscheiden sich stark zwischen Individuen. Mehrere Studien 
geben Grund zur Annahmen, dass diese Unterschiede zu einem wesentlichen Anteil genetisch 
bedingt sind. Neueste Resultate, die mit Hilfe eines lentiviralen Reporter-Systems gewonnen 
wurden, zeigen sogar, dass die Periodenlänge der zirkadianen Uhr in Fibroblastenkulturen in 
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vitro mit der in vivo gemessenen Periodenlänge übereinstimmt und somit das diurnale Verhalten 
beim Menschen spiegeln kann. Die genannten Ergebnisse deuten darauf hin, dass die Endpunkte 
der Signalwege in humanen Fibroblastenkulturen zukünftig ein exzellentes System zur 
Erforschung inter-individueller Unterschiede beim Menschen darstellen könnten. Dies ist die 
Eingangshypothese meines Promotionsprojektes.  
Der erste Teil dieser Arbeit widmet sich der Erforschung inter-individueller Unterschiede der 
zirkadianen Uhr des Menschen. Das vorrangige Ziel dieser Studie war die Etablierung einer 
Technologie zur Erfassung von expression quantitative trait mapping genomischer Loci (eQTL), 
die die Eigenschaften der Inneren Uhr des Menschen beeinflussen. Immortalisierte 
lymphoblastoide Zelllinien und Nabelschnurfibroblasten von gesunden Freiwilligen sind in 
genügend grosser Zahl vorhanden, um linkage oder association mapping kausativer genetischer 
Modifikatoren durchzuführen. Allerdings hat sich zu unserer grossen Enttäuschung 
herausgestellt, dass lymphoblastoide Zellen praktisch keinen messbaren zirkadianen Rhythmus 
haben und obwohl Nabelschnurfibroblasten zumindest messbar rhythmisch sind, auch hier die 
Amplitude dieser Oszillationen extrem niedrig war und zudem schnell gedämpft wurde. 
Neben dem zirkadianen Signaltransduktionsweg gibt es andere, nicht-zirkadiane 
Signaltransduktionskaskaden, die Schlüsselpositionen in der Regulation der vielschichtiger 
zellulären Kommunikation innehaben. Sie sind für viele essentielle biologische Prozesse 
verantwortlich. Ähnliche, wie die für die Erforschung der Variabilität der Inneren Uhr des 
Menschen entwickelte Technologien können auch auf die nicht-zirkadianen 
Signaltransduktionskaskaden angewendet werden. Im zweiten Teil der vorliegenden Arbeit 
wurde daher eine auf Lentiviren basierende Technologie entwickelt, die es erlaubt, die inter-
individuellen Unterschiede auf Ebene der Genexpression der wesentlichen 
Signaltransduktionskaskaden beim Menschen zu erfassen. In der Tat konnten mit Hilfe dieses 
Systems überraschend grosse inter-individuelle Unterschiede in den CREB, Elk1, und CHOP 
Signalwegen gefunden werden. Dieselben Unterschiede waren auch in der Expression von 
Zielgenen der jeweiligen Signalwege wieder zu finden. Zumindest in Zellen sind diese inter-
individuellen Variationen auch funktional relevant, denn Signalweg spezifische Medikamente 
haben differentielle Effekte und zeigen auch eine unterschiedliche Zelltoxizität. Um dies in einen 
weiteren, physiologisch bedeutungsvollen Zusammenhang zu stellen, habe ich die inter-
individuellen Unterschiede in menschlichen Fibroblastenkulturen im CREB Signalweg mit der 
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lichtinduzierten Melatoninsuppression, ein CREB-abhängiger Prozess, in denselben Menschen 
korreliert.  
Im dritten und letzten Teil dieser Arbeit gehe ich auf das immense Potenzial der von mir 
entwickelten Technologien ein. Ungesteuerte Vermehrung, Überwindung von Apoptose und 
unbeschränkte Vermehrung – die wichtigsten Merkmale der Tumorgenese – sind Anzeichen 
einer Veränderung in verschiedensten Signaltransduktionswegen. Dass die Balance zwischen den 
einzelnen Signalkaskaden, sowie die Integration der Signale in Tumoren verändert sein kann, ist 
eine vielfach publizierte Beobachtung. Das Wissen um pathologische Veränderung in diesen 
Signalwegen könnte daher als ein wichtiger Marker für die erfolgreiche Behandlung genutzt 
werden. Deshalb habe ich das von mir entwickelte lentivirale Reportersystem genutzt, um die 
Veränderungen in der Aktivierung von Sinaltransduktionswegen in wachsenden Tumoren im 
Tiermodell zu untersuchen. Dabei faszinierte besonders die Kinetik der Aktivierungsmuster 
einiger Signalwege während der Tumorentwicklung. Gerade weil die Krebsentstehung ein 
extrem komplexer Prozess unter Einbeziehung multiplen Ebenen der Zell-Zell Kommunikation 
ist, könnte das bessere Verständnis veränderter Signaltransduktionswege in Krebszellen dabei 
helfen die inter-individuelle Variabilität in der Krebs Pathogenese beim Menschen zu verstehen 
und die existierenden Behandlungsmethoden zu verbessern. 
Auf Ebene der Zelle wirken nahezu alle Medikamente auf regulierende Proteine innerhalb 
von Signaltransduktionskaskaden, die Information von der Zellmembran aufnehmen und eine 
Reaktion im Zytoplasma oder Nukleus der Zelle hervorrufen. Dies ist auch ein wesentlicher 
Grund für inter-individuelle Unterschiede in der Wirkung vieler Medikamente: Aufgrund 
genetischer Unterschiede kann die Expression oder aber auch die Struktur von Proteinen einer 
Signaltransduktionskaskade zwischen Menschen variieren. Die zellulären Determinanten, die die 
Grundlage für diese Unterschiede bilden, zu verstehen ist eine fundamentale Aufgabe der 
Pharmakologie und ist zum Ausgangspunkt für die personalisierte Medizin geworden. Während 
meiner Promotionsarbeit habe ich eine neue Hochdurchsatztechnologie zur Messung von inter-
individuellen Unterschieden im Ausgangssignal verschiedener Signaltransduktionskaskaden 
etabliert. Dieses System kann nun unter Anderem zur Charakterisierung verschiedenster 
pharmakologisch aktiver Substanzen direkt in humanen Fibroblastenkulturen Anwendung 
finden. Die individuell verschiedenen Genexpressionsmuster zu erfassen und so die molekularen 
Ursachen von phänotypischen Unterschieden zwischen Individuen zu verstehen, wird 
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weitreichende Einsichten, auch in die pathologischen Veränderungen dieser Muster bei 
Erkrankungen, ermöglichen. 
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CHAPTER 1  
General Introduction 
1.1 Time and Clock 
The nature and meaning of time has always been fascinating for people of all ages. While 
ancient Greek philosophers such as Aristotle believed that the universe is born as well as dies in 
endless cycles of infinite time, much later Sir Isaac Newton defined both space and time as 
absolute and uniform. Coupling of the Newtonian, Kant’s and Einstein’s theories by the 
theoretical physicist Stephen Hawking built up today’s modern and unique view of the generally 
accepted four – dimensional space-time where many relative rates of “local clocks" depend on 
their relative motion.  
As the time of the universe goes by, the most authoritative physical oscillation emphasizing 
our relationship with time is the day-night cycle ruling and organizing our lives in a 24 – hour 
schedules.  But … how do we perceive or measure time? As early as 3500 BC, the Sumerians 
and the Egyptians are thought to be the first who developed the simple shadow, sundial and later 
water clock. With time, clocks became more and more precise time – keeping indicators that 
measure and keep track of the daytime. However, having modern electric clocks in the pocket is 
not enough to coordinate our day – night cycle activities. There must be some endogenous, more 
sophisticated mechanism regulating nearly all aspects of our physiology, metabolism and 
behavior.  
It has been assumed for a long time, that circadian clocks - capable of being entrained to the 
external environment, are an evolutionary adaptation to life in a rotating planet. Nevertheless, a 
proof of their existence was successfully ignored for a long time. The first documentation of a 
circadian process can be dated to the 4
th
 century, where Androsthenes, admiral of Alexander the 
Great, described daily rhythms of leaves opening and closing. Unfortunately, this occurrence was 
assumed to be a direct response to the external stimuli and the discovery of the circadian rhythms 
was delayed until the year 1729. A French astronomer Jean Jacques d’Ortous deMairan went far 
beyond noticing the leaf movement. A simple experiment on the plant Mimosa revealed the 
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existence of an internal circadian rhythm. deMairan showed that even after the exposing the 
plant to the conditions of constant darkness leaves still possess their rhythmic behavior. 
deMairan also hypothesized that other factors (e.g. Temperature) might have a significant effect 
on the circadian rhythmicity. About a century later, a Swiss botanist Alphonse de Candolle added 
minor, but extremely valuable information into the science of circadian rhythms.  Following 
deMairan’s observations in Mimosa, he noticed that the period of the leaf’s rhythms is starting a 
little bit earlier with each day. This phenomenon was later defined as a free running period of the 
circadian rhythms.  
Given the origin of circadian biology, it is not surprising that the question of endogenous 
timing attracted the interest of many scientists from the field of neuroscience, molecular biology, 
genetics and physics and thereby propelled this scientific field forward.  
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1.2 Mammalian architecture of circadian clocks 
Enormous advances in molecular biology and genetics during the last few decades helped 
scientists to crack the nature and role of biological rhythms, especially endogenously generated 
circadian rhythms. The term circadian originates from the Latin circa diem what literally means 
‘about a day’. Nearly all inhabitants of Earth have developed this daily time - keeping system, 
which helps them to adapt better to external 24 - hour cycles.  
In mammals, a broad spectrum of physiology such as sleep – wake cycles, cognitive 
performance, cardiovascular system, hormone excretion, digestion and detoxification is 
orchestrated by the circadian system. The architecture of this system is generally organized in a 
hierarchy of oscillators with the central oscillator at the top. A separate input pathway delivers 
signals from the external environment to the central pacemaker, which in turn is able to receive 
and integrate incoming information. The physiology of the whole living system is then affected 
via output pathways controlled by this master oscillator. The three main blocks of the circadian 
system - input, central oscillator as well as output pathways, are the topic of the following 
chapters (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Architecture of the mammalian circadian system. Environmental input cues such as light, food, physical 
exercise etc. entrain the phase of the central oscillator, located in the SCN of the brain hypothalamus. The central 
pacemaker is then driving the rhythmicity in other parts of the brain as well as in peripheral tissues via various 
neural and humoral output signals. The central pacemaker and peripheral tissues are responsible for the daily 
rhythms in human physiology and behavior. Reproduced from Garaulet et al., 2010 [1]. 
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1.2.1 Suprachiasmatic nucleus – function and structure 
A chief oscillator of mammalian rhythmicity, able to generate and sustain the circadian 
oscillations is located in the suprachiasmatic nuclei (SCN) - in the rostroventral hypothalamus 
[2]. This tiny little paired structure just above an optic nerve contains approximately 16 000 
neurons and became an object of intense research in the mid-1970s.  
In 1972, Robert Moore’s studies revealed that external photic information is communicated to 
the brain via the main projection of the retinohypothalamic tract [3]. This discovery opened up a 
series of ablation and transplantation studies where Stephan and Zucker as well as others, 
determined that bilateral destruction of the SCN permanently eliminates circadian rhythmicity in 
drinking and locomotor activity of rats [4-7]. On the other hand, the transplantation experiments 
showed that just a small SCN neural graft can restore the circadian rhythms in a lesioned 
arrhythmic animal. Regardless of the host genotype or the direction of the transplant, the restored 
clock’s properties were always displaying the period of the donor genotype suggesting that the 
circadian period must be determined by the neuronal cells of the suprachiasmatic region [8].  
A diversity of neuronal cells, differences in neuropil volume and a variety of afferent/efferent 
connections indicate that the SCN is rather a heterogeneous than a homogenous unit. Although 
many electrophysiological studies and experiments on dispersed suprachiasmatic nucleus 
cultures have demonstrated a strong competence of SCN neurons to be an individual cell - 
autonomous oscillators [9, 10], it still was not clear whether or not all neurons of SCN exhibit 
rhythmic properties.  
Anatomically, the SCN is divided into two main partitions: 'shell' (dorsomedial area) and 
'core' (ventrolateral area) [11] (Figure 2). Intense research showed that cells possessing an 
endogenous rhythmicity in electrical activity, gene expression and protein phosphorylation are 
mainly localized in ventromedial, dorsomedial and rostral parts of the suprachiasmatic nucleus 
collectively called 'shell' (the distribution of these cells produce a shell like shape).  The study of  
this SCN subdivision by multi - electrode approaches revealed that the cells of the dorsal as well 
as ventral part exhibit spontaneous oscillations that persist over several days [12]. Furthermore, 
the shell’s molecular rhythms were confirmed by the  identification of the rhythmic expression of 
immediately early genes such as Fos, JunB or Fra2 in dorsomedial and rostral regions [13-16]. 
Vivid search for signs of rhythmicity within the SCN shell, led scientists to the discovery that 
protein phosphorylation, e.g. phosphorylation events occurring in mitogen–activated protein 
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kinase cascades (MAPK), could serve as a valuable marker for endogenously rhythmic cells 
[17]. For instance, Gau and colleagues found that peak levels of phosphorylated CREB (pCREB) 
in the mouse SCN appear during the subjective night, however, the regional localization of 
endogenously rhythmic pCREB was not showed [18, 19]. To the contrary, the levels of 
phosphorylated ERK were rhythmic with a clear peak during the mid-subjective day  and 
immunoreactivity of ERK overlapped with the distribution of Vasopressin - positive cells of the 
dorsomedial and ventrolateral part of the SCN [20].  
The second subdivision of the central SCN called 'core', seems to lack endogenously rhythmic 
cells. This part of the SCN has been characterized based upon light activated clock gene 
expression [21]. In contrast to the shell, which contains a large population of arginine 
vasopressin (AVP) and calretinin (CAR) expressing neurons,  the core -- a site of retinal inputs 
implicated in entrainment -- comprises predominantly VIP - (vasoactive intestinal polypeptide) 
and GRP - (gastrin releasing peptide) positive neurons co-localized with GABA [11, 22].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2 Coronal section of mouse SCN. Ventral core region is visualized by green fluorescent protein expressed 
in GRP neurons (green) and the dorsal shell region is delineated by immunofluorescent labeling for AVP (red). 
Optic chiasm is located below the SCN and third ventricle is between left and right SCN. Reproduced from 
Karatsoreos et al., 2004 [23]. 
Despite the structural and circadian heterogeneity of  dorsal and ventral part of the SCN [24, 
25], the central oscillator is able to conduct the physiological timing of the whole organism in 
respect to the external changes in the environment. Until now, we have quite broad knowledge 
about the mechanisms of external entrainment of the main oscillator (discussed in details in the 
Chapter 1.2.3.), but there is less known about the mechanism of the intra - neuronal 
synchronization within the SCN. Several laboratories found that neuropeptides such as 
vasoactive intestinal polypeptide [26], gastrin-releasing peptide, neurotransmitter γ- 
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aminobutyric acid [27] signals via G- protein subunit Gi/o  [28], as well as gap junctions [29], are 
implicated in the interneuronal synchronization and the concept of neuronal coupling based on 
the circadian neurotransmitter release regulation became a subject of intense study [30-33].  
 At the level of the SCN, the VIP neuropeptide signaling pathway is the most prominent 
player of inter-neuronal synchronization of firing rate and molecular pacemaking [34, 35]. VIP 
neuropeptide, which is rhythmically expressed by the ventrolateral neurons, acts through the G 
protein-coupled receptor VPAC2 (encoded by Vipr2 gene) that activates adenylyl cyclase [36], 
intracellular cAMP, protein kinase A (PKA) and ultimately CREB phosphorylation. The acute 
induction of Per genes expression by phosphorylated CREB is then followed by repression of 
PER and CRY in the subsequent cycle and a new phase of the circadian rhythm is re-established. 
(See chapter 1.2.2.1 for circadian clock genes) Most of our understanding about VIP function 
arises from the knockout animal studies. For instance, transgenic mice lacking VIP or VPAC2 
receptor expression (Vip
-/-
,Vipr2
-/-
) display similar behavioral deficits [34, 36, 37]. Moreover, 
molecular rhythms of core clock genes have been found to be strongly attenuated in Vipr2
-/-
 mice 
[36, 38].  Along with these molecular and behavioral phenotypes, altered firing rate rhythms and 
disrupted synchronization have been also reported in Vip
-/-
 and Vipr2
-/-
 SCN [34, 39]. 
Apart from the VIP, GRP neurotransmitter found in the ventral SCN and its BB2 receptor 
expressed in the dorsal SCN seem to play a role in the circadian rhythmicity of the SCN. Several 
studies revealed that GRP administration evokes phase shifts in firing rate rhythms, in SCN 
slices and behavior, while deletion of BB2 leads to attenuation of the phase – shifting effects of 
GRP [40-42]. In addition, Brown et al. showed that GRP can effectively promote cellular 
rhythmicity in Vipr2
-/-
 SCN slices [38]. So, as we can see here, the rising body of evidence 
suggests involvement of GRP in the SCN synchronization, however, the exact role of this 
neuropeptide in the neuronal coupling still remains undisclosed.  
Beside the neuropeptidergic signaling, gap junctions between two adjacent neurons promote 
synchronization and secure precision in the circadian activity and behavioral rhythms. Gap 
junction channels are typically formed by a connexin 36 protein. Long et al., in 2004, showed 
that Cx36 knockout mice elicit dampened circadian behavioral rhythms and delayed activity 
onset in constant darkness. Moreover, an electrical coupling between SCN neurons was lost. 
Taken together, electrical synapses in the SCN help to synchronize its firing activity that is 
necessary for normal circadian behavior [43].  
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1.2.2 Molecular bases of circadian clockwork  
The process that generates and maintains self-sustaining oscillations in most model organisms 
is thought to be approximately 24 – hour period transcriptional and translational oscillatory 
machinery. Extensive investigation of the genetic basis of circadian rhythmicity in many model 
systems such as cyanobacteria, fungi, protozoans, insects and mammals revealed the existence of 
core clock genes whose undisturbed action regulates many aspects of biological rhythmicity. 
1.2.2.1 Core Clock Genes and their implication in circadian machinery 
Core clock components are defined as genes whose protein products are essential for the 
generation of circadian rhythms [44]. The process of understanding the architecture of these 
components as an oscillating clock began with the discovery of clock mutants in the filamentous 
fungus Neurospora crassa and the fruit fly Drosophila psuedobscura. The identification of 
Neurospora clock mutants [45] led to the discovery and cloning of the Frequency locus (frq), one 
of the first known circadian clock genes [46]. Similarly, in Drosophila, the pioneering forward 
genetic screens of Roland Konopka and Seymour Benzer led to the discovery of the Period (per) 
locus [47, 48].  
Subsequent research in both organisms showed that their circadian oscillators are based upon 
autoregulatory feedback loops of transcription and translation [49] (Figure 3). This basic 
structure has been conserved in all species studied. Interestingly, however, these loops are not 
essential in cyanobacterial clocks, which are based upon cyclical rhythms of phosphorylation of 
clock components [50]. Although cyclical post-translational modifications of clock components 
play a prominent role in metazoan clocks as well, current evidence suggests that 
transcription/translation feedback loops consisting of both positive and negative elements are 
essential to their primary mechanism [51].  
In mammals, the positive elements of these loops include members of helix-loop-helix 
(bHLH)-PAS (Period –Arnt-Single-minded) transcription factor family, CLOCK and BMAL1. 
In some tissues including brain and liver, the NPAS2 protein can also play a pivotal role[52]. 
CLOCK or NPAS2 and BMAL1 heterodimerize and initiate transcription of target genes, which 
contain E-box cis- regulatory sequences. Negative feedback is achieved by a complex of other 
components including the PERIOD1-3 (PER) and CRYPTOCHROME1-2 (CRY) protein 
products. The genes encoding these products are activated by CLOCK:BMAL1 heterodimers via 
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E-boxes, and their cognate proteins then translocate back to the nucleus to repress their own 
transcription by preventing CLOCK:BMAL1 complex binding [49, 53]. The CIPC protein, 
which interacts with CLOCK:BMAL1 complexes and inhibits their activation activity, probably 
also plays a role [54].  
 A second type of loop is formed by CLOCK:BMAL1 heterodimers that activate the 
transcription of retinoic acid-related orphan nuclear receptor genes Rev-Erbα and RORα [55]. 
REV-ERBα and RORα subsequently compete dramatically to bind retinoic acid-related orphan 
receptor response elements (ROREs) which are present in the Bmal1 promoter. ROR as well as 
related proteins ROR β and γ) activate the transcription of Bmal1 and REV-ERBα (and probably 
its sister protein REV-ERBβ) repress it [55, 56]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Core clock components of the mammalian transcriptional - translational feedback loops. The positive 
elements of the primary feedback loop are represented by the CLOCK and BMAL1, which heterodimerize and 
initiate the transcription of target genes containing E-box cis regulatory enhancer sequences including Periods (Per1, 
Per2, Per3) and Cryptochromes (Cry1, Cry2). Negative feedback is achieved by PER: CRY heterodimers that 
translocate back into the nucleus and repress their own transcription. Casein Kinase 1 epsilon and delta are critical 
factors that regulate the core circadian turnover in mammals. The second regulatory loop induced by CLOCK-
BMAL1 heterodimers activates the transcription of retinoic acid-related orphan nuclear receptors (Rev-erbα, Rorα) 
that consequently compete to bind retinoic acid-related orphan receptor response elements (ROREs) in the Bmal1 
promote. RORs activate transcription of Bmal1, whereas REV-ERBs repress the transcription process. Reproduced 
from Ko & Takahashi 2006 [57].  
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1.2.2.2 Post translational modification of clock components 
Post-translational modifications of clock components and of other proteins play an important 
role in both loops. These modifications include phosphorylation and ubiquitination of clock 
components, chromatin modifications, and possibly even direct acetylation of some clock 
components by others. For example, PER proteins are phosphorylated by casein kinase 1 and , 
and probably by other kinases as well, and these phosphorylations affect both the nuclear 
localization and degradation via ubiquitination [58]. Ubiquitin ligase coupling via the FBXL3 
protein also affects degradation of other clock proteins such as CRYs [59, 60]. At the level of 
chromatin structure, circadian loci such as Dbp and Rev-Erb change each day from a repressive 
to an active chromatin structure via histone acetylation and methylation [61].  
Finally, CLOCK (the mouse circadian locomotor output cycles kaput) protein itself possesses 
a histone acetyltransferase activity and can acetylate BMAL1 [62]. Since the Clock can be 
acetylated, there must be also a mechanism of deacetylation. A recent report published in 2008 
showed that sirtuin1 ((silent mating type information regulation 2 homolog, SIRT1) which is a 
NAD
+
 - dependent rhythmic deacethylase, directly acts with CLOCK. Moreover, the 
pharmacological blocking of the SIRT1 activity resulted in disturbances of the circadian rhythm 
as well as in the inability of BMAL1 acetylation [63]. The complexity of this system was worked 
out by another group which showed that SIRT1 binds to a CLOCK – BMAL1 complex in a 
circadian fashion and evokes a deacetylation/degradation of PER2 [64]. In addition to 
phosphorylation and acetylation, it was shown that mouse BMAL1 is rhythmically SUMOylated 
on a conserved lysine residue (K259) in vivo, in a CLOCK dependent fashion [65].  
1.2.3 The afferent connections of the SCN 
Entrainment or synchronization of the circadian system to external environmental cycles is 
mediated by highly organized afferent neuronal pathways (Figure 4) which are conserved among 
different mammalian species ranging from rodents to humans. Photic as well non-photic stimuli 
have been shown to modulate the rhythmicity of the main brain circadian pacemaker, which 
ultimately orchestrates the downstream timing in the physiology and behavior. 
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1.2.3.1 Photic entrainment for the suprachiasmatic nucleus 
One of the most salient properties of the circadian system is the ability to be entrained by the 
external light – dark cycles. According to these cycles, SCN drives diurnal changes in behavior 
and physiology, and as it was demonstrated by many groups in controlled conditions (e.g. 
Constant light or constant dark) the period length of endogenous oscillations is remarkably close 
to 24 hours. 
The Retinohypothalamic tract 
In general, various photic and non – photic environmental timing cues ("Zeitgebers") are 
capable to entrain the circadian rhythmicity of the central pacemaker. Among many, light seems 
to be the most powerful photic zeitgeber. 
In mammals, the transmission of the light information from the external environment into the 
internal milieu of the brain is mediated by highly organized retinohypothalamic tract (RHT) [3]. 
The retinohypothalamic pathway originates in the small population of photosensitive retinal 
ganglion cells (RGC) that produce an opsin-like protein melanopsin [66-68]. The importance of 
melanopsin, rods and cones for circadian photo - entrainment was demonstrated by Hattar and 
colleagues where a triple mouse knockout induced the loss of ability to entrain to light/dark 
cycles [69]. The axons of the RGCs mostly project into the key centers of circadian photo - 
entrainment such as SCN, the intergeniculate leaflet (IGL) and the olivary pretectal nucleus 
(OPM) of the brain. The selective lesion of the RHT fibers projecting directly to the SCN 
revealed the so called "circadian blindness" however, no loss of vision was determined [70].  
The Geniculohypothalamic tract 
Apart from the direct projection of retinal cells to the SCN via RHT, there also exists an 
indirect pathway called geniculohypothalamic tract, which arises from the neurons of the lateral 
geniculate complex, the intergeniculate leaflet (IGL) and a portion of the ventral lateral 
geniculate nucleus (vLGN) of thalamus [71]. The IGL receives the direct projection from the 
retina and consequent integration of photic and non-photic cues modulates the SCN rhythmicity 
[72]. Many laboratories showed that the lesion of IGL alters the circadian system response to 
constant light condition [73, 74]. 
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The Serotogenic Tract 
The third key afferent input to the SCN is represented by the serotogenic tract, innervating 
from the midbrain raphe [75, 76]. Many studies showed a significant role of serotonin in the 
regulation of the SCN circadian oscillator. Lesion experiments in the midbrain raphe nuclei 
responsible for the serotogenic projection, showed an alteration in the locomotor activity of the 
rats [77, 78]. Moreover, pharmacological manipulation of serotonin (5HT) synthesis and 
degradation supported the hypothesis of the serotogenic modulation of photic response of the 
main oscillator [79, 80].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 The most important afferent connections to the SCN. RHT: retinohypothalamic tract, Glu: glutamate, 
PACAP: pituitary adenylate cyclase-activating peptide, SP: substance P., IGL: intergeniculate leaflet, GHT: 
geniculohypothalamic tract, NPY: neuropeptide Y, GABA: γ-aminobutyric acid, 5-HT: serotonin, DRN: dorsal 
raphe nucleus, MRN: median raphe nucleus. Adapted from Challet E.&Pevet P.,2003 [81].  
1.1.1.1.1 Signal transduction of photic messages within the mammalian SCN 
The light entrainment mechanism of the core clock oscillator is mainly based on the 
retinohypothalamic release of the neurotransmitters from the nerve terminals. Although, 
excitatory amino acid glutamate was recognized as a first neurotransmitter of the RHT pathway 
[82], later studies showed that pituitary adenylyl cycles activating polypeptide (PACAP) is also 
playing an essential part in the RHT light projection into the suprachiasmatic nucleus [83-86]. 
Besides these two main neurotransmitters, various metabotropic glutamate receptors as well as 
N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors of the SCN have been found to have a crucial role in glutamatergic regulation 
of the circadian rhythms [87, 88]. While activation of NMDA receptors initiates phase shifts, the 
pharmacological blocking of these receptors prevents light induced phase shifting of the 
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hamster’s circadian system [89, 90]. Independently from glutamate and PACAP, also other 
molecules have been suggested as neurotransmitters of RHT. For instance, neuropeptide Y 
(NPY) [91] and γ – aminobutyric acid (GABA) of the IGL innervate the rhythmicity of the 
clock. Moreover, L-aspartate [92], N-acetylaspartylglutamate [93], histamine [94] and the still 
discussed substance P (SP) [95] seems as well act as neurotransmitters involved in the light 
pathway. 
 
When we take a closer look at the molecular mechanism of signal transduction pathways 
orchestrating photic entrainment of circadian rhythmicity (Figure 5), Calcium (Ca
2+
) acts as a 
first mediator of light induced entrainment of the circadian clock. Indeed, it was demonstrated 
that Ca
2+
 levels regulate a variety of eukaryotic physiological processes such as cell division in 
the microorganism Euglena, leaf movement in Trifolium reopens or conidations in Neurosporra 
crassa [96-98]. Furthermore, Cowell reported that Ca
2+ 
exhibits daily fluctuations in duration 
and concentration level. Circadian – like oscillations in Ca2+ levels persisted even when the rats 
were kept in constant darkness, however, this was not the case for the condition of constant light. 
Ultimately, the observed Ca
2+ 
rhythms blocked by the application of Na
+
 or Ca
2+
 Voltage - gated 
channel inhibitor [99] suggest, that calcium levels could be modulated by extracellular events. 
  A                 B 
Figure 5 Signal transduction of photic messages in the mammalian suprachiasmatic nuclei. A) RHT releases 
glutamate onto SCN neurons and interacts with several types of receptors of which the NMDA receptor has been 
shown to mediate light effect. Moreover, calcium channels that are also present in the SCN could contribute to ion 
influx via the cytoplasmic membrane. B) Calcium influx via NMDA receptors induces CaMKinase and NOS 
activity that consequently modulate other kinases such as MAP kinases or PKG. Activation of the kinase cascades 
ultimately induce transcription factors ( such as CREB) that activate clock gene transcription and clock entrainment. 
Question marks represent yet unknown signaling mechanisms in the SCN. Reproduced from Golombek et al.,2003 
[100].  
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The depolarization event including immediate influx of Ca
2+
 into the retinorecipient SCN 
neurons appears to be mainly dependent upon a glutamate release acting on NMDA receptors 
[101-104]. Apart from NMDA, AMPA, Inositol triphosphate receptors (IP3) and other 
metabotropic glutamate receptors, Voltage - gated Ca
2+
 channels were found to be rhythmically 
expressed in some immortalized cell lines [105]. Downstream of the receptors, actual Ca
2+
 
activated multilevel signal transduction of the SCN relies on the harmonized interplay of various 
kinases (e.g. cAMP dependent protein kinase A (PKA), mitogen-activated protein kinase / 
extracellular signal – related kinase (MAPK/ERK), Ca2+/calmodulin – dependent protein kinase 
(CaMK) and downstream effectors (Ca
2+
- dependent proteases and transcription factors). 
 cAMP/PKA/CREB/CRE signaling  
The cAMP signal transduction cascade acting via the well-known cAMP response – element 
– binding protein (CREB) is the most often studied pathway associated with the photic 
entrainment [18, 19, 106] and the molecular mechanism of the circadian clock [107]. CREB is a 
member of the basic helix-loop-helix family of transcription factors whose activation is 
dependent on the phosphorylation by various kinases, such as CaMK and PKA. PKA as well as 
the levels of cyclic 3’5’-adenosine monophosphate (cAMP), intracellular second messenger, 
exhibits a significant diurnal fluctuation [108]. Moreover, in vitro application of cAMP analogs 
specifically inducing cAMP signaling pathways causes a stable phase shift of the isolated 
circadian pacemaker [109]. 
Even if the relationship between the cAMP signaling pathway and circadian clock genes is 
still not fully understood, it is clear that core clock genes (e.g. per1 and per2) [110, 111], as well 
as clock controlled genes containing a cAMP responsive element (CRE) represented by an 8-bp 
palindromic sequence are the targets of the cAMP/PKA/CREB/CRE pathway [112, 113]. 
 cAMP/ MAPK/CREB/CRE signaling  
Besides PKA and CREB, another downstream effector of the cAMP signal transduction 
cascade is critical for the clock entrainment. The highly conserved Mitogen activated protein 
kinase (MAPK) pathway has been found to be implicated in the regulation of many cellular 
processes such as cell proliferation, differentiation and cell death. In mammals, there are at least 
four distinct subgroups of MAPKs - extracellular signal- related kinase (ERK1/2), c-Jun N - 
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terminal kinase/Stress activated protein kinase (JNK/ SAPK), p38 MAP kinase and ERK5 
kinase. In the context of circadian rhythmicity and photic entrainment of the clock, several 
studies revealed that light induced MAPK triggers the activity of Stress-activated protein Kinase 
1 (MSK1) as well as p90 Ribosomal S6 Kinases (RSK) which in turn induce the phosphorylation 
of CREB at Ser133 and in this way initiate the regulation of CREB target genes [114, 115]. 
Moreover, light initiates not only the activation and the rhythmic phosphorylation of ERK [17, 
116] but also JNK and p38 kinases exhibited the light induced circadian rhythmicity at the post 
transcriptional level [117]. Along with ERK/MAPK pathway, mTOR (mammalian target of 
Rapamycin) signaling revealed a 24 - hour’s circadian rhythmicity which was correlated with the 
rhythm of the circadian clock gene per1 at the cellular level [118]. Except the role in the photic 
entrainment of circadian chief oscillator, cAMP responsive MAPK signaling seems to have an 
essential function in the synaptic plasticity and memory consolidation. A recent study published 
by Eckel - Mahan and her colleagues suggested, that circadian oscillation of the hippocampal 
cAMP and MAPK activity could be a valuable piece of a puzzle creating the story of the 
persistence of contextual memory [119]. 
 CAMKII/ nNOS/NO/GC/cGK signaling 
CAMKII/nNOS/NO/GC/cGK signaling is another alternative to the SCN light activated 
signaling pathway. CAMKII or Ca
2+
/calmodulin – dependent protein kinase type II is a 
serine/threonine protein kinase which was found to be rhythmically phosphorylated in the SCN 
under the entrained as well as free running conditions [120] and is assumed to have an 
implication in the resetting of the circadian clock by light [121, 122]. Under the entrained 
conditions, CAMKII is specifically phosphorylating its downstream target the neuronal nitric 
oxide synthase (nNOS) at Ser847. Pharmacological inhibition of CAMKII abolishes the increase 
of phosphorylation as well as light pulse induction of nNOS activity [120]. The main role of 
nitric oxide synthase is the production of nitric oxide (NO) from a precursor L-arginine and its 
linkage to the resetting mechanism of the clock was extensively studied [120, 123, 124].  
According to the literature, the signal transduction downstream of NO could be branched into 
the two main divisions: The cascade which seems to be responsible for the light induced 
circadian phase advance and the cascade representing phase delay. The light pulse stimulation 
during the late night, evoking phase advance of the circadian rhythms,  enhance the NO ability to 
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activate guanylyl cyclase (GC), which in turn elicit circadian changes in the level and activity of 
cGK (cyclic guanosine monophosphate dependent protein kinase, also called Protein kinase G, 
PKG) [125, 126]. Moreover, the pharmacological inhibition of cGK blocked light induced phase 
advances in vivo [127]. 
On the other hand, circadian phase delay seems to be induced by the activation of the 
rhodamine receptors, which are under circadian control [128, 129]. Despite the road junction of 
the NO/cGK pathways it is clear that NO and cGMP are capable to enhance a rapid and transient 
cGK phosphorylation of the final pathway effector transcription factor CREB in vitro [130], 
which in turn regulates transcriptional  activity of the circadian clock genes. 
1.2.3.2 Non-photic entrainment for the suprachiasmatic nucleus 
Apart from the light orchestrating the circadian rhythmicity of the main oscillator, other non-
photic cues such as induced physical activity, food or pharmacological compounds have an 
enormous potential to influence the rhythmicity of the circadian clock. Several studies 
demonstrated that time restricted access to a running wheel at a certain part of the day or 
exposure of the animals to a novel - wheel can successfully entrain the circadian system [131-
133]. In addition, restricted access to an unlocked running wheel in sighted or anophthalamic 
mice also revealed the ability of  clock synchronization [134] that is mediated via the 
geniculohypothalamic tract [135].  
Equally to the non – photic arousal entrainment, circadian clock can be synchronized by the 
restricted food availability during the daily cycle which was characterized by modulated ‘’food 
anticipatory activity’’ in corticosteroid secretion, body temperature and locomotor movement 
[136, 137]. It was shown, that the food expectancy or food synchronization is independent from 
the light entrainable circadian system by several lesion studies [138-141]. Since the temple of the 
light entrainment is located in the rostroventricular hypothalamus, many groups tried to identify 
the center of the food anticipation. Until now, according to a c-Fos neuronal activation, all 
hypothalamic nuclei with the exception of the SCN and ventromedial nucleus [142], likewise 
reward-related areas appear to be involved in food anticipatory activity [143]. At the molecular 
level, food restriction is undoubtedly synchronizing peripheral clocks, however, there is no effect 
on the expression of SCN clock genes [144]. In contrast, rats under the light/dark cycles and 
timed caloric restriction showed a circadian phase advance in the locomotor activity, body 
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temperature and melatonin [145]. Furthermore, the timed caloric restriction was sufficient to 
entrain the behavioral rhythms as well as the molecular machinery of the SCN - the phase of the 
core clock genes has been in phase with the time of feeding [146]. In addition to these findings, 
restricted re-feeding of the arrhythmic rats kept under constant light, re-induced the abolished 
PER2 expression and behavior rhythmicity [147].  
Altogether, photic and non-photic entrainment plays a decisive role in the resetting of 
rhythmicity of the central oscillator, indispensable for controlling many aspects of human 
physiology as well as behavior. In the absence of the main light zeitgeber for the SCN, restricted 
feeding seems to be able to entrain the SCN quite effectively. Beside basic research, 
understanding the entrainment mechanism for the suprachiasmatic nucleus rhythmicity could 
provide new insights into the clinical research of sleep and circadian rhythm disturbances and 
possibly improve therapeutic technologies.  
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1.2.4 The efferent connections of the SCN 
The generation and maintenance of the circadian rhythmicity in a mammalian system 
originates in the suprachiasmatic nucleus of brain hypothalamus. However, other parts of the 
brain including thalamic nuclei, amygdala, olfactory bulbs or cerebellum [148] as well as 
peripheral tissues possess circadian oscillations in the gene expression [149, 150]. 
In general, the SCN outputs are mostly mediated by neuronal efferences, but research in the 
last couple of years revealed also the existence of humoral signals. A very elegant experiment 
done by Silver and her colleagues showed, that the transplantation of encapsulated SCN tissues 
into a SCN ablated animal can restore the circadian locomotor activity, however, it fails to 
restore many rhythms in the neuroendocrine function. The neuroendocrine reactivation requires 
intact SCN neural projections. The coupled action of direct neuronal projection and diffusible 
factors seem to be essential for conduction of the timing signals into the other parts of the brain 
[151]. To understand the orchestrating role of the SCN, it is necessary to know how and via 
which neurotransmitter system are neuronal cells able to direct their efferent projections to 
transmit the timing information. SCN is composed of many different transmitters expressing 
neurons from which arginine vasopressin (AVP, [152]), vasoactive intestinal peptide (VIP, 
[153]) and gastrin releasing peptide cells (GRP, [154]) represent the majority. Besides them, 
other neurochemical molecules such as somatostatin, calretinin, calbicistin, neurotensin, 
neuropeptide Y or TNFα [155] were found to contribute to the timing system [156]. Last but not 
least, neurotransmitters that usually act at the synapse levels such as GABA and glutamate have 
also been found to play an important role in the transmission of the circadian information [157, 
158]. In the focus of neuroanatomy of the SCN outputs, the axonal connection mostly terminates 
within the SCN or along the midline of the hypothalamus, specifically paraventricular nucleus 
(PVT) and dorsomedial hypothalamus (DMH). Some efferent projections have been found to 
terminate in other hypothalamic and thalamic areas as the subparaventricular zone, the preoptic 
area, the bed nucleus of the stria terminals and the lateral septum [159].  
Beside the direct neuronal SCN outputs, the chase for molecular connection for circadian 
rhythms revealed the discovery of hormonal or so called diffusible factors that also exhibited the 
circadian makeup of the regulation. Testosterone, thyroid hormone, corticosteroids, growth 
hormone, as well as melatonin [160-164], showed the circadian rhythmicity in their secretion. 
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1.3 Central clocks vs. peripheral oscillators 
Genome - wide transcriptome analysis revealed that almost 10% of all detected genes possess 
rhythmic expression [165, 166]. This result actually only confirmed the fact that the circadian 
clocks are ticking not only in the SCN but in other peripheral cells and tissues as well [149, 167, 
168]. Moreover, the molecular basis of these peripheral oscillators seems to be the same as the 
one orchestrating in the SCN [169]. In contrary to the SCN, circadian rhythms of most peripheral 
tissues seem to damp out in the absence of the SCN [170]. A closer look at the single cell 
resolution of cultured fibroblasts, however, revealed that the dampening of the rhythmicity is 
rather a question of inter - cellular desynchrony than loss of individual cellular rhythms [171, 
172]. Moreover, Yoo et al. have shown that even apparently low amplitude of Per2 luciferase 
expression in some tissues like the liver and lungs can persist over twenty daily cycles [168]. 
In spite of the similarities given between the SCN and peripheral clock, scientists very often 
refer to a ‘’master’’ and ‘’slave oscillators’’ of the circadian system. In fact, SCN is a master 
oscillator, which through various signals coordinates not only the rhythmicity but also the 
synchronization of peripheral tissues. For instance, it was showed that the circadian phases of 
peripheral clocks in the SCN lesioned animals show significant differences. Moreover, Guo et al. 
showed that the transplantation of the SCN into the SCN ablated animal restored the phase 
continuity of circadian gene expression in liver, kidney, spleen, heart, skeletal muscle and 
adrenal medulla [173]. In addition to the SCN regulated peripheral slaves, local SCN 
independent oscillators in the retina and olfactory bulb can oscillate persistently without the SCN 
[174, 175]. 
1.3.1 Synchronization of peripheral oscillators 
One way in which the SCN probably influences circadian physiology and gene expression is 
via the pituitary-adrenocortical axis, specifically via glucocorticoid hormones. Glucocorticoids 
have many important functions, including regulation of glucose, fat, and protein metabolism. 
They also have anti-inflammatory actions, and can affect mood and cognitive functions. 
Glucocorticoids can bind the glucocorticoid receptor (GR) a nuclear hormone receptor found in 
many cell types but not in the SCN [176]. It has been shown that dexamethasone, a 
glucocorticoid analog, can induce Per1 expression in RAT1 fibroblasts, as well as change the 
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phase of circadian gene expression in peripheral tissues, but not SCN. It is clear that 
glucocorticoids are not the sole entraining signal from the SCN because mice lacking GR in liver 
possess normal circadian rhythmicity in this organ [177]. 
 Another dominant “zeitgeber” or timing cue for peripheral circadian clocks is food itself. 
It was shown that the expression profile of many circadian genes in the liver and other peripheral 
tissues is influenced by the timing of food intake. Specifically, restricted feeding uncouples 
peripheral circadian gene expression from that in the suprachiasmatic nucleus [178, 179]. The 
speed and the degree to which an organ changes its circadian rhythm to match the timing of food 
uptake vary among different organs. Interestingly, however, this phase shift happens more 
quickly in adrenalectomized animals or in tissues lacking the glucocorticoid receptor when 
feeding time and photoperiod are placed in opposition [178]. Therefore, it is likely that the twin 
signals of feeding time and glucocorticoid secretion act separately in vivo to set clock phase. The 
exact nature of the food-induced signal is unclear, but the observation that glucose alone can 
phase shift circadian gene expression in cultured cells in vitro suggests that basic food 
metabolites could suffice [180]. Once again, it is unlikely that food entrainment is the only 
timing signal in vivo, because mice that are fed frequent isocaloric meals still display robust 
circadian rhythmicity in peripheral organs [181].  
 A third basic class of signal that may entrain peripheral oscillators is fluctuation in body 
temperature. In heterotherms such as Drosophila [182] and Neurospora [183], it has been known 
for some time that shallow 24-hour temperature fluctuations – e.g. 12 hours at 37°C followed by 
12 hours at 33°C – can synchronize and phase-shift circadian oscillations in behavior and gene 
expression. More recently, however, we have shown that rhythmic body temperature can sustain 
peripheral circadian oscillators, and that inversion of temperature cycles in liver or brain cortex 
can invert circadian gene expression in these organs without affecting the phase of the SCN 
[184]. In spite of these promising results, temperature is also not the sole source of peripheral 
circadian entrainment in vivo, because “scrambling” of temperature cycles does not result in a 
loss or dampening of peripheral circadian rhythmicity. 
 Finally, Okamura and colleagues showed that communication between SCN and 
peripheral tissues can occur via a fourth channel: the sympathetic nervous system. In their study, 
periodically injected adrenaline in SCN-lesioned mice induced strong Per2 expression in liver. 
This result suggested that adrenergic regulation influences circadian clock gene oscillations in 
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peripheral tissues. Moreover, electrical stimulation of the sympathetic nerve increased mPer1 
transcription mainly in the liver of these mice. As a confirmation that the sympathetic nerve is 
critical for sustaining Per gene expression in peripheral organs, the mice were injected by 6-
hydroxydopamine.HCl which causes the destruction of sympathetic nerves. The expression of 
the Per2 gene significantly reduced. Together, these studies demonstrated that sympathetic nerve 
activity plays a crucial role in the delivery of the central clock information to at least some 
peripheral tissues [185]. 
Of course, although I have evoked four distinct channels of communication in the above 
discussion, significant overlap is possible and even likely. For example, corticosterone release 
from the adrenal gland can occur via the sympathetic nervous system, and food metabolites can 
be brain signaling molecules. Overall, the key message is that the SCN conveys its timing 
information to peripheral circadian clocks through a redundant mix of direct hormonal and 
nervous signals, and indirect environmental ones such as feeding and body temperature that are 
influenced by rest-activity cycles (Figure 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Organization of central and peripheral oscillators. Light is the principal timing cue that synchronizes the 
neurons located in the suprachiasmatic nucleus (SCN) of the anterior hypothalamus, whereas the SCN 
communicates with peripheral oscillators via a redundant web of direct and indirect signals. For the circadian 
system, light is received by both rod and cone cells containing traditional opsin pigments and retinal ganglion cells 
containing melanopsin. This message is sent to the SCN via the optic nerve and the retinohypothalamic tract. From 
the SCN, a variety of signals is transmitted to peripheral oscillators. These include direct signals from the 
sympathetic nervous system, hormonal cues, and indirect signals such as food metabolites and body temperature that 
are relayed via the control of the SCN upon appetite and locomotor activity. Reproduced from Cuninkova & Brown, 
2008 [186].  
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1.4 Measurement of Human Circadian Clocks  
1.4.1 Circadian Parameters 
The robust circadian oscillations are a fascinating property of various biological processes 
that occur within many cells and tissues. These rhythms repeat once a day, persist in the absence 
of any external zeitgeber and can be entrained or reset to match the local time. The nature of the 
circadian oscillations is thought to be determined genetically by a set of core clock genes and can 
be very well described by the three main variables: circadian period length, circadian phase and 
circadian amplitude (Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 The basic properties of the circadian rhythms. Period - peak to peak interval of the activity, Phase - the 
endogenous timing of peaks and troughs of the oscillation, Amplitude - the level of expression measured from the 
midline to the peak. Reproduced from Bell-Pedersen et al., 2005 [187].  
1.4.1.1 Period Length 
Circadian clocks are able to oscillate with a wide variety of periodicities. Under constant 
conditions, this period has a length which is very close to 24 hours. Several studies of circadian 
rhythms have shown that genetically determined circadian period length could be dramatically 
altered by the mutations of the core clock genes. For instance, Ralph and Menaker determined 
that the circadian period length of Syrian hamsters carrying the tau (an allele of the gene casein 
kinase I epsilon) mutation exhibits shorter (20-22hrs) than normal circadian period [188]. In 
addition, Vitaterna et al. showed that the Clock mutants display an abnormally long circadian 
period, which eventually leads to a loss of circadian rhythmicity in constant dark conditions 
[189]. 
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1.4.1.2 Circadian Phase 
Circadian clock has an ability to synchronize to the external time via external environmental 
cues. These zeitgebers dictate the endogenous timing of peaks and troughs collectively called a 
relative circadian phase. In human studies, several markers like melatonin, cortisol or even 
temperature (Chapter 1.4.1.) could be used to determine the circadian phase of an endogenous 
pacemaker. Although SCN neurons are competent self-sustained oscillators able to oscillate for 
more than 50 days [170] most of the peripheral oscillations damp out within a few cycles. This 
declining pattern was further investigated and Yoo et al. showed that the dumping differences 
between SCN and peripheral tissues seems to be a matter of quantitative rather than qualitative 
properties of peripheral oscillators. Moreover, he showed that peripheral tissues are capable of 
persistent rhythmicity for up to 20 days independently of the SCN input[168]. 
1.4.1.3 Amplitude  
Along with the phase, light also affects the amplitude of circadian rhythms. The measured 
amplitude of a circadian rhythm represents the half distance from the maximum to the minimum 
of the obtained circadian rhythm. Several studies revealed that while the light reduces rhythm’s 
amplitude to nearly zero during so called "critical phase" in the mid-subjective night when phase 
shifts are maximal, controversially amplitude increases by light pulses during the subjective day 
when phase shifts are minimal [190-193]. In human studies, both phase and the amplitude of 
melatonin, core body temperature or even cellular gene expression can be used to describe the 
properties of the circadian system. 
1.4.2 Human circadian markers 
Circadian oscillator of the central nervous system regulates the physiology (hormone 
excretion, blood pressure, temperature) and behavior (mood, sleep, alertness etc.) within the 24-
hours cycles synchronized to the external environment. Since this oscillator cannot be studied 
directly in humans, various circadian markers such as melatonin, core body temperature and 
cortisol have been used to reveal the function of human clock giving core oscillator. 
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1.4.2.1 Melatonin  
Melatonin, N-acetyl-5-methoxytryptamine, is a hormone of the pineal gland whose circadian 
secretion is regulated by the SCN. Multiple enzymatically regulated synthesis of melatonin from 
tryptophan includes a rate limiting step catalyzed by serotonin-N-acetyltransferase (AA-NAAT) 
whose activity rhythm underlies the rhythmic formation of melatonin [194]. At the molecular 
level, the entire circadian secretion of the mammalian melatonin begins by the adrenergic 
innervation of the pineal gland followed by the binding of the norepinephrine to a β1 – adrenergic 
receptor and activation of the cyclic AMP (cAMP) - signaling pathway [195], which modulates 
the levels and activity of AA-NAT via transcriptional and posttranslational mechanisms (Figure 
8Figure 8). This control mechanism involves a harmonized interaction of distinct transcription 
factors. At the first place, increased levels of cAMP mobilize cAMP - dependent protein kinases 
(such as PKA) which in turn activate CRE – binding protein (CREB). Phosphorylated CREB 
binds to the cAMP responsive element of AA-NAT promoter region and activate transcriptional 
activity of this enzyme [196-198]. Beside the CREB based induction, nocturnally elevated levels 
of norepinephrine also provokes a rise of the mRNA of an inhibitory acting transcription factor 
called inducible cAMP early repressor (ICER) - an induced isoform of cAMP-responsive 
element modulator (CREM) [199]. In the rat pineal gland before the dawn, ICER causes a rapid 
decline of increased AA-NAT mRNA levels what in turn decrease the production of melatonin 
[200]. A recent in vitro study showed that phosphorylated CREB accumulates at the beginning 
and declines with the rising amount of ICER during the second half of the night. This switch 
ratio between phosphorylated CREB and ICER is responsible for the generation of in vivo 
dynamics in mRNA as well as protein level of AA-NAT. Moreover, silencing of the ICER 
expression in pinealocytes enhanced the production of melatonin [201].  
Mammalian SCN expresses at least two (MT1 and MT2) high affinity G – protein coupled 
melatonin receptors via which melatonin affects many mammalian biological functions (sleep –
wake cycles, circadian rhythms etc.) [202]. Beside MT1 and MT2, the third melatonin binding 
site MT3 (quionone reductase 2) has been identified in the Syrian hamster hypothalamus [203], 
however, its function is still poorly understood [204]. 
Many different studies using mammalian cell lines (e.g. CHO, NIH 3T3 or HEK) expressing 
the recombinant forms of MT1 and MT2 revealed the linkage of multiple G - protein induced  
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Figure 8 Regulation of melatonin synthesis in rodents. AANAT-arylalkylamine N-acetyltransferase; AC - 
adenylate cyclase; AMP - adenosine monophosphate; ATP - adenosine trisphosphate; CBP - CREB binding protein; 
CRE - cyclic AMP response element; CREB - CRE binding protein; G - GTP-binding protein; HIOMT - 
hydroxyindole O-methyltransferase; ICER – inducible cyclic AMP early repressor; IP3 - inositoltrisphosphate; P - 
phosphate groups; PKAII – cyclic AMP-dependent protein kinase type II; PKC - protein kinase C; PLC - 
phospholipase C. Adapted from Ackermann & Stehle, 2006 [205] 
signal transduction cascades to the activation of these receptors. On one hand, activation of MT1 
melatonin receptors via Gi proteins (such as Gi2 and Gi3) inhibits forskolin activated formation of 
cAMP, which in turn down-regulate PKA activity to phosphorylate cAMP responsive element 
binding protein (CREB) [206, 207]. 
On the other hand, MT1 activation increases phosphorylation of MEK1/2 (extracellular signal 
– regulated kinase kinase 1 and 2) and ERK1/2 (extracellular signal –regulated kinase 1 and 2) 
[208]. Moreover, activation through Gq protein has been associated with the elevation of 
phosphatidylinositol turnover and calcium mobilization [209, 210] and it was shown that the 
release of G protein subunit β and γ potentiate stimulation of phospholipase C mediated by 
prostaglandin F2a and ATP [211]. Furthermore, activation of MT1melatonin receptors was found 
in the regulation of ion channels - activation of G protein coupled inwardly rectifying potassium 
channel (GIRK) Kir3 via MT1 melatonin receptor increase the conductivity of potassium 
channel [212]. Last but not least, Chan and colleagues showed that activation of MT1 melatonin 
receptors stimulated c-Jun N-terminal kinase activity through Gi and Gs, Gz and G16 proteins 
[213].  
  Chapter 1: General Introduction 
25 
 
Beside MT1 receptors, the activation of MT2 melatonin receptors also leads to an inhibition 
of cAMP production induced by forskolin as well as modulation of c-Jun N-Terminal kinases via 
Gi and G16 proteins [213]. In spite of these similarities, activation of MT2 but not MT1 
melatonin receptors can modulate cGMP levels through the soluble guanylyl cyclase pathway, in 
a dose dependent fashion [214]. In addition, activation of the MT2 melatonin receptors inhibits 
GABAA receptor in the hippocampus [215] and increase PKC activity with the circadian phase 
shift of the neuronal firing activity in the SCN of rat [216].  
Autoradiography with 2 – [125I] iodomelatonin binding, Western blot, immunohistochemistry 
analysis or RT-PCR have been used to determine the distribution of MT1 and MT2 melatonin 
receptors in different areas of the central nervous system and peripheral tissues. Starting at the 
circadian system, the mammalian retina expresses both MT1 and MT2 melatonin receptors 
which are prominent in regulation of a rod phototransduction pathway and in the maintenance of 
the circadian variation of an intraocular pressure [217-220]. 
Downstream of the retina, mRNA and proteins for MT1 and MT2 melatonin receptors were 
found in the mammalian SCN. Activation of these receptors in the SCN evokes several cellular 
responses. For instance, in SCN slices melatonin receptors activation inhibits neuronal firing 
[221] and function as an inducer of the phase advances at subjective dusk and subjective dawn 
[222] acting via MT2 receptors whose activation modulate the activity of PKC. Furthermore, von 
Gall et al. showed that in the mouse SCN melatonin inhibited PACAP - regulated CREB 
phosphorylation mediated via MT1 melatonin receptors activation [223]. 
Moving along the Hypothalamic – Pituitary – Gonadal Axis, where hypothalamus produces a 
gonadotropin-releasing hormone, pituitary gland producing luteinizing and follicle –stimulating 
hormone and gonads producing estrogen and testosterone, activation of melatonin receptors 
seems to play a role in the reproductive system and seasonality as well [224-226]. 
Another target of melatonin action via MT1 receptors includes modulation of glucose 
homeostasis and energy balance through the direct effect on adipocytes and pancreas cells [227-
229]. Additionally, melatonin was linked to a regulation of cardiovascular [230] and immune 
system [231]. Since melatonin has a direct effect on cell proliferation and cytokine secretion, it 
has been suggested as oncostatic agent [232, 233]. According to melatonin mediated responses, 
melatonin receptors seem to be challenging targets in the development of the new treatment for 
sleep, circadian, metabolic, endocrine disorders and cancer. 
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Since it is not possible to directly measure the functional timing of the SCN endogenous 
clock, melatonin rhythms determining the clock output are usually used to assess circadian phase 
position. Melatonin levels can be easily measured in human blood or saliva but the detection of 
melatonin metabolite 6-sulfatoxymelatonin from urine also showed a strong correlation with 
plasma and serum levels of melatonin [234]. Circulating levels of melatonin are very often 
preferred as a circadian marker due to the robustness in the presence of various external factors. 
For example, while excessive intake of carbohydrate causes significant changes in core body 
temperature, concentration of melatonin remains practically unaffected [235]. However, 
numerous researches showed that ocular light is causing an acute suppression of nocturnal 
plasma melatonin that is dependent on various light parameters (such as intensity, duration, 
wavelength and time of administration) [236] and other factors such as individual susceptibility 
or experimental design. It has been found that melatonin used as a circadian phase marker should 
be measured as a dim – light melatonin onset, since it’s thought to be minimally masked by 
exogenous factors. Beside the light, melatonin can be influenced by posture [237], physical 
exercise [238], caffeine and sleep [239] likewise by the distinct groups of drugs such as 
benzodiazepines and β- blockers [240, 241]. 
1.4.2.2 Core body temperature 
The first description of the circadian rhythm in core body temperature (CBT) was described 
by Gierse in 1842. This rhythm is characterized by a nocturnal decrease and daily maximal 
increase of the body temperature. Aschoff and his colleagues showed that the rhythms in core 
body temperature are caused by changes in heat production and heat loss [242]. The nadir of the 
core body temperature was traditionally used to assess the circadian phase of the endogenous 
oscillator [243, 244]. Likewise the stable melatonin marker, CBT rhythm is also ‘’masked’’ and 
influenced by many different factors such as sleep, activity level or posture [245-247] as well as 
by external conditions like ambient temperature, sound or bright light [248, 249]. To minimize 
these effects, many constant routine protocols have been implemented [243, 250]. 
1.4.2.3 Cortisol 
Since the endogenous pacemaker generates the circadian rhythms in hypothalamic-pituitary-
adrenal axis through a multisynaptic suprachiasmatic adrenal pathway, the secretion of cortisol is 
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highly rhythmic [251]. In contrast to melatonin, the peak levels of cortisol have been determined 
in the early morning with forthcoming decline during the daytime and a nadir at midnight. 
Genetic twin studies determined that the timing of this cortisol nadir is a robust marker of human 
circadian phase and is dependent on the endogenous period length [252]. Serum free cortisol 
diffuses into saliva and the measurement of salivary cortisol reflects the concentration of serum 
free cortisol more accurately than measurement of total cortisol in the serum [253]. Beside the 
cortisol nadir, the onset of the evening rise or the end of the quiescent period are the most often 
analyzed parameters of cortisol [254, 255]. Although cortisol seems to be a reliable marker to 
define the endogenous circadian phase, there are several factors influencing cortisol secretion. 
Among many, light was shown to significantly increase morning – cortisol peak [256, 257]. In 
addition, physical stress, aging and sleep – wake cycles have also been shown to play role in the 
secretory activity of cortisol [254, 258, 259]. 
1.4.2.4 Transcriptomics and Metabolomics 
As it was already discussed in previous chapters, circadian rhythms exist in a variety of 
biological processes and control a broad spectrum of physiology such as sleep/wake cycle, 
hormone and neurotransmitter excretion. It is also well known that altered circadian cycle might 
lead to metabolism defects that are characterized for example by obesity or other metabolic 
syndromes [260, 261].  The main regulator of metabolism has been found in the liver. Several 
studies revealed that the liver transcriptome as well as proteome oscillates in expression activity 
that is extensively dependent on the food zeitgeber [262-264]. Beside the liver, very recent study 
revealed that approximately 15% of plasma and saliva metabolites are also under the circadian 
control [265]. Moreover, other biochemical molecules such as cAMP or NAD
+
 [107, 266, 267] 
as well as several blood metabolites also revealed circadian oscillations that are dependent on an 
intact endogenous clock [268]. Taken together, all discussed results suggest that various so 
called small molecule biomarkers that are under the control of the circadian clock might provide 
a valuable approach for the determination of  human circadian properties in the future, such as 
circadian phase as well as they can serve as a tool to detect human pathologies. 
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1.4.3 In vivo protocols to study human circadian properties 
The measurement of human circadian properties such as free running period, circadian phase or 
circadian amplitude required an implementation of various protocols, which eliminate all 
influencing external factors, the so called "masking factors" and can desynchronize internal 
timing from the external. 
1.4.3.1 Phase Response Curve, Free running period 
One of the principal difficulties in determining the genetic linkage between human behavioral 
disorders and the circadian oscillator is simply measuring the properties of the human circadian 
clocks that determine the behavior. In principle, two different properties can be measured: free-
running period, or the length of one oscillation under constant environmental conditions, and 
phase response / entrainment, the ability of the clock to alter its phase in response to external 
stimuli.  Though formally distinct, these two properties are under normal circumstances inter-
related because the mechanism by which circadian clocks are synchronized by light is non-
parametric [182]. In other words, to entrain to the daily light-dark cycle, the circadian oscillator 
responds differently to light at different phases of its cycle. This differential effect is most easily 
visualized as a Phase Response Curve (PRC), which plots phase shifts of a circadian rhythm as a 
function of the circadian phase that a stimulus, or zietgeber, is given. The characteristic form of 
this curve was first described by DeCoursey thirty years ago in the flying squirrel [269], and can 
be determined by a number of different protocols, as described by Aschoff (1965) [270]. From 
such a curve, one can make deductions about the phase, period and amplitude of the central 
oscillator (Figure 9).   
In human beings, the measurement of either free-running period or phase response is 
extremely expensive and labor-intensive because it demands extensive subject observation under 
controlled laboratory conditions. Nevertheless, reliable estimates have been made by a variety of 
methods for both human period length (24.2-24.4 hours) [271, 272] and the human phase 
response to bright light pulses [273]. By comparing human free-running period length to 
behavioral chronotype, it has also been possible to observe a correlation between these properties 
[274, 275]. Similar observations of morning-type behavior in individuals of short endogenous 
period and evening-type behavior in individuals of long endogenous period have been observed 
previously in other animal systems [276]. 
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Figure 9 Phase response curves in different organisms. A.) The phase response curve to a bright light stimulus in 
humans. Circadian phase was measured as the midpoint of melatonin expression. (Panel reproduced from Khalsa et 
al.,2003 [277].) Positive values reflect phase advances and negative values reflect phase delays. B.) Phase response 
curve to a bright light stimulus in the cockroach Nauphoeta cinerea. Circadian phase was estimated via the timing of 
locomotor activity. (Panel reproduced from Saunders & Thomson, 1977 [278]) 
 PRCs can also be performed with other phase-shifting agents such as drugs or 
temperature. For example, a physiological dose of the hormone melatonin shifts circadian 
rhythms in humans according to a phase-response curve (PRC) that is nearly opposite in phase 
with the PRCs for light exposure: melatonin delays circadian rhythms when administered in the 
morning and advances them when administered in the afternoon or early evening. This difference 
points to multiple different pathways for the entrainment of the human circadian oscillator. More 
practically, the human melatonin PRC also provides critical information for using melatonin to 
treat circadian phase sleep and mood disorders [279]. 
1.4.3.2 Forced Desynchrony 
The first forced desynchrony protocol done in 1938 was performed by Nathaniel Kleitman 
who scheduled subjects to live on artificial daylights in Mammoth Cave in Kentucky. In these 
conditions (e.g. Sleep-wake cycles scheduled into the extremely short 20 - hours or long 28 - 
hours day lengths), the circadian clock cannot entrain and starts to oscillate with its own 
endogenous period [280]. Many scientists followed Kleitman and began to study the circadian 
clock using the same principle. In 1995 Dijk et al., scheduled eight men subjects to a 28-hours 
sleep/wake cycle for 36 days what resulted in sleep episodes at all phases of the endogenous 
circadian cycle [281]. Since this protocol was too elaborate and time consuming, Hiddinga used  
120 hours lasting protocol where the circadian variation in the body temperature was studied 
[282]. 
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1.4.3.3 Constant routine protocol 
Beside the forced desynchromy, constant routine protocols have been used to reveal 
unmasked circadian rhythms. In this protocol, subjects under the time - free conditions are 
usually kept in constant posture, under the dim light and controlled temperature. Moreover they 
are given small isocaloric snacks as well as water each 2 hours during the 40 hours of total sleep 
deprivation [283]. By this way, protocol minimizes masking and can provide reliable estimates 
about the phase or amplitude of the circadian rhythm by measuring core body temperature or 
melatonin [284]. Since these protocols are still demanding  the subjects, several modification 
such as "constant bed rest" protocol [285] and "multiple nap" protocol has been developed [286]. 
These protocols are preventing an accumulation of sleep pressure, so an esteemed masking factor 
is reduced and the circadian rhythm appears very clearly.  
Taken together, there are various possibilities to measure in vivo circadian rhythm in humans. 
Biological markers such as melatonin, core body temperature and cortisol levels have been used 
to determine the phase of the circadian rhythms and if these parameters are measured longer than 
for a one cycle also the endogenous period of the circadian pacemaker could be determined.  
1.4.4 Ex vivo and In vitro studies of human circadian properties  
Since the human in vivo studies are quite expensive and labor demanding, the big challenge 
was to develop methods that would be effective and robust in defining inter-individual 
phenotypic differences but still sufficiently cost-effective to screen a large number of 
individuals. A duplication of the circadian oscillators in the periphery gives an enormous 
advantage to determine the various circadian properties by using tissue explant as well as 
cultured cells. Brown and his colleagues developed a cell culture method which allowed them to 
measure inter-individual variation in circadian rhythms directly in human skin biopsy fibroblasts. 
By introducing a stably integrated lentiviral – luciferase circadian reporter, these authors showed 
large inter-individual differences in the circadian period length. The same reporter system was 
employed in mouse circadian mutants and showed the correlation of the circadian period length 
from mouse fibroblast cultures with behavioral rhythms of these clock mutants [287]. Moreover, 
it was showed that there are individual differences in circadian phase-shifting responses and 
amplitude in fibroblasts from human subjects, and these differences are correlated with their 
diurnal phase preferences [288]. Later on, Pagani et al., also measured circadian period in human 
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primary fibroblasts and for the first time showed the positive correlation between circadian 
period length in physiology and in the gene expression of fibroblasts measured via lentivirally 
delivered circadian reporter [289]. Beside "human in vitro" bioluminescence measurement, 
luciferase reporters found an application in many different circadian studies starting from the 
simplest microorganisms to more complex mammalian species. 
1.4.4.1 Peripheral Oscillators as tools to study human behavior 
Although the central clock of the SCN that specifies behavior is quite difficult to access at a 
molecular level, the circadian clocks that exist in peripheral cells appear to use many of the same 
components. Hence, a major breakthrough for mammalian circadian biologists has been the 
ability to use these cells as proxies -- albeit imperfect ones -- for the clocks of the SCN. The 
period of electrical firing in the SCN has been observed to correlate closely with the period of 
behavior in hamsters [290], so it is possible that there exists a direct parallel between human 
circadian behavior and the molecular properties of human peripheral oscillators. Importantly, 
genetic differences appear to manifest themselves in both peripheral and central oscillators [291, 
292]. Though the clocks of peripheral and central oscillators are similar, they are not identical. In 
mice containing a PER2: luc fusion protein, the free-running period of luciferase expression 
varies by up to three hours in explants from various tissues. Fibroblast period was one of the 
closest to that of the SCN [293]. Nevertheless, genetic differences appear to be exaggerated in 
fibroblast circadian period compared to that of the SCN. For example, the disruption of the Per1 
gene in mice results in a one-hour shortening of the behavioral circadian period in the mouse, but 
a four-hour reduction in the period of fibroblast gene expression [291, 294]. Similar 
exaggerations can be seen for multiple other circadian mutations [291, 294]. Recent research 
suggests that this increased robustness of the central clock versus peripheral clocks is due to 
intercellular coupling of neurons within the SCN. This coupling can occur via both 
neuropeptidergic mechanisms and electrical synapses [295, 296]. Another source of difference 
between SCN and peripheral oscillators may occur because of their use of slightly different 
suites of the circadian clock proteins. For example, the CLOCK protein appears to be essential to 
proper clock function in peripheral oscillators, but dispensable for SCN oscillations and 
circadian behavior in vivo in mice [52]. Similarly, the tau mutation in syrian hamsters that result 
in shortening of the free-running period of behavior also affects the SCN and peripheral tissues 
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differently [297]. Thus, the correlation between the circadian period of behavior or SCN 
electrical firing and the circadian period of peripheral gene expression is not exact. Indeed, 
neither period is an exact value. Different free-running periods of behavior can be measured for 
human beings kept under conditions of forced desynchrony (a day: night cycle so long or short 
that the endogenous circadian clock “free-runs” to reflect its endogenous period rather than 
adjusting to the environment) and under constant conditions [298, 299]. Similarly, the period of 
circadian gene expression in fibroblasts can be altered by changing growth conditions such as 
incubation temperature and media supplements like serum. [276].Importantly, however, these 
properties appear to be trait-like: under similar conditions, they remain constant for a given 
individual.  
Our laboratory has been able to measure the period length of circadian gene expression in 
fibroblasts by using lentiviruses containing a circadian reporter (Figure 10) [287]. Populations of 
cells from different individuals measured in this fashion showed an average period that 
corresponded to what has been measured for human behavior in other studies, but a standard 
deviation that was much broader among different individuals, implying the same sort of 
peripheral cell “exaggerations” to which we have alluded earlier [294]. It is possible that this 
enhancement of individual differences makes fibroblast period a good choice for a quantitative 
trait in genetic mapping studies to find the genes responsible for differences in human circadian 
behavior. Such differences are likely to arise from a variety of different underlying genetic 
causes. A recent study of fibroblast circadian clocks in human morning-types and evening-types 
showed not only period differences among cell cultures from some individuals in the two groups, 
but also differences in the amplitude of circadian gene expression and in the phase-response 
properties of cells from people with opposite behaviors but identical free-running fibroblast 
periods [276]. Specifically, it was possible to determine phase-response curves subject 
fibroblasts to forskolin, a chemical stimulus that activates adenyl cyclase via a mechanism 
reminiscent of the actions of the photopigment melanopsin upon the circadian oscillator. These 
curves clearly show that the phase of circadian gene expression can be altered by factors other 
than endogenous period length. Indeed, it has been shown previously that the reduction of 
circadian amplitude in mice containing a mutant CLOCK allele can enhance phase-shifting by 
light in these mice [300]. Results using human peripheral fibroblasts imply that human circadian 
behavior may be determined by a rich mixture of causes including the period length, amplitude, 
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and phase-resetting properties of the endogenous circadian oscillator, and that these properties 
can be studied in peripheral fibroblasts. 
 It is possible that fibroblasts or other peripheral cell types might be used not only in the 
mapping of the genetic variations responsible for differences in human daily behavior, but also 
for the diagnosis of underlying causes of human circadian disorders in some individuals. For 
example, Vanselow and colleagues introduced a mutation in PER2 believed to be responsible for 
human Familial Advanced-Phase Sleep Syndrome (FASPS) into fibroblasts, and were able to 
recapitulate the phase-advance in the behavior of FASPS patients as an advanced phase of clock 
gene transcription in synchronized FASPS fibroblasts. Subsequent molecular analyses allowed 
them to show effects of this mutation upon phosphorylation at multiple sites in the PER2 protein, 
and to further demonstrate that these modifications affected both PER2 protein stability and 
nuclear localization [301].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 Measurement of the circadian period length in human skin fibroblasts. Primary skin fibroblasts are 
derived from the simple punch biopsy. Transduction of such primary fibroblasts with the circadian lentiviral reporter 
allows for the direct real-time measurement of human circadian period in primary cells. 
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1.5 Circadian Rhythm in Physiology and Human behavior 
The circadian system has an important influence on human physiology and behavior. Indeed, 
considering the extent of circadian regulation, it is perhaps not surprising that disruption of 
biological clocks has a negative effect. One of the most obvious manifestations is jetlag, 
misadjustment of circadian phase due to travel. Links have also been established between 
circadian irregularities and psychiatric disorders, including various forms of depression and 
mania. Prolonged disruption of circadian rhythms is believed to have significant adverse health 
consequences on peripheral organs outside the brain as well, particularly in the development or 
exacerbation of cardiovascular disease and cancer [302, 303]. Conversely, chronopharmacology 
– the timing of treatment in coordination with the body clock – may significantly increase 
efficacy of various therapies, and reduce drug toxicity or adverse reactions [304]. 
1.5.1 Human chronotype 
Even under normal conditions, the complex nature of circadian behavior is evident from the 
fact that phasing of the cycle during the day varies widely for individuals, resulting in extremes 
colloquially called larks and owls. Morningness-eveningness, or “chronotype”, is an individual 
characteristic that refers mostly to the phase of sleep timing [305]. Because of this effect of the 
circadian system upon sleep, most circadian rhythm disorders (discussed in the chapter 1.5.3.) 
are therefore classified as sleep disorders. Nevertheless, circadian sleep disorders and true sleep 
disorders are likely to be mechanistically unrelated, and therefore it is both scientifically and 
clinically relevant to distinguish between them. 
Sleep is an active and as yet poorly understood process during which many physiological and 
cerebral events occur. Indeed, even sleep itself is actually an ultradian process represented by the 
alternation of different electrophysiologically defined sleep states (Box 1). In general, the daily 
sleep-wake cycle is under circadian control, although the urge to sleep appears to be controlled 
by brain functions that are independent of the circadian system [306]. This independence led 
Borbely and colleagues to propose a model for the regulation of sleep that includes a homeostatic 
process that accumulates during wakefulness and diminishes during sleep, as well as an 
independent circadian drive [307]. Each of these processes can operate independently; thus, sleep 
duration is not correlated with sleep phase in humans [308].  
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1.5.2 Clock genes and sleep  
A number of studies suggest that the clock genes contribute to the control of sleep 
homeostasis [309]. Starting with the positive elements of molecular circadian clockwork, 
homozygous Bmal1
-/-
 mice exhibiting arrhythmic circadian phenotype [310] showed longer 
REM and NREM periods under LD and DD condition and delta power during the light phase 
seemed to be constantly elevated. On the other hand, under the condition of sleep deprivation, 
Bmal1 mutants revealed an attenuated homeostatic response [311]. Besides Bmal1, a second 
positive element of transcriptional/translational loops of the circadian machinery, namely a Clock 
gene, has also been found to be implicated in sleep homeostasis. Clock mutation prolonging 
circadian period, caused around 2h reduction of a total time of sleep under the light dark 
conditions and had 51% smaller increases in REM sleep during 24h recovery than wild-type 
mice [312]. Furthermore, studies focused on a functional paralog of Clock gene, Npas2, 
demonstrated that Npas2 deficient mice showed approximately 25% decrease in NREM and 
REM sleep [313] and under sleep deprivation these mutants exhibit a smaller compensatory 
increase in NREM sleep and in delta activity [314].  
In addition to the positive players, the impact of negative loop elements representing Cry1/2 
and Per1/2 has been also the focus of several studies directed on sleep homeostasis. While single 
Cry1 and Cry2 knockouts did not show any significant effect on sleep homeostasis, both NREM 
and EEG delta power were increased during the light phase in Cry 1/2 
-/-
 mice. Moreover, these 
mice showed attenuated responses to prolonged wakefulness [315]. Similarly, single Per gene 
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mutations exhibited an altered 24h distribution of sleep but normal responses to sleep deprivation 
[316, 317]. However, arrhythmic Per1/2 double knockout animals showed decreased NREM and 
REM sleep periods during the light phase and slightly increased delta power after sleep 
deprivation [318]. Although many laboratories investigated the role of the core clock genes in 
sleep homeostasis, Dbp knockout mice were used as first animal model to challenge this task. 
Dbp – deficient mice showed reduced REM sleep during the light phase, likewise a decreased 
delta power activity in the dark. In addition, under the sleep restriction protocol, significantly 
attenuated REM responses were observed [319].  
The last but not least, a fascinating study was done recently by He and coworkers. They 
identified a miss-sense mutation in the human DEC2 gene responsible for the sleep length in 
humans. When this mutation was reproduced in mice, the decrease of the total sleep including 
NREM and REM phases was obtained without effect on the circadian period [320]. 
To conclude, clock genes do not only influence sleep architecture, but they might also be 
implicated in sleep function of living organisms. In many cases, clock gene mutations and sleep 
disorders share the same phenotypes and a better understanding of the underlying mechanisms 
can help to improve the therapeutic strategies of many associated disorders.  
  
  Chapter 1: General Introduction 
37 
 
1.5.3 Circadian rhythms sleep disorders and their treatment 
The so-called “circadian rhythm sleep disorders” can result from alterations in the properties 
of the endogenous circadian clock (for example delayed sleep phase and advanced sleep phase) 
or changes in the physical environment in relation to the endogenous clock (shift work disorders 
and jet leg). In the former class, which is unrelated to human choice, genetic variations in 
circadian genes have been found to associate with these disorders. Table 1 shows a list of 
polymorphisms that have been linked to known clock genes. 
 
 
Table 1 Reproduced from Cuninkova & Brown, 2008 [186] 
1.5.3.1 Familial Advanced Sleep Phase Syndrome 
One of the most-studied syndromes is the Familial Advanced Sleep Phase Syndrome 
(FASPS). Individuals with this syndrome can wake up and go to sleep hours earlier than normal. 
This phase change is believed to be related to a change in the endogenous free-running period of 
the human circadian oscillator. Normally around 24 hours, it has been measured to be only 20 
hours in an individual from an extensively-studied FASPS lineage [330]. In this lineage, the 
Disease Location of SNP Affected genes 
Familial advanced sleep phase syndrome  
(FASPS)
[321]
 
662 S/G 
44 T/A 
Per2 
Ck1δ 
Extreme diurnal preference
[322] T2434C Per1 
Bipolar disorder (BD)
[323, 324]
 11p15 
1p36.23 
12q12-q13 
Bmal 1 
Per3 
TIMELESS 
Delayed sleep phase syndrome (DSPS) 
[325]
 647 V/G 
S408N 
Per3 
CK1ε 
Seasonal affective disorder (SAD)
[326]
 471 L/S NPAS2 
Non-Hodgkin’s syndrome (NHS) [327] 394 A/T NPAS2 
Schizophrenia
[328]
 31111 T/C Clock 
Winter depression
[329]
 SNP 10870 
SNP rs2290035 
Per2 
Arnt1 
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source of the circadian change has been mapped to a change from serine to glycine at residue 
662 of the Per2 gene. This mutation abolishes one of the phosphorylation target sites for CK1ε. 
In vitro experiments confirm that the mutation reduces the ability of CK1ε to phosphorylate 
PER2 protein [331]. A second independent lineage confirmed the importance of casein kinase-
mediated phosphorylation to human chronotype. This time, the corresponding mutation was 
mapped to a missense (T44A) change in the CK1locus that results in a lower kinase activity in 
vitro and shorter periods when introduced into mice in vivo [321].  
Treatment: Chronotherapy, timed light exposure and pharmacotherapy with melatonin 
include the therapeutic approaches for Advanced Sleep Phase Syndrome. Delay of the circadian 
rhythms timing by bright light therapy improved sleep and daytime performance in older 
individuals suffering by ASPS [332, 333]. In addition to light treatment, different administration 
strategies for melatonin medication were a topic of broad investigation. Based on the phase 
response curve to melatonin, early morning application of melatonin would fall in the curve’s 
advance portion and therefore cause advance of the sleep-wake cycle timing, however many 
questions have been raised considering the safety about taking melatonin – a sleep promoting 
compound, in the morning [334, 335].  
1.5.3.2 Delayed Sleep Phase Syndrome (DSPS) 
Not surprisingly at all, not only extreme early phase but also extreme late phase has been 
correlated with genetic alterations in clock genes. For example, a genetic association study of 
105 individuals has linked a length polymorphism in the Per3 gene to Delayed Sleep Phase 
Syndrome [336]. Other studies have seen various degrees of association not only between DSPS 
and this Per3 allele [337], but also other Per3 alleles [338] and a CLOCK allele [339], though not 
all studies have drawn the same conclusions [340]. In addition, an allele of CKIε has been found 
to be anticorrelated with DSPS, implying that it may play a protective role against this syndrome. 
Although the basis of altered chronotype in this suite of mutations is unknown, many of them are 
presumed to alter endogenous period length in fashions similar to FASPS, principally because 
there is an association between free-running period length and entrained behavioral phase in 
humans and in other animals [341]. Moreover, genetic mapping studies in inbred strains of 
laboratory mice suggest that many different loci other than those of known clock genes might 
influence free-running behavioral period [342]. 
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Treatment: Effective treatment for circadian rhythms disorders requires a combined 
approach based upon re-alignment of the circadian clock with desired sleep and wake schedule. 
Correct sleep hygiene, avoidance of bright light in the evening or increasing light exposure in the 
morning could be basic steps in the treatment of DSPS. For instance, bright light of 2500lux for 
2h in the morning has shown to successfully induce phase advance of the circadian rhythm of 
core body temperature in DSPS patients [343, 344]. Beside the light therapy, pharmacological 
administration of melatonin has shown promising effects on DSPS [345]. 
1.5.3.3 Non-24-h sleep-wake syndrome (FRD) 
Non-24-h sleep-wake syndrome (free-running disorder, FRD) occurs when endogenous 
circadian pacemaker is not able to entrain to a 24h period and its start to "free-run" usually 
longer than 24h. Most individuals with this syndrome are totally blind and the failure to 
synchronize circadian rhythms is coupled to the lack of photic input to the circadian pacemaker 
[346, 347]. This incapability to entrain causes a chronic pattern of a disease with 1-2h daily delay 
in sleep onset and wake time. Beside the studies in blind individuals, few reports showed the 
presence of non-entrained type of sleep disorder in sighted individuals [348], however the 
etiology of this disorder is unknown. 
Treatment: Both behavioral and pharmacological options are available for the treatment of 
free-running disorder, depending on whether the patient is blind or sighted. For blind people 
timed exposure to non-photic entraining agents and melatonin administration are the primary 
therapies. An appropriate melatonin timing and dosage are the factors limiting the success of the 
treatment and several studies showed that melatonin should be administrated a few hours before 
the predicted endogenous melatonin onset (DMLO). Patients after this scheduled therapy showed 
less wake after sleep onset and better sleep efficiency, however, discontinuation of this treatment 
causes the recurrence of the free-running rhythm [349-351]. Due to the rareness of the FRD in 
sighted individuals, most published reports represent case reports. The basic approach of the 
treatment includes exposure to bright light during the day as well as maintaining a regular sleep, 
wake and work scheduled as well as exogenous melatonin application [348]. 
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1.5.3.4 Irregular sleep wake rhythm (ISWR) 
Very poor sleep consolidation where sleep and wake periods are distributed in three or more 
short bouts throughout the 24h is the main feature of Irregular sleep-wake disorder (ISWR). The 
disrupted entrainment pathway to the SCN results in a decreased exposure to environmental 
synchronizing agents. Although the prevalence of this disorder is unknown, the individuals 
suffering by this disease also exhibit neurological disorders such as mental retardation, brain 
injury or dementia [352, 353]. 
Treatment: The final targets in the treatment of ISWR are to increase the duration of 
consolidated sleep periods during the night and improve daytime function. A multi-therapeutic 
approach coupling bright light exposure and behavioral modifications seem to be effective for 
young and older patients with ISWR [354-356]. 
1.5.3.5 Jet leg  
Temporary misalignment among the endogenous circadian sleep-wake rhythm and the 
external environment due to a change in time zones characterize a transient Jet leg disorder. 
Usual Jet Leg symptoms include insomnia, daytime sleepiness as well as decreased performance 
[357] and few studies showed a rising severity of these symptoms in elderly individuals[358, 
359]. In addition to in vivo studies, the disruptive effects of jet leg have been also demonstrated 
at the molecular level of the SCN clock genes as well as in the clock machinery of peripheral 
tissues [360, 361]. Beside these studies, researches also looked at the pathological consequences 
of Jet Leg and showed that the disruption of the circadian clock coordination might have a 
pivotal role in the malignant progression[362].  
Treatment: Treatments for jet lag are mainly directed on adjustment of the endogenous 
circadian cock to the destination time zone. Non-pharmacological approaches as proper sleep 
hygiene, adjusting the sleep schedule prior to travels or timed light exposure have been shown to 
help to decrease symptoms and accelerate circadian adjustment [363, 364]. 
1.5.3.6 Shift work disorder (SWD) 
Night work and shift work has been associated with negative effects such as shortened and 
disturbed sleep, decreased alertness cognitive decline and risks to cardiovascular and 
gastrointestinal health [365, 366]. Moreover, a number of health problems like metabolic 
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syndrome, ulcer disease, cancer pathologies and mental and physical fatigue have been reported 
[367-369].   
Treatment: Similar to jet lag, appropriately timed light therapy and maintained entrainment 
to the shift schedule reduces the symptoms of shift work disorder. Several light therapy directed 
studies used intensities of the light between 1,200 and 10,000 lux for a period of 3 to 6 hours 
during night shifts. In addition to the circadian phase re-setting effects of the light, melatonin 
treatment of SWD has been a focus of several studies, however several mixed conclusions have 
been raised [370-373]. 
1.5.4 Circadian Mood disorders  
One striking feature of circadian rhythm sleep disorders is that they are often associated with 
other mood disorders. Indeed, a part of this association is by definition: an established clinical 
symptom of diseases like major depressive disorder (MDD) and bipolar disorder (BD) is 
abnormal sleep/wake, appetite and social rhythms [374, 375], which are also the hallmarks of 
circadian rhythm disorders. Nevertheless, an increasing body of evidence suggests that there 
exists a compelling genetic basis for this correlation. In bipolar patients, a single nucleotide 
polymorphism in the 3’flanking region of the CLOCK gene associates with a higher recurrence 
rate of bipolar episodes [376]. This mutation is specific to bipolar depression: a similar 
association was not found in the Major Depressive Disorder (MDD, or unipolar depression) 
[377]. Another mutation, this time linked to the onset of illness in Bipolar Disorder, has been 
localized to the glycogen synthase kinase 3β promoter [378]. This enzyme is the target of 
lithium, a common treatment for BD, and can phosphorylate the clock component REV ERBα 
[379]. It is likely that multiple other genetic associations remain to be found between the various 
forms of depression and clock genes. A pilot study of circadian genes and their linkage to 
Bipolar Disorder 1 unearthed Bmal1, Timeless, and Period3 as possible candidates [380]. 
Schizophrenia is also accompanied by severe sleep-wake disturbances, and has been 
associated with clock gene polymorphisms in this and other preliminary studies [381]. Finally, 
dementia has also been linked with circadian dysfunction in Huntington’s Disease, though in this 
case the dysfunction is believed to be a neurological consequence of HD pathology upon the 
SCN, rather than a genetic linkage between dementia and circadian rhythm disorders [382]. 
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Treatment: Light therapy, melatonin administration as well as pharmacological strategies by 
using antidepressant drugs and mood stabilizers are the possible choices for therapy. However 
better understanding the principles and the molecular basis of circadian rhythm disorders are 
necessary steps to correctly phenotype the disease and accurately set up the medical treatment.  
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1.6 Interplay of the circadian signaling pathway with other 
major signal transduction events 
Many organisms possess internal highly organized systems that allow them to orchestrate 
their physiology and behavior to better adapt to our constantly changing environment. At the 
most basic level, complex mechanisms exist side by side to help cells to deal with environmental 
adaptation and anticipation. When change occurs in a predictable way such as cyclic changes of 
day and night, an internal circadian timing system anticipates these changes and regulate daily 
rhythms of target genes expression necessary to respond to these events [383]. On the other 
hand, unanticipated changes (e.g. exposure to the damaging UV light) trigger the activation of 
non-circadian cellular responses such as conserved MAPKinase and other major signaling 
pathways at any time of the day [384, 385] (Figure 11).  
 
Figure 11 Complex circuitry of signal transduction pathways. The genes highlighted in red have been found to be 
implicated in the epigenetic reprograming of the signaling circuit in cancer cells. Reproduced from Hanahan et al., 
2000 [386].  
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1.6.1 Circadian clock and Mitogen-activated protein kinase pathways 
MAPK pathways mediate information routes in which cells can transduce environmental 
signals in the inside of the cells to conduct appropriate responses [387]. Three consecutively 
activated protein kinases - MAPKKK, MAPKK and MAPK compose the module of mitogen-
activated protein kinase signaling. These components are often used in multiple pathways 
resulting in gene expression, cell division, proliferation and cell survival [388, 389]. Four distinct 
MAPK family subgroups have been identified in mammals: 1) Extracellular signal-regulated 
kinases (ERK), 2) Stress-activated MAPKs (SAPKs) and ERK/big MAP kinase, 3) c-Jun N-
terminal kinase (JNKs) and 4) the p38 family of MAPKs [390]. Although circadian and MAPK 
response mechanisms have been thought to be independent, increasing evidence indicates that 
they share some remarkable linkages [391]. The association of MAPK and the circadian clock 
has been shown in several studies in insects, birds or mammals [17, 392, 393]. For instance, 
rhythms in the phosphorylated form of ERK were obtained in the mouse SCN under constant 
environmental conditions with the peak expression occurring during the day [17]. Moreover, 
daily rhythms in phospho -38 and JNK of low amplitude have been reported [117, 393]. 
1.6.2 Circadian clock and immune signaling pathways 
Multiple mechanisms also conduct efficient and rapid inflammatory responses including feed-
forward and amplification loops. About a decade ago, NF-κB (nuclear factor 'kappa-light-chain-
enhancer' of activated B-cells), JNK (c-Jun N terminal kinase), p38 MAP kinase, STAT (signal 
transducers and activators of transcription) and P13K (phosphatidylinositol-3-kinase) pathways 
have been identified as interconnected, cross talking signaling cascades implicated in immune 
activity. Circadian signaling pathways as one of the cross talking pathways is also linked to 
immune responses and time of day-dependent variation of the immune system parameters such 
as lymphocyte proliferation, activity of natural killer cells, humoral immune responses likewise 
levels of cytokine and serum cortisol has been reported [394-398]. Moreover, it was shown that 
circadian signaling pathway modulates inflammatory gene expression. Keller et al showed that 
approximately 8% of the macrophage transcriptome is under circadian control. This circadian 
transcriptional regulation was found at four levels of LPS-induced immune response: 1) Factors 
regulating LPS binging to TLR4 (Toll-like receptor 4), 2) components of MAPK pathway (ERK) 
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and cytokine protein processing (MEK1), 3) NF-κB and AP-1 (activating protein-1) transcription 
factors involved in pro-inflammatory cytokine transcription and 4) components controlling 
cytokine mRNA stability and localization [399]. Broadening our knowledge in circadian immune 
regulation will have a strong impact on understanding of pathological inflammatory responses 
and certainly might help to improve the development of anti-inflammatory compounds. 
1.6.3 Circadian clock, cell cycle and cancer 
In this thesis, I developed a novel cell – based system that allows us to study  human inter 
individual variation in the circadian clock properties as well as in other vital signaling pathways 
(Chapter 3.2) and their relationship to disease, especially cancer (Chapter 3.3). Therefore, the 
current chapter 1.6.3 devoted to the circadian clock, cell cycle and cancer is followed by the 
discussion about signaling pathways implicated in the cancer pathogenesis.   
Several molecular and conceptual similarities are shared by the circadian clock and the cell 
cycle. (General scheme and description of the cell cycle is in the Box 2) Clock and the cell cycle, 
periodically repeated within 24 h cycles are intrinsic to most cells and interlocked autoregulatory 
loops rely on sequential phases of transcription, translation, post-translational modification and 
degradation [400]. The circadian clockwork regulates the cell cycle related gene expression and 
can oscillate accurately and independently [401]. At the molecular level, circadian control of key 
cell cycle gene regulators, such as Wee1 (GM2/M transition), c-Myc (G0/G1 transition) and 
Cyclin D1 (CCND1, G1/S transition) has been reported in mammals. 
Wee1 is a nuclear kinase belonging to the Ser/Thr family of protein kinases that inactivate the 
cell division cycle 2 (CDC2) by phosphorylation at T15 to control the G2/M transition. The 
binding of CLOCK/BMAL1 to the E-boxes of Wee1 promoter region activates a robust circadian 
oscillation of this gene in the liver as well as a deregulated expression of Wee1 was demonstrated 
in Cry1
-/-
 Cry2
-/-
 arrhythmic mice [401, 402]. Under normal conditions, CLOCK-BMAL1 
heterodimers bind to the E-boxes of the promoter region to inhibit the transcription of c-Myc 
gene. Except the cell proliferation, c-Myc transcription has been found to play a crucial role in 
apoptosis. Oncogenic transformation mediated by c-Myc must overcome the proapoptotic 
activity where modulation of p53 regulated apoptosis play an important role [403]. 
Overexpression of this gene can induce DNA damage and compromise p53 function, most 
possibly via a mechanism mediated by reactive oxygen species (ROS) [404, 405]. The last key 
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gene in the cell cycle which is under the circadian clock control is Cyclin D1. Overexpression 
studies of this gene showed its implication in tumorigenesis as well as in breast cancer pathology 
with poor diagnosis [406].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Taken together, the normal regulation of signal transduction events among various cell types 
is evidently a crucial checkpoint of many functions of living organisms. But what happens when 
the functions of these signal transduction pathways, including circadian signaling become altered 
or deregulated? Accumulating epidemiological and genetic evidence indicate that disruption of 
specialized pathways might be directly linked to the cancer pathogenesis (Figure 12). For 
instance, an altered circadian signaling pathway controlling the cell proliferation can result in a 
transformation and cancer [407, 408]. Modified light schedules disrupt the circadian timing 
mechanism in rodents resulting in a significant increase of the frequency of tumors [409]. As 
well as transgenic mice with defective circadian rhythms exhibited an accelerated malignant 
growth [410], also mice deficient in mPer1 or mPer2 clock component have an increased 
incidence of tumors, where the tumors have lower hPer1 and/or hPer2 levels [411-413]. Several 
human studies also contributed to support an association between defects in circadian rhythms 
and cancer development. For instance, the expression of all three Per genes has been found 
deregulated in breast cancer cells and mutations in NPAS2 have been linked with an increased 
risk of breast cancer and non – Hodgkin’s lymphoma [411, 414]  
  Chapter 1: General Introduction 
47 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 The most common signaling pathways altered in the cancer. Adapted from Dreesen et al., 2007 [415].  
1.6.3.1 JAK/STAT signaling pathway and cancer 
Apart from the direct link among the circadian signaling dysfunction and tumorigenesis, many 
other conserved signal transduction pathways regulating cell growth and differentiation are 
almost invariably altered in cancer. For example, the JAK/STAT signaling pathway contributes 
to tumorigenesis. These receptor-associated Janus Kinases (JAKS) phosphorylate tyrosine 
residues of the ligand bound receptors. Phosphorylated interacting Signal Transducers and 
Activators of Transcription (STATs) form homodimers that shuttle to the nucleus and regulate 
the transcription of a wide variety of genes[416]. The JAK/STAT pathway has an important role 
in mediating apoptosis, cell differentiation and proliferation in a response to growth factors and 
cytokines. Mutations as well as the amplification of various compounds of this pathway such as 
HER2 (Human Epidermal Growth Factor Receptor 2), epidermal growth factor-receptor have 
been found in mammary, breast, brain and stomach tumors [417-419]. In addition, constitutively 
activated STAT3 is a key marker of lung, breast, head/neck and hematologic tumors [420].  
1.6.3.2 Notch signaling pathway and cancer 
One of the hematologic tumors represents T-cell acute lymphoblastic leukemia that is caused 
by unrestrained proliferation of immature T-cells. Mutation in the Notch signaling pathway has 
been associated with almost 60% of human T- cell acute lymphoblastic leukemia. Beside human 
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lymphoma, recent studies showed an implication of abnormal Notch signaling in breast tumors, 
melanoma, medulloblastoma and ovarian cancer. The possible mechanism of cancer initiation 
via Notch signaling includes activation of its downstream target c-myc whose deregulation has 
been found in a wide range of cancers [421-423].  
1.6.3.3 MAPK signaling pathway and cancer 
The third pathway found to be deregulated in a broad spectrum of human tumors is the SOS  – 
Ras – Raf – MAPK signaling cascade. The RAS-Mitogen activated Protein kinase signaling 
plays a crucial part in cell adhesion, proliferation, migration and survival [424]. RAS, a small 
membrane bound GTPase is activated by Son Of Sevenless (SOS) - a guanine exchange factor. 
Upon receptor activation, activated GTP-bound RAS activate RAF kinase that consequently 
induces mitogen-activated protein kinases (MAPK/ERK). ERK1/2 translocate to the nucleus 
where they induce the Jun/Fos transcription factors. Many mutations of this transduction cascade 
occur in RAS and RAF resulting in constitutive activation of this pathway. While colon and 
pancreatic cancer’s hyper-proliferative states are linked to RAS mutations, two thirds of all 
melanoma are the result of mutations in RAF [424, 425].  
1.6.3.4 PI3K/AKT signaling pathway and cancer 
Similarly to MAPK/ERK pathway, the phosphatidylinositol 3-kinase / protein kinase B 
(PI3K/AKT) pathway responds to a variety of extra- and intracellular stimuli via harmonized 
action of hormonal receptors, transmembrane tyrosine kinase-linked receptors and intracellular 
factors that regulate cellular proliferation, cell death and cytoskeletal rearrangements [426, 427]. 
The basic elements of this biochemical network include growth factors activated receptor 
tyrosine kinases (RTKs), which then induce two key signal transduction components: the small 
GTPse Ras and the lipid kinase PI3K. Alterations in the PI3K pathway are common in cancer 
and play a role in neoplastic transformation [386]. Mutational activation of PI3K has been found 
in many different cancers such as breast, bowel and ovarian cancers, head and neck and cervical 
squamous cancers, gastric and lung cancers as well as in glioblastoma multiform and 
medulloblastomas [428-431]. Most of these tumors harbor activating mutations on the master 
regulators of this pathways (K-ras, H-ras, N-ras, the p110  PI(3)K subunit and RTKs) or 
inactivating mutations in negative regulators of these proteins (phosphatase and tensin 
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homologue (PTEN) and neurofibromin 1 (NF1)). In addition, recent genomic studies revealed an 
existing mutation in several downstream components of PI3K/AKT  pathway[432-434].  
1.6.3.5 NF-κB signaling pathway and cancer 
The nuclear factor-kappa-B signaling pathway regulates many genes involved in cell 
proliferation, stress response, innate immunity and inflammation [435, 436] and has been found 
significantly altered in human cancers. NF-κB transcription factor family consists of p50/p105, 
p52/p100, c-Rel, RelA and RelB controlling the transcriptional expression of hundreds of target 
genes. c-Rel, RelA, RelB, p50 and p52 form homo- and heterodimers and subsequently shuttle to 
the nucleus where they bind DNA regulatory κB sites. Inactivated NF-κB dimers are located in 
the cytoplasm. A variety of extracellular stimuli such as TNF-α, interleukin-1, growth factors, 
oxidative stress etc. activate NF-κB signaling via phosphorylation and consequent ubiquitination 
of I-κB by the E3 ubiquitin ligase complex. The liberated NF-κB dimers translocate to the 
nucleus and activate transcription of target genes [436]. A variety of cancers such as Hodgkin’s 
lymphoma, B-cells and natural killer T-cells lymphomas showed  mutations and miss-regulation 
of NF-κB [437, 438].  
1.6.3.6 Wnt signaling pathway 
Among the evolutionary most conserved signaling pathways, Wnt pathway is involved in a 
variety of cellular, embryological and physiological activities from C. elegans to humans. From 
three central branches of this pathway - Ca
2+
, the planar polarity and the canonical branch, the 
last canonical branch has been implicated in tumorigenesis. The Wnt pathway consists more than 
30 extracellular Wnt ligands [439]. These ligands bind to a receptor and activate a protein called 
Dishelved (Dsh) which in turn inhibits the Glycogen-Activated Kinase-3 (GSK-3) that targets β-
catenin-Adenomatous Polyposis Coli (APC) complex for ubiquitination and proteolytic 
degradation. Upon Wnt signaling, stabilized β-catenin translocate into the nucleus where it 
interacts with DNA-binding proteins of the T-cell Factor / Lymphocyte Enhancer binding Factor 
(Tcf/Lef) family. Tcf/Lef transcriptionally activates proliferation stimulating genes such as c-
myc and cyclin D1 [440]. Mutations in APC or β-catenin are frequently found in small intestinal 
adenocarcinomas and gastric polyps  as well as in chronic and acute myeloid leukemia [441].  
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1.6.3.7 TGF-β signaling pathway 
Another evolutionary conserved and most complicated signaling pathway of metazoans, 
discovered as an antiproliferative signal in tumors is the Transforming Growth Factor-β (TGF-β) 
pathway. As Wnt, the TGF-β pathway has also three main branches: the SMAD1/5/8, the 
SMAD2/3 and the TAB/TAK branch. Down regulation or mutation of TGF-β receptors, 
inactivation of SMAD4 or p15
INK4B
 has been found in pancreatic ductal adenocarcinomas [442] 
as well as Bone Morphogenic Protein (BMP) is significantly increased in lung carcinomas [443]. 
1.6.4 Circadian clock, metabolism and Cancer 
As mention previously, cancer is a disease in which various genetic alterations result in 
uncontrolled cell proliferation that is outside the context of normal tissue development. In a 
majority of tumor types, an accelerated rate of glucose uptake is observed and therefore serves as 
a reasonable initial point for understanding differential metabolism in tumors. Several studies 
also revealed a close relationship between circadian rhythms and metabolism. Genes implicated 
in the metabolic pathways such as glucose-6-phosphatase and phosphoenolpyruvate 
carboxykinase 2 (PCK2, gluconeogenesis), pyruvate kinases (glycolysis), glucokinase (glycogen 
synthesis), glucose transporter 2 (glucose transport) and HMG-CoA (3-hydroxy-3-
methylglutaryl-coenzyme A, cholesterol metabolism) exhibit a circadian expression pattern. In 
addition, studies done in animals lacking core clock genes such as Clock and Bmal1 revealed the 
presence of metabolic defects such as metabolic syndrome or abolished oscillation in plasma 
glucose and triglycerides [444, 445]. Another example of the circadian regulation of the cellular 
metabolism by CLOCK was obtained in the case of liver glucokinase whose mRNA levels 
oscillate in the liver of wild type, but not in Clock/Clock mutant liver [446]. Moreover, it is 
assumed that perturbation in the expression of CLOCK and SIRT1 circadian regulators might be 
connected with increased cell proliferation in cancers as well as in defects of various metabolic 
pathways [446, 447]. Circadian clock genes are in general regulated via epigenetic mechanisms 
of histone phosphorylation, methylation and acetylation. SIRT1, NAD
+
- dependent deacetylase 
sirtuin-1, plays an important role in metabolism and survival by regulating gene expression via 
histone modification and deacetylation of several proteins. On one hand, SIRT1 has been 
associated with tumor growth, where deacetylation of p53 leads to its inhibition resulting in 
reduced apoptosis after genotoxic stress [448]. In addition, SIRT1 can also promote cancer cell 
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survival by deacetylating the DNA repair protein KU70 that block mitochondrial translocation of 
BAX and prevent apoptosis [449]. On the other hand, SIRT1 can also act as a tumor suppressor, 
an effect demonstrated by the impaired DNA damage response in SIRT1 deficient mice [450]. 
Moreover, ectopic induction of SITR1 suppresses intestinal tumorigenesis and colon cancer in 
vivo [451].  
As mentioned above, SIRT1 is a NAD
+
- dependent deacetylase. Circadian oscillation of SIRT 
activity suggested that cellular NAD
+
 levels might also oscillate. Indeed, it was shown that 
NAD
+
 levels oscillate and are controlled by the circadian clock. Moreover, beside NAD
+
 levels 
also nicotinamide phosphoribosyltransferase (NAMPT) exhibits circadian oscillations that are 
regulated by the core clockwork in mice. [266, 267] Given control of SIRT1 deacetylase activity 
by NAD
+
, circadian regulation of NAD+ seems to be crucial mechanism controlling circadian 
rhythms, metabolism and cell growth. Interestingly, altered levels of NAMPT have been also 
linked to the metabolic disorders and cancer [452].  
Although the direct link of defects in a clock-mediated metabolic pathway and cancer still 
remains to be disclosed, circadian control of NAD
+
 levels suggests an intriguing route. Further 
studies are needed to uncover the precise function of oscillating SIRT1 and NAD
+
 in the 
regulation of metabolism and tumorigenesis. Determination of this missing part could amplify 
our knowledge of cancer growth and metabolism as well as it can open the new strategies for 
chronotherapy.  
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1.6.5 The nature and extent of inter-individual variation in gene 
expression 
Over the last few decades, exploration of the genetic basis of inter-individual differences in 
human physiology and behavior has become a ‘hotspot’ topic, as research teams from different 
fields have initiated a hunt for genes and signaling pathways linked to the complex traits that 
relate genome to physiology and behavior. In general, the regulation of gene expression through 
signal transduction cascades not only plays a prominent role in natural inter-individual variation, 
but can also affect many aspects of disease susceptibilities and their medical treatment. 
Fascinatingly, only a handful of major signaling cascades are responsible for this very dynamic 
regulatory process - the biochemical interactions conducting cellular signaling are universally 
conserved and very often reused throughout different cell types, so that the same transduction 
cascade can regulate a variety of biological processes [453, 454].  
At a very basic level, the vast array of genetically-determined differences in human behavior 
and physiology are caused by changes in DNA sequence – so-called “polymorphisms” by which 
individuals or populations vary. Recent sequencing of multiple human genomes has revealed 
notably large differences. In fact, it was estimated that about 0.5% variability exists between two 
haploid genomes [455]. Some of these polymorphisms occur in structural proteins that lead 
directly to morphological differences in a particular tissue, e.g. in hair color. More globally, 
however, there is equally great heterogeneity in many signaling pathway components expressed 
in all tissues. Many such polymorphisms appear in known regulatory and transcribed regions of 
genes, allowing one to guess at potential functional consequences. Even more occur in genomic 
domains with yet unknown function. As a whole, these genetic differences not only elicit 
differences in physiology and behavior, but also inter-individual variation in treatment efficacy 
and drug toxicity among different patients for many diseases [456, 457].  
To identify specific polymorphisms responsible for particular differences, geneticists have 
used high-density quantitative trait mapping. Starting from a large population of genotyped 
subjects (typically more than a thousand), the occurrence of a particular trait is quantified in each 
subject, and then probabilistically related to each polymorphism in the genome.  Invention of this 
technique has revealed hundreds of chromosomal regions possessing genes implicated in several 
diseases such as Alzheimer’s disease [458], diabetes [459-462], obesity [463], asthma [464] or 
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cancers [465-467]. Thus, genetic mapping offers a powerful approach to discover genes and 
cellular pathways affecting disease traits and responses to drugs and environmental exposures. 
1.6.6 Cell – based approaches to study gene expression variation and 
human inter-individual differences in a drug response 
Unlike the various model organisms that can be repeatedly exposed to drugs or toxins in the 
laboratory and subsequently phenotyped, the determination of either natural or diseased human 
inter – individual phenotypes represent substantial limits. Beside  ethical and safety issues, there 
is usually an inability to control different in vivo environmental factors as well as there are 
difficulties to manipulate the in vivo system to evaluate biological changes. Due to these 
restrictions, in vitro cell-based approaches became a rational solution to overcome  this problem. 
Various human cell lines have been already used for human disease modeling as well as in 
preclinical drug development to determine drug-induced cell growth inhibition or cell death or to 
identify interactions between the target compounds and drug metabolizing signaling transporter 
proteins or enzymes.  
In recent years, there has been a rising utilization of lymphoblastoid cell lines (LCLs) as an 
accessible and renewable resource for functional genomic studies in humans. Although LCLs 
were originally established as  DNA sources [468], they are now being extensively employed in 
studies of the genetic and epigenetic determinants of gene regulation [469-473], likewise for the 
exploration of the host responses to different perturbations or treatments, such as knockdown 
[474], radiation [475, 476] and drugs [477, 478]. Since the genetic makeup has been shown to 
play an important role in differential drug response among  human individuals, the availability of 
extensive genotype data for many panels of human LCLs allows performing the study of genetic 
variants contributing to inter – individual variation in susceptibility to drug [479].  
Besides LCLs, for example hepatic cells have been used as a model system to study the 
pharmacogenetic effects of cytochrome P450 family of enzymes [480]. Additionally, these cells 
have been used in determining the genetic control of expression and splicing differences in drug 
–metabolizing genes [481]. Although hepatocytes are very often the most relevant tissue to 
determine variant gene function in drug metabolizing enzymes for many pharmaceutical agents, 
this tissue is expensive and moreover difficult to access. Thus, the molecular phenotyping of 
more accessible cell types such as blood cells, lymphocytes or skin fibroblasts may represent 
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equally valuable cell – based systems that could be employed in the basic as well as applied 
research.  
Along with the cell lines derived from healthy human subjects, cells obtained from diseased 
tissues such as NCI – 60 bank of cancer cell lines have shown to be useful models for the 
investigation of direct effect of a drug on a variety of tumor tissue types. As with LCLs, mRNA 
expression [482, 483], SNP genotype data [484] and proteomic data [485] are available for these 
cell lines. Usage of this cell-based disease model has resulted in identification of transcription 
factors that predict sensitivity to chemotherapeutics as well as proteomic and microRNA profiles 
predicting drug response [486-489]. Moreover, polymorphisms in candidate genes associated 
with drug response in vitro have been successfully identified as well [490-492]. In addition, a 
combination of SNP data and gene expression profiles for the panel of tumor cell lines revealed 
that cytotoxicity to the alkylphospholipid analog perifosine is associated with MAPK and 
apoptotic pathways [493]. 
The recent revolutionary discovery of induced pluripotent stem cells (iPSCs) [494-497] 
opened a new avenue of cell – based approaches applicable in drug discovery, in vitro disease 
modeling, as well as in cell replacement therapy. Recent studies demonstrated that the 
recapitulation of in vitro disease phenotype via iPSCs seems to be feasible for numerous 
monogenic diseases [498-503]. The availability of such a disease relevant pathological cell 
obtained directly from the patient might definitely benefit the drug discovery.  Thus, "a patient in 
a dish" represented by iPSCs seems to have a promising perspective in the discovery of various 
drug effects and drug toxicity among the population of patients.  
Until now it is clear, that human cell systems could serve as a powerful tool to study human 
inter-individual differences in a natural as well as disease state. Development of cell – based 
system that is the most relevant for the phenotype of interest is a challenging task and one of the 
most significant considerations is whether the chosen cell lines express the relevant 
pharmacodynamic signaling pathways. 
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CHAPTER 2  
Thesis Aims 
Accurately functioning signal transduction pathways, including circadian signaling, are 
responsible for the human physiology and behavior. Therefore, it’s not surprising that mutations 
in these cascades have been linked to the pathogenesis of different human disorders and cancer. 
Although the drug targeting of these pathways seems to be useful for a variety of diseases, rising 
evidence of inter-individual variation in the therapeutic responses becomes a challenge for the 
development of pharmaceutically effective drugs. Given the role of gene expression in shaping 
phenotypic variation in health and disease, exploring the nature of causative variation is crucial. 
In general, a relatively small set of conserved signal transduction pathways is implicated in 
control mechanisms of the gene expression regulation. The inter-individual differences within 
these pathways contribute to a variation of gene expression that is in turn responsible for the 
overall phenotypic makeup of each individual.  
The main aim of this thesis was to develop an innovative and possibly high throughput 
profiling technique that would in future afford the opportunity to perform genetic mapping of the 
factors responsible for the natural inter – individual variation in circadian (Chapter 3.1) as well 
as other major non – circadian signaling pathways (Chapter 3.2). This noninvasive cell-based 
signaling profiling technology showed a potential to give more light into cancer, behavior and 
pathogenesis (Chapter 3.3). Understanding inter – individual differences in the expression 
pattern of major signal transduction events will certainly bring more insights into the knowledge 
of natural human variability regulated by complex operation of these pathways. Especially for 
the case of disease, coupling gene expression profiling with the results of genome wide 
association studies could be a promising way forward to unravel the principal mechanisms 
resulting in disease pathogenesis. 
                                              Chapter 3: Inter-Individual Variation in Human Circadian Rhytmicity 
57 
 
CHAPTER 3  
Results 
3.1 Inter-individual variation in human circadian 
rhythmicity 
 
 In 2007, Science magazine reported it’s each year 
"Breakthrough Of The Year" News – Human Genetic 
Variation, that was devoted to the latest remarkable 
advances in understanding the genetic basis of normal 
human phenotypic diversity and susceptibility to a broad 
range of diseases. Prior to that in the same year, "the 
breakthrough paper" published by Levy and his colleagues 
reported that the human genome, composed of 3 billion 
nucleotides, varies by 0.5% among individuals [504]. This 
genetic variation that differs from person to person 
influences the human phenotypic differences such as eye 
color, height or disease perceptivity and responses to 
various drugs. As discussed in Chapter 1 (General Introduction), circadian clocks that are 
genetically determined, orchestrate many aspects of human physiology and behavior and any 
genetic or epigenetic alteration of this important timing system leads to a development of various 
disorders. Given the advances of genomic approaches and conservation of circadian clocks in 
various peripheral tissues and cells, we decided to develop a technique that would eventually 
reveal the genetic origins of the human individual differences in circadian chronotype and other 
behaviors at the cellular level. These studies are described in the following chapter.  
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BACKGROUND 
The circadian molecular pathway is responsible for production and maintenance of daily 
rhythms in human behavior and physiology and several studies demonstrated that properties of 
this human circadian signaling pathway differ widely within the population. Moreover, it was 
also discovered that not only SCN neurons of the central circadian pacemaker but also many 
other peripheral tissues possess circadian clocks that have similar features as the one found in the 
SCN. Thus, this duplication opens the possibility to study human differences in peripheral tissues 
at a cellular level.  
METHODS/RESULTS 
The initial step of the study was to define the type of human cells (lymphoblastoid cells- 
LCLs or umbilical cord fibroblast cell line - UCFs) for the measurement of human circadian 
properties such as circadian period length or phase. Different transfection methods including 
lentiviral, adenoviral and Herpes Simplex Virus amplicon vector-mediated gene transfer as well 
as electroporation of an Epstein-Barr Virus-based vector containing the circadian reporter, 
showed significant circadian gene expression in control cell lines, however, no circadian 
expression pattern for the LCL and UCFs was obtained. Additionally, the detection and 
quantification of mRNA for circadian clock genes during a 24 hours cycle revealed only 
irregular circadian gene expression of low amplitude.  
CONCLUSIONS/SIGNIFICANCE 
For the measurement of circadian period length, one has to introduce a circadian reporter 
construct. Human umbilical cord fibroblasts display a lot of advantages such as easy isolation 
and cultivation, and high amplification potential. On the other hand, lymphoblastoid cell lines 
(LCLs) with very poor transfectability are commercially available as large human pedigrees, and 
would therefore be immediately suited to linkage and association studies. However, lack of 
circadian rhythmicity in both LCLs and UCFs makes these cell lines unsuitable for the mapping 
of genetic loci responsible for differences in human daily behavior. Despite these results, we still 
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believe that an adequate library of for example human primary skin fibroblasts, would be a 
perfect system in which the human phenotype of circadian period length, could be used as a 
quantitative trait for linkage or association studies, and would certainly provide more insights 
into the genetic origin of human variation in circadian signaling pathways. 
3.1.1 INTRODUCTION 
Circadian rhythms represent a biological phenomenon that controls a variety of essential 
processes in living systems, ranging from bacteria to humans [187, 505]. Beside the body 
temperature, hormone secretion, cell cycle progression and drug metabolism, the most obvious 
function regulated by circadian rhythms is the daily sleep/wake cycle in mammals. Many studies 
showed that human individuals differ in the circadian preferences as well as in their sleep habits. 
These variations occurring in the daily behavior have been mainly assessed by the questionnaires 
designed to associate human individuals with the temporal preferences called "morningness – 
eveningness" [506]. Briefly, a so called morning type person often labeled as "Lark" is someone 
who gets up easily and exhibits more alertness in the morning than in the evening. On the other 
hand, "Owl" -- an evening type of person -- is more alert at night and is able to sleep late in the 
morning. However, most individuals are on the scale position somewhere between the morning 
and evening-type and are described as neither type [507].  
Despite the fact that age, gender or work schedules [508-511] remarkably affect 
scores/questionnaires, several recent studies revealed an existence of a genetic basis that 
underlies the trait-like character of the human chronotype. Both twin and family studies suggest 
that diurnal preference is 50-60% heritable [512-515] and various single nucleotide 
polymorphisms have been associated with chronotype preference as well as with sleep-wake 
syndromes. For instance, the first such report described a single nucleotide polymorphism (SNP) 
in the human 3’flanking region of the CLOCK gene (3111C/T) that showed allele association 
with eveningness [339, 516]. Moreover, the mutation in Per2 has been linked to the advanced 
sleep phase syndrome, potentially by disrupting the target site for casein kinase 1ε 
phosphorylation [517-520]. Two other reports have associated PER3 alleles with delayed sleep 
phase syndrome, where one rare haplotype represented by a missense mutation was reported by 
Ebisawa and subsequently associated with diurnal preferences in European population [338, 
521]. The other report revealed a variable tandem repeat polymorphism within the Per3 coding 
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region in which the shorter allele was linked to delayed sleep phase syndrome. Interestingly, the 
shorter allele in the normal population was associated with extreme evening preference while the 
longer allele with extreme morning preference [522]. The three period genes are the main 
elements of the negative feedback loops. As well as mutations in the Per2 and Per3, the T2434C 
polymorphism in the Per1 gene was associated with human extreme diurnal preference. The C 
allele was more frequent in subjects with morning than in subjects with extreme evening 
preference [523]. 
Thus, the importance of circadian core clock genes in the human diurnal behavior is 
undeniable and their harmonized interplay within the networks of the transcriptional – 
translational feedback loops became a molecular keystone of circadian biology. Beside the 
master oscillator, located in the suprachiasmatic nucleus; the expression of core clock genes has 
also been identified in "the peripheral slave oscillators". Both, master and slave oscillators seem 
to possess the same circadian molecular makeup what predicts the oscillating peripheral tissues 
or cells to be a suitable model system to study various aspects of circadian biology.  
Until recently, the characterization of human clocks and their genetic diversity was limited by 
labor – intensive difficulties and expense, since the measurement of human circadian properties 
under laboratory conditions requires prolonged subject observation. As mentioned previously, a 
considerable innovation came with the discovery of peripheral oscillators and many mouse 
studies began to use in vitro circadian gene expression to complement behavioral analysis. In 
these studies, constructs coding the luciferase gene fused to a circadian promoter have been 
utilized to determine the circadian period length, phase or amplitude in a simple real-time 
bioluminescent measurement [168, 524]. Moreover, the same technology was applied to measure 
high-amplitude circadian gene expression in mouse NIH 3T3 fibroblasts and rat fibroblasts [171, 
172]. A novel method employing a lentivirally delivered circadian reporter to measure the human 
circadian rhythms from various cell types was introduced by Brown and his colleagues in 2005 
[287]. The developed lentivector construct contains a firefly luciferase gene whose expression is 
controlled by the promoter and 3’untranslated region of the mouse Bmal1circadian gene, flanked 
by the long terminal repeats. Introducing the so called "enhancer trap decoy" represented by the 
strong human Elongation Factor 1α promoter (EF1α) followed by an SV40 transcription 
terminator resulted in excellent circadian oscillations of the luciferase activity. Besides blood 
monocytes and hair keratinocytes, easily accessible primary fibroblasts derived from the simple 
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tissue biopsy showed big potential in the study of human circadian rhythms. Indeed, several 
recent studies utilized human skin fibroblasts to access the human circadian behavior. For 
instance, it has been shown that the primary skin fibroblasts derived from healthy individuals 
could not only predict human diurnal behavior but also the circadian period length measured in 
these fibroblasts in vitro was nicely correlated with the physiological period of tested individuals 
[288, 289]. Additionally, significant differences in the period length among the human subjects 
has been reported [287].  
Given the genetic origin of circadian variation, conservation of circadian clocks in fibroblasts 
as well as robustness of the lentiviral reporter technologies suggested exciting routes for my 
initial study, where for example the period length or phase of daily rhythmicity can be used as 
quantitative traits in linkage and/or association studies. With advances in genetic mapping 
strategies, it would be possible to determine genetic modifiers that underlie the human circadian 
individuality. The success of such linkage or genome-wide association (GWA) studies is 
strongly dependent on their proper design. The primary concern in this kind of studies is usually 
focused on the probability of detecting a causal variant, also called the power of the study. The 
number of individuals used in the study is a crucial determinant of the power. Although the 
number of subjects used in traditional and expression QTL mapping widely varies from one 
study to another, it was shown that eQTLs mapping using in vitro data need much lower power 
necessary to carry out GWA studies [525]. For this purposes, various cell banks over the world 
have been established to meet the requirements of genetic analysis. In this study we used 
lymphoblastoid cells from the completely genotyped human pedigrees as well as umbilical cord 
fibroblasts that are conveniently stored as easily accessible cell libraries. 
3.1.2 RESULTS 
Several transient as well as stable transfection techniques have been developed to introduce 
foreign DNA molecules into the eukaryotic cells with the aim to study the gene expression. Since 
lentivirus based vectors, adenovirus vector – mediated reporter system as well as Herpes simplex 
virus type – 1 amplicon vectors are the most powerful systems able to infect a broad spectrum of 
dividing and quiescent cells, we employed these technologies to determine the circadian clock 
gene patterns in Lymphoblastoid (LCLs) and Umbilical Cord Fibroblasts (UCFs) cell lines.  
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3.1.2.1 Use of lentiviral and adenoviral circadian reporters in LCLs did not show 
circadian oscillations  
Considering the ability to transduce a wide variety of cell types, stable integration and 
potentially long lasting and heritable gene expression, HIV-1 derived lentiviral vectors offer 
unique robustness and versatility as natural vehicles for gene delivery. Our laboratory developed 
a lentiviral reporter construct containing a mouse Bmal1 promoter, the firefly luciferase coding 
region and the Bmal1 3’UTR, flanked by the long terminal repeats, that allows us to measure 
human circadian period length directly in the primary skin fibroblasts. Therefore, we employed 
this reporter system to determine circadian gene expression pattern in a lymphoblastoid cell line. 
Since lymphoblastoid cell lines show lower transfection levels, simple incubation of the 
lentiviral supernatant and cells was coupled with a spinoculation method. In this way, 
lymphoblastoid cells were resuspended in the viral supernatant of two distinct concentrations 
(10x and 100x) and centrifuged (spin down) in the presence of polybrene - a reagent that was 
shown to enhance retroviral transfection efficiency. Since only a fraction of cells integrate and 
express the gene of interest, it is usually necessary to include a selection scheme to isolate 
positive transformants. Hence, a puromycin mediated selection has been done to obtain the 
homogenous population of cells carrying the circadian lentiviral construct. Besides LCLs, 
NIH3T3 mouse fibroblasts have been used as a control cell line. Several days after the lentiviral 
transduction and antibiotic selection, a real-time bioluminescence measurement revealed no 
circadian gene expression in LCLs, even when we used different virus concentrations (Figure 
1A, B). Although signals were at background levels in LCLs, the antibiotic resistance of the cells 
proved that infection had indeed occurred. 
  
          
   
 
 
 
 
            
 
Figure 1 Bioluminescence measurement of the circadian gene expression. A) control NIH 3T3 fibroblasts and B) 
Lymphoblastoid cell lines after transduction with the lentiviral reporter construct coding the expression of luciferase 
gene under the control of the circadian Bmal1 promoter. LCLs were transduced with two different virus 
concentrations: 10x, and 100x. Measurement was done in the presence of luciferin as substrate after 20 min of the 
synchronization with dexamethasone. Reading time: 1min intervals.  
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Apart from retroviral reporters, adenoviral vectors also possess several advantages such as 
large carrying capacity, wide tropism and ability to infect non – dividing cells what predict them 
to be a reliable system for both in vitro and in vivo studies. Due to these benefits and the fact that 
the lentiviral reporter system was insufficient to deliver our reporter construct into LCLs, we 
employed adenovirus vectors coding the Bmal1 circadian reporter construct to determine the 
circadian gene expression in LCL and control NIH3T3 cell lines. Prior to the bioluminescence 
measurement, both cell lines have been incubated in the presence of adenoviral particles for 24 
hours and after transfection, the cells were cultivated for additional 48hours in the normal growth 
medium. While the control NIH3T3 cell line showed a regular circadian gene expression of 
expected amplitude, no – circadian pattern of low bioluminescence levels was observed for 
lymphoblastoids (Figure 2). 
          
 
 
 
 
Figure 2 Bioluminescence measurement of circadian gene expression. A) control NIH 3T3 fibroblasts and B) 
Lymphoblastoid cell lines after infection with the adenovirus circadian reporter construct coding for the expression 
of luciferase gene under the control of Bmal1 circadian promoter. Measurement was done in the presence of a 
substrate luciferin after 20 min of synchronization using dexamethasone. Reading time: 1min intervals. 
3.1.2.2 Herpes Simplex Virus amplicon reporters showed high infection rates, 
however no circadian oscillations 
Since lentiviral and adenoviral vectors failed to show any circadian gene expression in LCLs, 
we next tested a DNA virus that belongs to the Herpesviridae family - Herpes Simplex Virus 
amplicon vector (HSV – 1). The usual HSV-1 amplicon consists of a plasmid backbone 
harboring a bacterial origin of DNA replication plus antibiotic resistance, two non-coding 
sequences from the wild type HSV-1 genome necessary for replication and packaging of the 
amplicon into infection particles; and a transgene expression cassette. Due to the absence of viral 
gene expression, the amplicon is replication defective and its episomal existence results in stable 
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maintenance in post-mitotic cells. Among many advantages, HSV-1 vectors have an impressive 
capacity for delivering transgene unit up to 150kb. Moreover, since it does not integrate into the 
host genome, the conventional amplicon does not lead to insertional mutagenesis.  
To determine transfection rates of the gene delivery, LCLs have been initially infected with 
the HSV – 1 amplicon vector coding green fluorescent protein (GFP) under the control of the 
cytomegalovirus (CMV) promoter. As previously, cells transfected by Herpes Simplex viral 
particles were incubated for 24 hours and monitoring of the GFP expression was examined. As 
shown in Figure 3, the control HEK 293A cell line exhibited 50-80% transfection efficiency and 
the lymphoblastoid cells showed 20-30% transfection efficiency during 24-48 hours after the 
transfection.  
A     B          C            D        
 
 
 
 
 
Figure 3 Gene transfer mediated by Herpes Simplex virus (HSV-1) amplicon vectors. A) and B) represent the 
control HEK293A cell line and C), D) lymphoblastoid cell line 48hours after the transfection with HSV-1 vector 
coding the expression of green fluorescent protein under the control of CMV promoter. 
The promise of this result led us to develop a luciferase version of this vector, where the 
expression of firefly luciferase gene is driven by the strong CMV promoter. Secondly, the 
circadian version of HSV-1 vector was prepared by the restriction cloning of the Bmal1 – 
luciferase reporter cassette into the standard amplicon plasmid, pHSVPrPUC. As shown in 
Figure 4, luciferase expression in HEK293A as well as LCLs reached reasonable 
bioluminescence levels, although the expression levels have been declining much quicker for 
LCLs than in the control NIH 3T3 cell line. Consequently, the circadian HSV-1 vector was used 
to transduce the control U2OS side by side with LCLs. Unfortunately as seen previously, the real 
– time bioluminescence measurement revealed an expected circadian pattern in the control cell 
line, however, no circadian gene expression has been observed in LCLs. 
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Figure 4 Herpes Simplex Virus - 1 amplicon vector mediated transduction:HSV-1 vector coding luciferase gene 
under the control of CMV promoter in A) control NIH 3T3 fibroblasts and B) Lymphoblastoid cell lines. Circadian 
Bmal1 – luciferase version in C) control U2OS and D) Lymphoblastoid cell line. Dexamethasone synchronization 
was performed for C) and D) measurement. Real time bioluminescent measurements were done in the presence of a 
substrate luciferin. Reading time: 1min intervals.  
3.1.2.3 Epstein Barr virus – based vectors revealed moderate delivery of a 
circadian reporter construct but no circadian effect 
Altogether, none of the three viral based vectors tested, showed a sufficient transfection 
efficiency in the lymphoblastoid cell line. Since it is possible that these viruses are becoming 
rapidly inactivated and consequently the target gene expression is abolished within the LCLs, we 
tried to overcome this problem by utilization of episomal (extrachromosomal) eukaryotic 
expression vector that offers an attractive alternative. Such episomal vectors based on Epstein – 
Barr virus components have found significant and increasing use in molecular biology as well as 
in biotechnology. In the first step, we cloned the circadian cassette into the pCEP4 episomal 
mammalian expression vector and as a transcription method the electroporation/nucleofection 
method has been selected. Cells resuspended in a mixture of the plasmid DNA and buffer 
solution were exposed an electrical pulse and kept for 24hours in the normal growth medium to 
recover. After this period, we performed a real-time bioluminescent measurement of the 
circadian gene expression (Figure 5). The robust Bmal1 – circadian gene expression was 
obtained in the control NIH 3T3 fibroblast cell line during seven days of measurement, however, 
again no circadian gene expression was found for lymphoblastoid cell line.  
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Figure 5 Bioluminescent measurement of nucleofected episomal circadian mammalian vector (pCEP4-Bmal-luc 
reporter). A) control NIH 3T3 and B) lymphoblastoid cell line during seven days. The synchronization of the 
circadian phases was performed by dexamethasone treatment over 20 min and luciferin was added as a substrate for 
the measurement. Reading time: 1 min  intervals. 
3.1.2.4 Lymphoblastoid cell lines show poor circadian rhythmicity at the level of 
mRNA 
Neither viral integrating nor extrachromosomal eukaryotic reporters showed circadian gene 
expression in the lymphoblastoid cell line, which suggested an altered or defective circadian 
clock gene expression within LCLs. To verify this prediction resulting from our datasets, we 
performed a so called "around-a-clock" experiment, in which the dexamethasone synchronized 
lymphoblastoid cells have been harvested every four hours during a 24h cycle. Total RNA was 
isolated and used for quantitative real – time polymerase chain reaction to determine the 
circadian variation of Bmal1 and Rev-Erbα clock genes within 24 hours. NIH 3T3 fibroblasts 
that possess strong circadian gene expression were used as a control cell line. Q-PCR results that 
are shown in the Figure 6, revealed no circadian gene expression in the lymphoblastoid cell line 
and the expression of Bmal1 and Rev-Erbα circadian clock gene showed rather disturbed and 
random gene expression patterns with very low amplitude level.  
Facing these results, it became clear that lymphoblastoid cell lines seem to have strongly 
down regulated and altered expression of the circadian core clock genes, which regrettably make 
them completely unsuitable for our study and the mapping of the genetic modifiers that are 
responsible for the human circadian variation in the daily behavior.  
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Figure 6 Results of quantitative Q – PCR. A) Bmal1, B) Rev - Erbα RNA expression from NH 3T3 cell line and C) 
Bmal1, D) Rev – Erbα RNA expression from lymphoblastoid cell lines harvested each 3 hours around a clock. Each 
sample represents the average +/- standard deviation for two replicates for each time point.  
3.1.2.5 Umbilical cord fibroblasts show weak circadian clock gene oscillations 
For genetic studies of human inter – individual circadian variation, large libraries of the human 
cell lines are desirable. Although lymphoblastoid cell lines are stored as such a library, we 
discovered that this cell line is lacking a robust circadian gene expression and is therefore 
unsuitable to accomplish the aims of our study. Despite this big disappointment, we attempted to 
utilize the library of umbilical cord fibroblast cell line that has been show to share common 
characteristics with human skin fibroblasts that are known to possess a strong circadian clock 
gene expression.  
To determine the circadian gene expression in this UCFs cell line, the same strategy as the 
one used for LCLs was applied. The lentiviral reporter construct coding the circadian expression 
of firefly luciferase gene was used to transduce this cell line over 24 hours and the real-time 
photon count measurement was performed after the puromycin selection of the positive 
transformants (Figure 7). Although umbilical cord fibroblasts showed reasonable levels of 
bioluminescence expression, circadian expression of Bmal1gene was significantly damped in 
contrary to the robust and high amplitude rhythms obtained in the control U2OS cell line. 
Moreover, a different synchronization protocol (e.g. high content serum - 50%) didn’t show any 
improvement of the amplitude of these rhythms (data not shown). 
 To verify this observation, we performed a similar around a clock experiment as in the case 
of LCLs to determine the levels of mRNA for circadian clock genes in UCFs. Control NIH 3T3 
fibroblast cell line side by side with umbilical cord fibroblasts have been synchronized by 
synthetic glucocorticoid dexamethasone and dishes of cells were harvested each four hours  
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Figure 7 Real-time bioluminescence measurement of the circadian gene expression. A) control NIH 3T3 
fibroblasts and B) umbilical cord fibroblasts measured after the transduction with the lentiviral reporter construct 
coding the expression of luciferase gene under the control of the circadian Bmal1 promoter. Measurement was 
performed in the presence of a substrate luciferin after the 20 min of the dexamethasone synchronization. Reading 
time: 1min intervals. 
during 24h hours. Total RNA was then extracted and used for qPCR measurement. As can be 
seen in Figure 8, umbilical cord fibroblasts showed only random and low level Bmal1 and Rev-
Erbα gene expression (Figure 8C and D) when compared to the circadian pattern of the control 
mouse fibroblasts cell line (Figure 8A and B). As for the lymphoblastoid cell line, the lack of a 
robust circadian gene expression in UCFs is interfering with our goal to perform the genetic 
mapping of the loci that underlie the circadian differences within the human population. 
Figure 8 Results of quantitative RT – PCR. A) Bmal1, B) Rev - Erbα mRNA expression from NH 3T3 cell line 
and C) Bmal1, D) Rev – Erbα mRNA expression from umbilical cord fibroblasts harvested each 4 hours around a 
clock. 
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3.1.3 DISCUSSION 
Human circadian clock, whose activity varies widely among even normal healthy individuals, 
is responsible for the regulation of human physiology, mood and cognition. Several studies 
showed that in addition to a “master clock” located in the suprachiasmatic nucleus of the brain, 
nearly all mammalian peripheral tissues such as heart, liver, lungs, spleen or kidney possess 
circadian clocks whose molecular set up is in general the same as the one operating in the 
SCN[168]. Besides these, cell autonomous and self-sustained circadian rhythms have been 
widely demonstrated in peripheral cells such as human primary skin fibroblasts or keratinocytes 
[169, 526]. Additionally, various blood cell types possess circadian gene oscillations as well. For 
instance, human peripheral mononuclear blood cells (e.g. leukocytes, monocytes, macrophages) 
display circadian properties [527-531] and the functional molecular clock mechanisms has been 
found in the class of lymphocytes called Natural Killer cells [532, 533] as well as in primary B 
lymphocytes [534]. Thus, blood beside the skin, is the most accessible and common tissue source 
at the clinical levels. Therefore circulating leukocytes, lymphocytes or other cycling cells might 
be an ideal source for the study of the human circadian clock.  
The primary goal of this study was to establish a technique and cell lines that would allow us 
to perform the expression quantitative trait mapping to reveal the genetic modifier that underlie 
the differences in the circadian signaling pathway among human individuals. For this purposes, 
suitable number of subjects or better said cell lines derived from the human individuals is 
necessary. Lymphoblastoid cell lines and umbilical cord fibroblasts are stored as large cell 
repositories that already contain genome-wide transcriptional information and therefore are 
perfect for such studies. As mentioned above, several reports showed the existence of circadian 
rhythms in peripheral as well as human PMBCs including primary B-cells, however, to our 
knowledge there is no report about the molecular signature of the circadian clock in LCLs or 
umbilical cord fibroblasts.  
Circadian promoter-luciferase reporters have proven to be useful tools for circadian 
biologists, reporting such basic clock properties as period length, phase, and amplitude via 
bioluminescent reporting of circadian gene expression [186]. To deliver such reporters into cells 
for stable sustained gene expression, our laboratory developed a lentivirus-mediated gene 
transfer that offers a plethora of advantages. Beside the potentially long lasting and heritable 
gene expression, these vectors have a large packaging capacity and the ability to infect various 
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dividing and non-dividing cell lines. Since human primary cell cultures as well as LCLs are quite 
resistant to transient technologies and a large amount of introduced DNA can itself alter gene 
expression, a lentiviral delivery system seemed a reasonable choice [535]. To our surprise, 
lentivector mediated gene transfer showed very poor transfectability of lymphoblastoid cells and 
revealed only slight circadian rhythms with extremely low amplitude in umbilical cord 
fibroblasts. Experiencing these results, we next tested other known viral vector systems that have 
been previously shown to be powerful tools for the delivery of reporter constructs into various 
difficult to transfect cell lines. However, neither adenoviral nor Herpes Simplex Virus amplicon 
vectors revealed a circadian gene expression pattern of LCLs.  At this point, all results suggested 
that viral vectors tested might be actively repressed within the LCLs and therefore ineffective to 
show the circadian gene expression or that the circadian gene expression by itself is down-
regulated or strongly altered in LCLs. To distinguish between these two possibilities, we 
employed non integrative Epstein – Barr virus based episomal vectors carrying our circadian 
reporter cassette. Unfortunately, no circadian gene expression in LCLs besides the normally 
oscillating control cell line was observed. Since it was unlikely that LCLs are refractory to all 
transduction techniques, we performed mRNA profiling of the circadian core clock genes. As 
lymphoblastoid cells also umbilical cord fibroblasts showed only a random, irregular circadian 
expression of low amplitude when compared to the regularly cycling NIH3T3 control cell line.  
Lymphoblasts are immature cells that usually differentiate to form mature lymphocytes. 
Infection by the Epstein-Barr virus induces transformation of these mature cells into 
lymphoblastoid cell lines that provide an unlimited source of patient DNA as well as other 
biomarkers.  Although the circadian gene expression of primary B lymphocytes was reported in 
several studies, our results suggest that this biological phenomenon could have been lost by a 
simple transformation of B cells. Thought this transformation technique creates easy to maintain 
highly proliferative lymphoblastoid cell lines, long term cultivated LCLs revealed significant 
genetic instability with a somatic mutation rate of 0.3% [536] that might for example affect the 
circadian clock genes function. On the other hand, it was shown that the B lymphoblastoid cell 
lines have about 2.5-fold enhanced proliferation rates when compared to the T cell lines [537]. 
Although, in this case we cannot speak about the " cancer cell transformation", higher cellular 
proliferative rates as well as defects in the cell cycle have been associated with the deregulation 
of many signal transduction pathways (e.g. MAPKinase signaling, JAK/STAT etc.) likewise 
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with the alteration of the circadian clocks. One can only speculate that EBV transformation of B 
lymphocytes might have a more significant effect on the circadian clock gene function as well as 
the defect in MAPKinase signaling pathway could be reflected into the core clock gene 
expression. To reveal the basis of altered circadian clock gene function in LCLs would therefore 
need a separate approach, however, that was not the goal of our study. 
Primary cells are a good model to study various aspects of circadian biology. Some features 
such as circadian period length remain stable even under in vitro conditions. However, the 
measurement of the circadian period length of derived cells is exaggerated when compared for 
instance to the period length of the SCN neurons. One hypothesis of this phenomenon is the 
absence of the coupling mechanisms among the peripheral cell’s oscillators [287, 538]. The 
discovery that the human umbilical cord fibroblasts lack the circadian gene expression still 
remains unclear to us. These cell lines do not undergo any transformation procedure and their 
isolation from the umbilical cord is quite straightforward. Both, morphologically and based upon 
the expression of the cell surface markers or collagens, UCFs share common similarities with the 
human primary skin fibroblasts. Since our results showed that these cell lines are able to be 
transduced by the lentiviral reporters (according to the high levels of photon counts during the 
measurement), the dampening or very low circadian amplitude rhythms could be due to loss of 
synchrony among these cells. Various synchronization options (besides those tested) as well as 
single-cell analysis of bioluminescence would help us to distinguish if the UCFs circadian 
rhythms are due to a gradual loss of synchrony among independent oscillators or dampening of 
individual cellular rhythm, if any circadian rhythms exist within this cell lines.  
To conclude, our laboratory possesses a powerful lentiviral reporter system that allows us to 
study human inter-individual circadian variation among the human population. However, the 
libraries of LCLs or umbilical cord fibroblasts are unsuitable to study these differences between 
human individuals. A collection of for example human skin primary fibroblasts, which have been 
already used for the study of human circadian rhythms, would meet the requirements for the 
expression quantitative trait studies of the human daily behavior.    
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3.1.4 MATERIALS AND METHODS 
Cell culture 
Lymphoblastoid cell lines as well as human primary fibroblasts have been purchased from the 
Coriel Institute for Medical Research, Camden, New Jersey. Such LCLs were established by 
Epstein – Barr Virus transformation of peripheral blood mononuclear cells using 
phytohemaglutinin as a mitogen. RPMI 1640 growth medium containing 2mM L-glutamine and 
15% fetal bovine serum was used to cultivate this cell line in T25 tissue culture flasks with 10-
20ml medium upright position at 37ºC under 5% carbon dioxide. Human primary fibroblasts 
have been established by outgrowth of undifferentiated mesodermal cells from a biopsy. The 
medium to culture these fibroblasts was DMEM containing 20% fetal bovine serum, 1% 
Penicillin/Streptomycin, 1% gentamycin.  
Vector production and virus preparation 
Lentiviral circadian reporter construct carries the Bmal1 – luciferase  reporter cassette as 
previously described in [287]. This cassette has been initially inserted via restriction cloning into 
the pENTR4 gateway vector replacing ccdB gene located between two attL1 and attL2 sites for 
site – specific recombination of the entry clone with Gateway destination vector. Subsequent 
recombination reaction between the pENTR4 – Bmal1 – luciferase clone and a gateway 
destination vector pLDEST-Puro was performed by using Gateway® LR Clonase® II reaction. 
Adenoviral circadian reporter carries an identical Bmal1 – luciferase reporter cassette that has 
been described previously for the lentivirus based vector [287, 288]. Viruses were prepared as 
described previously [539]. 
Herpes Simplex Virus type 1 amplicon vector for our experiments was prepared by the 
introduction of CMV-GFP, CMV-Luciferase and Bmal1 – luciferase reporter cassette into the 
pHSVPrPUC vector via restriction cloning. The virus production was performed as described in 
Fraefel et al., 1996 [540]. 
Preparation of the circadian variation of the episomal expression vector was done by 
restriction cloning. pCEP4 episomal vector purchased from Invitrogen (Cat.no V044-50) was 
digested by SalI restriction endonuclease and via blunt end cloning the Bmal1 – luciferase 
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reporter cassette was inserted into the vector. The verification of the correct orientation of the 
insert was performed and the plasmid was amplified for the nucleofection procedure.  
Transfection of the LCLs and UCFs 
Lentiviral transfection of LCLs: 1x10
6
 cells resuspended in 1ml of warmed lentiviral 
supernatant in the presence of 200mM HEPES and 4µg/ml polybrene. Cells were spin down for 
90 minutes at 2500 RPM at RT. After the spinoculation, virus was removed and the cells were 
resuspended in the fresh warm RPMI 1640 medium containing 10% FBS and 2mM L-glutamine 
and incubated 48 hours at 37C, 5% CO2. Lentiviral transduction of UCFs was performed on the 
semi confluent 35mm Petri dishes containing 2.5-5x10
5
 cells. Cells were incubated for 6-25hours 
and the viral supernatant was aspirated. Cells were washed twice with warmed 1x PBS and the 
fresh growth DMEM medium containing high glucose, 20% FBS, 1% Penicillin/Streptomycin, 
1% gentamycin was added. Four day after the transduction, antibiotic selection with the presence 
of 2ug/ml Puromycin was initiated. Another three day after the selection, cells were ready for the 
measurement.  
Adenoviral transfection was performed similarly to lentiviral transduction, without the 
spinoculation. Briefly, cultures of LCLs and UCFs were incubated for 6-24 hours with 
adenoviral supernatant. After this incubation, cells were washed twice with 1xPBS and cells 
were cultivated next 48-72 hours within the normal growth medium and the bioluminescence 
measurement was performed.  
Nucleofection of pCEP4 - Bmal1 – luciferase plasmid was performed by using and optimized 
T16 nucleofector program. Shortly, 1x107 of lymphoblastoid cells were mixed with 5µg of 
plasmid in 100µl of the nucleofector buffer V and placed into the electroporation cuvette. After 
the application of the optimized strength of the electrical pulse (T16 nucleofector program), cell 
were immediately transferred into the 2ml of prewarmed RPMI 1640 growth medium containing 
15% FBS, 1%, 1% Penicillin/Streptomycin, 1mM Sodium Pyruvate. Cells were cultivated during 
the next 48hours at 37C, 5% CO2. 
Real-time bioluminescence measurement of the circadian gene expression 
After the transduction or nucleofection as described above, circadian rhythms in cell 
population were synchronized with a synthetic glucocorticoid dexamethasone for 20 min or with 
the high content of 50% FBS for 30 min or one hour. Medium containing dexamethasone was 
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replaced with 1x PBS and cells were washed twice. 3-5 days of real time bioluminescence 
measurement was done in the normal culture medium lacking phenol red but supplemented with 
the 0,2mM substrate luciferin and 25mM HEPES as described previously [172]. Data were 
analyzed using Microsoft excel and/or the Lumicycler Analysis program (Actimetrics).  
RNA isolation, cDNA production and Quantitative RT-PCR  
Total RNA was extracted as described previously in [541]. 0.5µg of RNA was transcribed to 
cDNA with SuperScript II (Invitrogen) using random hexamer primers according to the 
manufacturer’s instruction. For quantitative real-time PCR 20ng of cDNA was used with the 
Taqman PCR mix protocol (Roche) using AB7900 thermocycler. Primers used for the detection 
ale listed in the table below.  
Gene Orientation Sequence 
Bmal1 
Sence GAAGACAACGAACCAGACAATGAG 
Antisence ACATGAGAATGCAGTCGTCCAA 
Probe TGTAACCTCAGCTGCCTCGTCGCA 
Rev-Erbα 
Sence TCACCTGGCAACTTCAATGC 
Antisence CCTGATTTTCCCAGCGATGT 
Probe AACCATGCATCAGGTAGCCCTCCAGC 
Per1 
Sence CGCCTAACCCCGTATGTGA 
Antisence CGCGTAGTGAAAATCCTCTTGTC  
Probe CGCATCCATTCGGGTTACGAAGCTC 
Per2 
Sence GGGCAGCCTTTCGACTATTCT 
Antisence GCTGGTGTCCAACGTGATGTACT 
Probe CATTCGGTTTCGCGCCCGGG 
Cry1 
Sence CACCATCCGCTGCGTCTAC 
Antisence AGCAAAAATCGCCACCTGTT 
Probe CGCCGGCTCCTCCAATGTGG 
Cry2 
Sence CCCGCCTGGATAAGCACTT 
Antisence AGAGACAACCAAAGCGCAGGTA 
Probe ATGAGAGACCCCGAATGAACGCCAAC 
GAPDH 
Sence CACATGGCCTCCAAGGAGTAA 
Antisence GTGAGGGTCTCTCTCTTCCTCTTGT 
Probe TGGACCACCAGCCCCAGCAAGA 
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3.2 Profiling inter-individual differences in human cellular 
signaling 
 
PREFACE: The circadian molecular pathway is only one of many signaling cascades 
responsible for the regulation of human physiology and behavior. The same technologies 
developed for the circadian clock could equally be applied to these other cascades. Therefore, 
during the last few years, we have extended the focus to other major signal transduction 
pathways, including MAP-Kinase pathways, the inflammatory responses (IFN-γ), immune 
system responses (NFAT and NFκB) as well as apoptosis (p53). At a cellular level, nearly all 
drugs act upon so-called “signaling cascades” of regulatory proteins that transmit information 
from the cell surface in order to elicit cytoplasmic or nuclear changes. Therefore, the widespread 
problem of inter-individual variations in responses to many classes of drugs actually begins here: 
due to genetic variation, the expression or structure of signaling cascade proteins can differ from 
one person to another. Understanding the cellular determinants of these differences is an 
important question for pharmacology, and is the basis of “personalized medicine.” The following 
chapter of this thesis called "Profiling inter-individual differences in human cellular signaling" 
mainly focuses on the development and the utilization of a 
novel high-throughput viral system that is capable of 
measuring differences in the output of several signaling 
cascades among primary fibroblasts derived from different 
individuals. 
 
 
 
 
 
Adapted from http://esciencecommons.blogspot. 
com/2011/09/biochemical-cell-signals-quantified- 
for.html  
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BACKGROUND 
Basic intracellular signaling pathways are highly conserved among different cell types. 
Signaling defects have been implicated in many types of human disease, and genetic differences 
in signaling pathways are presumed to be responsible for inter-individual differences in patient 
response to many classes of drugs. Nevertheless, elucidating the molecular basis for these 
differences at the level of individual patients remains a major challenge for medicine. 
METHODS/RESULTS 
We have developed a novel lentivector-based system to profile drug-induced activation of 
major signaling pathways in human cells. Using this system, we examined the activation profiles 
of three principal signaling pathways in fibroblasts from ten healthy human subjects.  
Surprisingly wide inter-individual differences were observed in all pathways, ranging from 
fivefold to twentyfold in outliers. These differences were matched by genome-wide differences 
in transcription from promoters known to be activated by these pathways, as well as by 
differences in cellular toxicity and efficacy of pathway-specific drugs. Fibroblast profiling of 
CREB signaling was used to predict the degree of suppression of the hormone melatonin by light 
in human volunteers, demonstrating the applicability of cellular signal profiling to more complex 
responses in non-accessible tissues. 
CONCLUSIONS/SIGNIFICANCE 
We show here that the amplitude of drug-induced signaling varies widely in human 
fibroblasts, and can be easily profiled using lentiviral reporters. The resulting information can be 
a potent predictor of both simple drug efficacy and of more complex responses. We suggest that 
individual fibroblast profiling could be useful both clinically to determine optimal treatments for 
different individuals, and genetically to map human modifier loci for drug response. 
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3.2.1 INTRODUCTION 
Within individual cells, complex information flow is operated by highly organized signal 
transduction pathways. Such a pathway typically begins by the binding of a large repertoire of 
extracellular signaling stimuli to the cell surface receptors. The main function of these mostly 
membrane-integral receptor proteins is to conduct and integrate incoming signals to a variety of 
cytoplasmic transducers and amplifiers. These in turn stimulate the activity of various effector 
proteins, and ultimately evoke essential cellular responses ranging from cytoskeletal changes to 
nuclear transcription. 
Accurate and rapid translation of information from the cell surface to the nucleus plays an 
important role in fundamental cellular homeostasis. Thus, not surprisingly, mutations in these 
cascades have been associated with the pathogenesis of various human disorders and the 
development of different types of tumors. Drugs targeting these pathways have proven 
therapeutically useful for a wide variety of diseases. 
One of the most interesting findings in the last decade was that only a few major signal 
transduction cascades, each conserved among many different cell types, are responsible for this 
sophisticated intracellular communication. Although the initial sensor or receptor can vary 
among cell types, and the activated genes also differ according to local epigenetic modifications 
and the availability of co regulatory factors, the “cytoplasmic part in the middle” is the same. For 
instance, one can express a photoreceptor and an ion channel in a kidney cell, and the result is 
that the kidney cell depolarizes like a retinal ganglion cell in response to light [542]. Another 
example is the circadian molecular pathway, responsible for nearly all aspects of behavior and 
physiology [543-545].  Although a core clock oscillator located in the suprachiasmatic nucleus 
(SCN) of the brain hypothalamus orchestrates the generation and maintenance of circadian 
behavior ([546, 547], the cellular mechanism of this clock is in fact conserved in most other cells 
of the body: many studies have revealed that not only the SCN but also other peripheral tissues 
such as kidney, liver or even skin cells exhibit circadian functions [167, 548, 549], and the 
operating molecular clock mechanism seems to be the same as the one in SCN neurons [550]. 
Even if signaling cascades themselves are highly conserved among different cell types, an 
increasing number of studies show that inter-individual genetic variations can alter these 
pathways considerably from one person to another. Recent sequencing of multiple genomes have 
revealed variation of about 0.5% between two genomes [455]. Therefore, understanding these 
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alterations probably holds the key not only to understanding differences in human behavior and 
physiology, but also to deciphering the reasoning behind variations in patient responses to many 
classes of drugs.   
Unfortunately, because the functional consequences of most genomic variations remain 
unknown, the tools to analyze these differences remain relatively crude, especially in human 
beings. Very few tissues are readily available. Nevertheless, the study of signaling pathways and 
genetic differences within available tissues has repeatedly proven diagnostic of wider 
physiological differences. For example, study of the circadian clock properties in human skin 
fibroblasts has proven diagnostic of diurnal behavior (chronotype) [551]. More broadly, most 
genetic alterations in cellular processes are generally reflected in the expression signatures of 
many genes, and therefore can be characterized by gene expression profiling. By this technique, 
genetic contribution to inter-individual variation in gene expression has been associated with 
diseases such as breast cancer or diabetes [552, 553]. 
Nevertheless, the complexities of intracellular signaling – including crosstalk among many 
different pathways – has rendered the task of quantifying such differences difficult. For this 
reason, various in vitro cell-based reporter assays have been used in attempts to reveal the 
fundamental role of signaling pathways in health and disease [554-556]. In contrast to a 
traditional ‘’end-point’’ DNA microarray approach, they provide an accurate functional activity 
of targeted genes in a cellular and physiological context. However, introducing these reporters 
into cells in a high-throughput nondisruptive fashion has proven a barrier to widespread 
application of such technology. 
For this purpose, the use of viral systems can provide an ideal solution. Because of their 
ability to transduce a wide variety of dividing or quiescent cells, and their stable integration and 
potentially long lasting and heritable gene expression, HIV-1 derived lentiviral vectors offer 
unique robustness and versatility as natural vehicles for gene delivery [557-562]. For example, 
the use of lentivirally delivered reporters to study inter-individual differences in circadian clock 
function in human fibroblasts has revealed that circadian period length in these cells extensively 
varies among human individuals and furthermore, that individuals classified as early chronotypes 
have in general shorter circadian period lengths than individuals of late chronotype [563], as has 
been established in more laborious behavioral studies. In fact, there is a direct correlation 
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between the physiological period length measured in vivo and the circadian period length 
obtained from human skin fibroblasts [564]. 
Similar technologies could easily be used to study inter-individual genetic differences in other 
conserved signal transduction pathways, and could provide a more reliable readout than 
conventional expression profiling. In this paper, we describe the development of a set of 
lentivirus-based reporters which allows one to monitor the transcriptional endpoints of major 
signaling pathways directly in living human primary fibroblasts in real time over multiple days. 
Besides interesting kinetic patterns, we demonstrate that the peak activation of CREB, ELK1 and 
CHOP in response to a specific drug stimulus significantly varies among fibroblasts from healthy 
human individuals. Moreover, we show that these variations in signaling expression pattern are 
correlated with the transcriptional changes genome-wide, as well as with cellular responses to 
several pertinent drugs. Finally, we show that signaling responses in one human pathway 
measured in fibroblasts, CREB, correlate with the more complex physiology of melatonin 
signaling – which is known to be CREB-dependent from rodent studies. Therefore, our 
observations suggest that the signals obtained from our potentially high-throughput cell based 
reporter system could serve as valuable biomarkers for individual therapeutic response and 
physiological function. 
3.2.2 RESULTS 
3.2.2.1 Lentiviral reporters respond dose-dependently to pharmacological 
activators in primary cells.  
We have developed a lentiviral cell-based reporter system which allows us to profile drug-
induced transcriptional activation of major signal transduction pathways directly in living human 
primary fibroblasts. This system consists of a set of VSV-G pseudotyped lentiviral vectors 
(Figure 1A). The first virus is a Reporter Virus carries a synthetic minimal promoter with five 
tandem repeats of the yeast GAL4 binding site that controls the expression of the firefly 
luciferase gene. This virus also contains an antibiotic resistance marker so that homogenously 
infected populations of cells can be obtained. The second virus is a Specific Activator Virus 
containing the human cytomegalovirus (CMV) immediate early promoter driving expression of a 
GAL4 DNA binding domain fused with a pathway-specific transcriptional activator (CREB, 
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Elk1, CHOP, c-jun, NFAT etc.). The resulting fusion protein is universally expressed in 
transfected cells, but only transcriptionally active when phosphorylated by the pertinent cellular 
pathway. The third virus is a Normalizing Control Virus encoding the secreted alkaline 
phosphatase (AP) gene under the control of the CMV promoter. Co-transduction of mammalian 
cells with these lentiviruses allows specific activator-dependent luciferase signal to be expressed 
as a ratio relative to AP, thereby controlling for pathway-independent effects such as infection 
efficiency, toxicity, etc. 
 
In total, reporters were designed for eight major signal transduction pathways: CREB, ELK1, 
CHOP, NF-KB, p53, c-JUN, NFAT, and SRE. In a first test, each of these was transduced into 
primary human skin fibroblasts, which were then treated with a pharmacological agent known to 
activate the pertinent pathway, and bioluminescence was then measured over several days via 
real-time bioluminometry in the presence of luciferin. Our initial test for these chosen signal 
transduction pathways showed interesting individual kinetic patterns of pathway-specific 
transcriptional activation in response to specific drug stimuli (Figure 1B). For our further 
analyses, we decided to concentrate upon three important signal transduction pathways: CREB, 
essential for cAMP-dependent G-protein-coupled signaling from a wide variety of receptors; 
ELK1, a mitogen-activated protein kinase (MAP kinase) important in cell growth signaling; and 
CHOP, known to be responsive to endoplasmic reticulum stress and involved in DNA damage, 
growth arrest, and apoptosis. For each pathway, we next determined non-toxic, sub-maximal 
concentrations of a drug stimulus which would be used in subsequent experiments (Figure 1C). 
Each pathway showed dose-dependent responses to its pertinent drug. For example, a 5µM 
concentration of the diterpene forskolin, commonly used to raise levels of cyclic AMP, was 
determined as sufficient to induce CREB phosphorylation in our assay. 100ng/ml concentration 
of Phorbol 12-myristate 13 – acetate (PMA), a structural analog of diacylglycerol able to activate 
PKC, was chosen to induce ELK1 signaling pathway. Finally, 10ng/ml of methyl 
methanesulfonate, an alkylating agent and carcinogen, was used to activate the transcription 
factor CHOP. 
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Figure 1 A. Lentiviral cell based reporter system. Specific Activator Virus (1) expresses a chimeric pathway-
specific transcriptional activation domain fused to the GAL4 DNA binding. Reporter virus (2) contains the firefly 
luciferase gene under the control of a minimal synthetic promoter with GAL4 DNA-bdining sites. Normalizing 
Virus (3) expresses secreted Alkaline Phosphatase. B. Pathway-specific transcriptional activation in human primary 
fibroblasts responds to specific drug stimuli. Raw bioluminescence profiles of human fibroblasts infected with 
pathway specific reporters, and then treated at time 0 with pathway-specific activating compounds. Drugs used for 
activation: CREB- Forskolin(5µM); Elk1- phorbol 12-myristate 13-acetate (PMA, 100ng/ml)); c-JUN-
Dexamethasone(5µM); CHOP- methyl methanesulfonate (MMS, 10ng/ml); NFAT- phorbol 12-myristate 13-acetate 
(PMA)/ calcimycin (100ng/ml); NFkB-human tumor necrosis factor α (hTNFα, 50ng/ml), GAS- human tumor 
necrosis factor α (hTNFα, 50ng/ml); p53- Actinomycin D(5nM). C. Dose response curves for the specific drug 
stimuli used to activate CREB, ELk1 and CHOP signaling pathways. 
In order to be useful, a viral reporter system should be robust to most changes in infection 
efficiency, viral titer, or cell confluence, passage, and health, and should be uniform across 
different biopsies from the same individual. (Of course, since some of these factors themselves 
influence intracellular signaling, not every pathway should be robust to all of them!) We 
systematically tested each of these factors for each pathway, and showed that measured pathway 
induction – expressed as a ratio of luciferase to AP – was uniform under these conditions. 
Although factors such as different biopsies, cell confluence at the time of the transduction, or 
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passage number dramatically changed raw luciferase signals, they had no significant effect when 
normalized to signal from the AP vector (Supp. Figure 1). 
3.2.2.2 Signaling pathway amplitude varies widely in fibroblasts from different 
individuals 
Having our lentiviral cell based reporter system, we were interested if the activation profiles 
of these three basic signaling pathways measured in skin fibroblasts differ among ten healthy 
young subjects. To measure inter-individual differences in the expression levels of CREB, ELK1 
and CHOP in primary human fibroblasts, semi-confluent dishes of primary skin fibroblasts, each 
corresponding to an individual subject, were transduced with lentiviral reporters and signals were 
measured and normalized as described in Materials and Methods. In addition to pathway-specific 
kinetic patterns, we found surprisingly large inter-individual differences in the peak expression 
of these tested pathways. Nearly 10-fold differences were obtained in CREB induction between 
the most extreme subjects (in response to identical 5uM concentrations of forskolin), 5 - fold 
differences for Elk1, and 20-fold differences for CHOP induction among the tested subjects 
(Figure 2). Importantly, subjects showing differences in pathway expression varied from 
pathway to pathway, thereby arguing against systematic bias. To assure that obtained differences 
in expression patterns were not due to a differential degree of transduction or a possible 
variability in virus titer, we performed further measurements of “outlying” subjects (showing 
maximal and minimal induction) for each pathway, and showed that differences were well-
preserved across four different concentrations (1x, 5x, 10x and 25x) of the lentivirus used for the 
experiment (Supp. Figure 2). 
 
 
 
 
 
Figure 2 Fibroblasts from different individuals show widely varying induction of different pathways. Fibroblasts 
from ten subjects were infected with pathway-specific reporters for CREB (A), Elk1 (B), or CHOP (C), and then 
identically stimulated with 5µM Forskolin (A), 100ng/ml PMA (B), or 10ng/ml MMS(C). Peak activation for each 
subject is plotted as a ratio to constantly-expressed alkaline phosphatase in the same cells, with the average /- 
standard error from four replicates in two separate measurements. Approximately 10-fold differences for CREB, 5-
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fold differences for Elk1 and 20-fold differences for CHOP were obtained among the most extreme subjects, who 
were different for each pathway.  The probability by Student’s t-Test  that the most different  individuals (CREB – 
Subject 1 vs Subject10, Elk1 – Subject 8 vs Subject 6, CHOP – Subject 7 vs Subject 6) have the same expression is : 
CREB/ P=0.0013 , Elk1/ P= 0.025 and CHOP/ P= 0.0008. (*P<0.05, **P<0.01, ***P<0.001) 
3.2.2.3 Reporter-based variations in pathway signaling are mirrored by genome-
wide transcriptional variation 
The pathway-specific inter-individual differences that we observe were significantly larger 
than what other studies have shown for microarray-based gene expression. Therefore, we next 
compared the results from our pathway profiling with corresponding experiments performed via 
microarray-based transcriptome analysis of the same cells harvested at the time of maximal 
observed induction for each pathway. Using published lists of human genes activated by each 
pathway (as identified by chromatin expression and microarray analyses by others) [565, 566], 
we found notable differences in the gene expression profiles of CREB, Elk1, and CHOP target 
genes between subjects identified as “high inducers” and “low inducers” for each pathway. For 
example, looking at the expression profile of CREB target genes, we found that forskolin evoked 
an average 4-fold difference in activation of the fifty most-induced CREB target genes among 
the “high” and “low” subjects (red vs. black bars, Figure 3A). The same strategy to analyze the 
data was adapted for differential expression of Elk1 and CHOP target genes [565, 566]. This 
approach revealed the 3 – fold difference and 2.5 – fold difference in transcription from 
promoters known to be activated by Elk1 and CHOP pathway, respectively (Figure 3B, C.) 
Where suitable antibodies could be purchased, these differences also corresponded with inter-
individual variations in the levels of the endogenous transcription factors: not surprisingly given 
the transcriptomic data, we found that that the levels of phosphorylated CREB as well as 
phosphorylated Elk1 differ among these individuals (Supp. Figure 3). 
Importantly, no difference was seen in the average expression of the full chip gene set (Figure 
3D). Surprisingly, when standard differential expression analyses (GeneGO, KEGG) were 
conducted upon these gene sets, in each case the activated pathway was not identified as 
significantly different among subjects, and in fact was not even identified as one of the principal 
induced pathways when compared to microarray datasets from uninduced cells (Supp. Datasets 
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1-3). Stated another way, crosstalk between signaling pathways introduced a level of noise in the 
data that made direct conclusions from raw microarray data difficult. 
 
A                 D 
 
 
 
B 
 
 
 
C 
 
 
 
Figure 3 Microarray analysis shows fibroblast transcriptome-wide differences in pathway-specific gene targets 
among extreme subjects. Whole-transcriptome analysis was performed on cells from the indicated subjects, treated 
as in Figure 2. For A) CREB, B) Elk1 and C) CHOP, fold-activation of the 50 most activated genes for each 
pathway are plotted for the subject identified as maximally inducing (red bars, left panel) and minimally inducing 
(black bars, left panel). Average differences in induction of all pathway-specific genes induced more than 2x is 
shown in the right panel. For each case, single-dye gene expression microarray analysis was performed in three 
technical replicates. D) No differences were seen among subjects in whole-transcriptome-wide expression from the 
same microarray datasets. 
3.2.2.4 Inter-individual differences in pathway signaling correspond to cellular 
differences in drug toxicity or efficacy.  
Alterations in the extracellular environment cause changes in gene expression levels which in 
turn lead to physiological responses. Understanding the variation in the gene expression patterns 
within human populations could provide important insights into the basic phenotypic diversity; 
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likewise, it could be useful to better interpret the pattern of gene expression variation in disease. 
To demonstrate the relevance of our findings for drug toxicity and efficacy, we looked at 
cytotoxicity mediated via CHOP phosphorylation. CHOP, a small nuclear protein also known as 
DNA damage gene 153 (GADD153), induces growth arrest in response to various extracellular 
stresses such as UV radiation, endoplasmic reticulum stress or alkylating reagents [567]. We 
tested methyl methanesulfonate (MMS), an alkylating agent inducing phosphorylation of CHOP 
and DNA damage [568]. As predicted, the cells corresponding to the subject with the higher 
CHOP expression level showed decreased cellular viability after MMS treatment (Figure 4B) 
compared to untreated controls (Figure 4A).  
A              B 
 
 
 
 
 
 
 
Figure 4 Cytotoxicity mediated via CHOP phosphorylation differs among extreme subjects. Human primary 
fibroblasts from the subjects exhibiting the lowest and the highest expression level of CHOP were treated with the 
toxic concentration of methyl methanesulphonate (100ng/ml) during several days and viability was measured via 
Trypan blue staining each day. The cells corresponding to the subject with the higher CHOP expression level 
showed decreased cellular viability after MMS treatment (B) compared to untreated controls (A). (Student’s t-test, 
P= 0.04.) (*P<0.05, **P<0.01, ***P<0.001) 
3.2.2.5 Inter-individual differences in cellular pathway signaling correspond to 
physiological differences in human neuroendocrine response 
Our results also point to unsuspected variability in the amplitude of CREB-dependent 
signaling in primary fibroblasts from different human subjects. It is well-known that this 
pathway is conserved in many different tissues, where it regulates a variety of processes. For 
example, in the brain CREB signaling has been found to be involved in the control of melatonin. 
Melatonin is a hormone of the pineal gland whose circadian secretion is regulated via 
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multisynaptic neuronal pathway coming from the SCN. At the molecular level, the circadian 
secretion of mammalian melatonin begins by the adrenergic innervation of the pineal gland, 
followed by the binding of the norepinephrine to a β1 – adrenergic receptor and activation cyclic 
AMP (cAMP) - signaling pathway[569] which through CREB modulates the level of the rate-
limiting AA-NAT enzyme [197, 570, 571]. Nocturnal light results in inhibition of this cascade, 
giving rise to the well-studied phenomenon of “melatonin suppression” by light [572, 573].  
From these experiments in rodents, one would predict that the magnitude of CREB-dependent 
signaling would affect the rate of melatonin synthesis, and therefore the degree of melatonin 
suppression by light. To test this hypothesis, 16 additional subjects were recruited; fibroblasts 
were cultivated from each, and infected with CREB reporter. From the same subjects, the degree 
of melatonin suppression in response to an evening light pulse was also measured by half-hourly 
sampling of salivary melatonin before, during, and after light administration. As predicted, an 
inverse correlation was observed between the degree of melatonin suppression and the 
magnitude of CREB signaling in fibroblasts, reflecting the dependence of melatonin synthesis 
upon CREB (Figure 5A,B). Thus, signal profiling in fibroblasts can be relevant to various 
complex responses in other tissues that are impossible to access directly. (Note that absolute 
levels of melatonin are critically dependent upon the size and calcifications of the pineal gland 
itself, so no correlations were observed between CREB and peak melatonin levels in these 
subjects.)   
A               B 
 
 
 
 
 
 
 
Figure 5 CREB expression in fibroblasts predicts melatonin suppression and production in human subjects. 
Correlations between melatonin suppression (left y axis) or melatonin production under full spectrum light exposure 
(right y axis) in human subjects is plotted compared to fibroblast CREB induction in response to forskolin (x axis). 
A) The area under the curve from the full spectrum light condition divided by het area under the curve from the dim 
                             Chapter 3: Profiling Inter-Individual Differences in Human Cellular Signaling 
87 
 
light condition is plotted against CREB induction (r = -0.666 p = 0.009). B) The minimal melatonin value from the 
full spectrum light condition divided by the maximal melatonin value from the dim light condition is plotted against 
CREB induction (r = -0.688 p = 0.007).  
3.2.3 DISCUSSION 
Trait-like variation in the expression of individual genes in a given tissue is well-known, and 
the invention of technologies to profile the expression of all RNAs in the transcriptome has 
enabled correlations between patterns of expression of specific gene sets with specific disease 
states, for example in different tumors [574]. Similar technologies have been applied to look at 
differences in gene expression that correlate with patient responses to different drugs [457], and 
comparable methods have been equally successful with the proteome (the sum of all proteins 
produced by the transcriptome) and the metabolome (the sum of all small molecules 
enzymatically created by the proteome) [575]. A major problem with such technologies is that 
effect sizes are typically quite small, probably because most genes possess regulatory elements 
that bind a host of different factors. For example, Zhang and colleagues used a chromatin 
immunoprecipitation (CHIP) as well as microarray approaches to identify CREB target genes in 
different human tissues [565]. The authors identified 4,084 putative CREB target genes. 
Nevertheless, only 100 or ˂2% were activated in response to forskolin, a strong stimulant of 
cAMP signaling. 
In this study, we have used GAL4-based chimeric transcription factors to create a series of 
reporters that represent relatively clean, optimized promoters to detect activation of a single 
pathway, and delivered them into unmodified human primary cells via lentiviral vectors auto-
normalized to eliminate differences in transduction efficiency. From these reporters, we find 
surprisingly high inter-individual variations in pathway expression among even a small sample 
of young, healthy individuals. In retrospect, the large variations that we observe make sense, 
because the reporters that we use are endpoints of signaling cascades designed to amplify small 
differences in receptor occupancy into nearly binary transcriptional responses. The validity of the 
inter-individual differences that we observe is confirmed by correlation with smaller 
transcriptional responses genome-wide measured via microarray, but only considering the most 
induced target genes for a particular pathway. Therefore, we conclude that pathway profiling of 
primary cells could provide valuable information missed by conventional approaches.   
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One obvious application of such information would be to inter-individual differences in drug 
response. To demonstrate this, we have treated cells showing minimum and maximum induction 
of the CHOP signaling pathway with methyl methansesulfonate, which induces cytotoxic 
endoplasmic reticulum stress and DNA damage at high levels. Since the CHOP pathway 
promotes apoptosis, we reasoned that cells showing high induction would be more prone to cell 
death, and that was indeed the case. 
Of course, in order for such a cellular method to be useful for actual personalized medicine, 
the differences in pathway response observable in fibroblasts must be able to be generalized to 
other tissues. Even if it is clear that signaling pathways in general are highly conserved, the 
question of how well inter-individual differences in gene expression are conserved from one 
tissue to another remains a matter of controversy [576, 577]. Therefore, we attempted to apply 
pathway profiling technology to a pathway well-dissected in rodents and well-studied but not 
mechanistically understood in humans. In rodents, synthesis of melatonin by the pineal gland is a 
well-characterized CREB-dependent process. In humans, the suppression of melatonin by light 
has attracted broad interest because of its possible role in seasonal depression [578, 579]. We 
show here that CREB induction in fibroblasts predicts melatonin suppression in the same 
subjects. Although this correlation is highly simplistic, it nevertheless works: since the effect of 
light is antagonistic to CREB-dependent synthesis, one would anticipate a negative correlation 
between CREB pathway induction and melatonin suppression, and that is exactly what is 
observed. 
Many recent studies showed that the use and easy access of peripheral cells could be a 
valuable tool to study not only various aspects of disease connected with alterations in signal 
transduction pathways, but peripheral cells can also serve as a powerful model in the drug 
development and screening processes [580, 581]. Moreover, a rising evidence of a wide human 
inter-individual variability in a response to standard doses of drug therapy suggests that the cell 
based systems could be very useful in the assessment of the drug action, toxicity, or efficacy 
[582]. Recent papers have also highlighted that skin fibroblasts can even be de- and re-
differentiated into different cell types such as cardiomyocytes and neurons to predict disease 
phenotypes [583-585]. Our data shows that the inherent conservation of basic signaling pathways 
can already allow simple fibroblasts to predict complex behavioral responses, and that wide 
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inter-individual differences in signaling pathway function in these cells could be highly useful to 
personalized medicine. 
3.2.4 MATERIALS AND METHODS 
Human subjects 
Protocols used with human subjects in this study were approved by the ethical committees of 
the University of Groningen (NL) and the Karolinska Institute (SW).  All subjects were 
university students (age 20-24), equally gender-distributed, with no regularly used medications 
except oral contraceptives. 
Tissue isolation and culture 
As described previously[563], human primary fibroblasts were isolated from two skin 
biopsies from 10 young healthy subjects by 4 - 7h digestion of the tissues in 2ml of DMEM 
containing 10%FBS, 1% Penicillin/Streptomycin, 1% gentamycin, 0.325 W.U./ml Liberase 
Blendzyme3. After the isolation, human primary fibroblasts were kept in DMEM/ high glucose 
medium supplemented by 20% FBS, 1% Penicillin/Streptomycin, 1% gentamycin and 2.5µg/ml 
Amphotericin B. Antifungal Amphotericin B was left out from the growing medium after one 
week. 
Vector production 
The cell-based reporter system used for the measurement of the transcriptional activation of 
CREB, Elk1 and CHOP signaling is based upon the Stratagene In Vitro Path Detect system. This 
system features a reporter construct coding for firefly luciferase downstream of a synthetic 
promoter which is joined to five tandem repeats of GAL4 binding elements. A transcriptional 
activator construct containing coding sequences for the activation domains of CREB, Elk1 or 
CHOP fused with the DNA binding domain of yeast transactivator GAL4 is separately expressed 
from the CMV promoter. Lentiviral derivates of this reporter system were produced by the 
restriction cloning of the coding sequences of activator plasmids (pFA2 - CREB, pFA2 - Elk1 
and pFA2 - CHOP) and reporter plasmids (pFR-Luc) into the pENTR4 gateway entry vector 
(Invitrogen) between attL1 and attL2 sites. Ultimately, Gateway® LR Clonase® II reaction was 
used to recombine and transfer inserts from entry vectors into a lentiviral destination vector 
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containing either Hygromycin (pLDEST-CREB-Hygro, pLDEST-Elk1-Hygro, pLDEST-CHOP-
Hygro) or Puromycin (pLDEST-FR-Luc-Puro) selection marker. In addition to the reporter and 
activator construct, a third virus consisting of a secreted alkaline phosphatase gene under control 
of the CMV promoter was also included. All viruses were produced and concentrated as 
described in Cepko C., 2001 [586]. 
Bioluminescence measurement of the transcriptional activation of different 
signaling pathways 
Semiconfluent plates (2.5 -5 x10
5
 cells in 35mm Petri dish) of primary fibroblasts initially 
transduced and selected for the lentiviral luciferase reporter construct carrying puromycin 
resistance (pLDEST-FRLuc-Puro) were additionally cotransfected with the activator (pLDEST-
CREB-Hygro, pLDEST-Elk-1-Hygro or pLDEST-CHOP-Hygro) and normalizing  lentivirus 
vector (pLDEST CMV-SEAP Hygro) without selection. Prior to bioluminescence measurement 
of the transcriptional activation, aliquots of the medium taken from the fully confluent samples 
were used to detect levels of secreted alkaline phosphatase  by Phospha-Light™ Secreted 
Alkaline Phosphatase Reporter Gene Assay System (Cat. N. #T1015). Ultimately, DMEM 
medium high glucose, w/o phenol red, 10% KnockOut™ Serum Replacement, 
1%penicilin/streptomycin, 1% Gentamycin, 0,1mM luciferin was used to measure basal levels of 
the light emission during 20 - 30 min. Consequently, pathway specific drug stimulus was added 
to the tested samples (5µM Forskoline for CREB activation, 100ng/ml PMA to induce Elk-1 and 
10ng/ml MMS for CHOP) and the signal was recorded over the 24-48 hours. 
Data analysis and normalization 
A single experiment included samples measured in four replicates, from two biopsies. Each 
sample was normalized by dividing the activator activity (maximal photon count value of CREB, 
Elk-1 and CHOP induction) by the control reporter activity (photon counts corresponding to 
SEAP values). Replicate samples were then averaged and the same calculation was done for all 
tests.  Results are expressed as average +/- standard error. 
 Protein purification and Western Blot Analysis 
Proteins from uninduced and induced human primary fibroblasts samples (for CREB – 
Subject 1, 10; Elk-1 – Subject 10, 5; CHOP – 7, 8) were extracted at the time of the maximal 
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transcriptional activation (CREB – after 5h, Elk1 – after 8h, CHOP after 24h) according to the 
NaCl - Urea - NP-40 protocol previously described by Laverz and Shibler (1993). 25 µg of 
protein was resolved by 10% SDS-PAGE, transferred to Protran® Nitrocellulose membrane, 
rinsed in PBS-0.1% Tween , and incubated 1h at room temperature with either primary 
polyclonal antibody against Phospho – CREB. (1:50 dilution, Cell Signaling Technology, 
#9191S), or polyclonal antibody against Phospho-Elk-1(1:50 dillution, Cell Signaling 
Technology, #9181) IRDye 680 Goat anti-Rabbit IgG secondary antibody was used in dilution 
1:10000, 1h, room temperature. Washed and dryied membranes were used to detect and analyse 
the signal intensities by using the Odyssey infrared imging system (Li-Cor).Anti – Actin, clone 
C4 Monoclonal Antibody (Cat. No. #MAB1501) was used as a loading control for each 
immunoblot. 
RNA isolation, whole genome expression analysis 
Total RNA from CREB (Subject 1,10), Elk-1 (Subject 10, 5) and CHOP (Subject 7,8)  
uninduced and induced fibroblast samples were extracted as described by Xie and Rothblum 
1991. RNA quality and quantity was determined by Agilent 2100 Bioanalyser. Single color gene 
expression microarray analysis was performed by using Human Whole Genome OneArray™ 
(Phalanx Biotech Group, Belmont, CA, USA). For each sample three technical replicates were 
performed. The data from all microarrays was passed to Rosetta Biosoftware for analysis, and 
returned a single average expression value for each gene.  For each subject, induced values were 
divided by uninduced, and then ordered by fold induction.  Relative fold inductions were 
calculated by dividing fold induction for a given gene and subject by the same value for another 
subject.  To calculate values for an overall pathway, a list of pathway-specific genes was taken 
from [565, 566] and NEXTBIO Y platform for CHOP.  Within this set, the average fold 
induction of the 50 most induced genes was then used as a measure of the overall induction of 
the pathway. 
Viability Determination 
In vitro sensitivity of the human primary fibroblasts from CHOP extreme subjects (Subject 7, 
8) to an alkylating agent Methyl Methanesulfonate (MMS) was assessed by the Trypan Blue 
Exclusion Test of Cell Viability [587].  1.5x10
4
 cells were seeded into 48 - well microculture 
plates and kept for an additional day in the incubator at 37ºC and 5%CO2. On day three, 
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100ng/ml of MMS was added to the microculture plates and viability of fibroblasts cells was 
determined over the next four days.  Measurement for each sample was done in six replicates and 
untreated cells were used as a control. 
Measurement of melatonin suppression 
The study consisted of 2 nights in the lab between June 19
th
 and August 7
nd
 2010, the 
Netherlands. Each night was separated by a minimum of 1 and a maximum of 2 weeks. All 
subjects stayed in individual rooms. After 2 hours of dim light (< 5 lux) conditions, subjects 
stayed randomly in the dim light condition or in a full spectrum light condition (Philips TL-
D36W/830 mounted on the ceiling, horizontal 627 ± 16 lux, vertical 164 ± 33 lux) from 23:00 
till 7:00. Subjects stayed awake during the whole night and did computer (of which the screen 
was covered with a colour filter to block blue light transmission, E-colour +, 105 Orange; Rosco 
Laboratories Inc., U.K.) tests and questionnaires, which are not subject of this paper. They 
received hourly snacks of 100 Calories and 130 ml water. Each hour (from 21:30 till 6:30), using 
cotton swabs (Salivettes®, Sarstedt B.V. Etten-Leur, The Netherlands), saliva samples were 
collected for melatonin analysis, which was performed by radioimmunoassay (RK- DSM; 
Bühlmann Laboratories AG, Siemens Medical Solutions Diagnostics, Breda, The Netherlands). 
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Supplementary Figures: 
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Supplementary Figure 1 Robustness of the lentiviral cell based system in response to experimental variation. 
Human cells from the same subject were infected with lentivectors for CREB (left panels), Elk1 (middle panels), 
and CHOP pathways (right panels). In each case, equivalent pharmacological inductions were performed under 
conditions of different A) Cell confluence, B) Viral Titer, C) Different biopsies from the same subject and D). 
Passage number. Data is plotted as the maximal induction observed in each experimental condition, divided by the 
expression of alkaline phosphatase in the same cells. Each sample represents the average +/- standard error for at 
least two replicates of two independent measurements. With the exception of passage number for ELK (expected 
because of its involvement in cell division and senescence), no significant differences were observed. 
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Supplementary Figure 2 Intersubject differences in pathway expression are independent of viral titer. For 
maximally and minimally inducing subjects for the CREB (left panels), Elk1 (middle panels), and CHOP pathways 
(right panels), as determined in Figure 2, human primary skin fibroblasts were transduced with different 
concentrations of the CREB, ELK, and CHOP lentiviral vectors. 1x Viral Titer represent unconcentrated filtered 
viral supernatant. 5x, 10x and 25x viral titers were concentrated by ultracentrifugation. Each sample shows the 
average +/- standard error from two replicates in two separate measurements.  
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Supplementary Figure 3 Different levels of endogenous phosphorylated CREB and phosphorylated Elk1 are 
observed in maximally and minimally inducing subjects. For subjects maximally and minimally inducing the 
CREB (A) and ELK pathway (B), each pathway was pharmacologically induced in fibroblasts using forskolin (A) or 
PMA (B). Whole cell extracts were prepared, and western blots were performed against phospho-CREB (A) and 
phospho-ELK (B) proteins. B-actin was used as a loading control.  Top panels, raw blots; bottom panels, 
quantifications 
 
Subject 1   Subject 10 
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3.3 Imaging of signal transduction pathways within the 
growing tumor 
 
PREFACE: Self-sufficiency in growth signals, insensitivity to the growth inhibitory signals, 
evasion of apoptosis, limitless replicative potential, tissue invasion and metastases are all 
hallmarks of human tumorigenesis that have been found to be major signatures of deregulated 
cellular signal transduction cascades. Although these interconnected signaling events are being 
slowly elucidated, understanding the alterations that lead to cancer still remain a substantial 
challenge. Therefore, the same technologies that we have developed for the determination of 
natural inter-individual variation in the human cellular signaling could be equally suited to trace 
and study the behavior of signaling pathways within developing and progressing tumors. Since 
the cancer progression is a multilevel process that involves highly organized signal transduction 
pathways, better understanding the basis of the signal transduction alteration will certainly bring 
more insights into the variability of cancer pathogenesis among the human population as well as  
improve current approaches for cancer therapy.  
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BACKGROUND 
Tumor formation and progression occur via a broad range of defects that develop within and 
outside of the cancer cell. Defects in signaling pathways allow cancer to alter the normal 
programs of cellular proliferation, migration, transcription and even death. Changes in the 
surrounding tissues as well as in immune response potentiate the tumor to expand, form new 
blood vessels and spread into other organs. Therefore, different model system and various anti-
cancer compounds have been developed to target different proteins that act in all of these 
pathways. However, rising evidence of inter-individual differences in the tumor development 
and progression as well as huge cancer heterogeneity complicates the development of successful 
cancer therapeutic strategies.   
METHODS/RESULTS 
To conduct in vitro and  in vivo real-time bioluminescent measurement of signaling pathways 
in a mouse C51 allograft model, we employed our lentiviral cell-based system previously used 
for the profiling of natural inter-individual differences in human signaling. While the profiling of 
eight different signaling pathways (CREB, Elk1, cjun, CHOP, NFAT, NFκB, GAS, p53) in vitro 
revealed pathway-specific transcriptional activation, in vivo bioluminescence imaging of these 
signaling events showed mostly monotonic increase of the signal along with tumor development. 
To determine, whether the activity of signaling pathways can be modulated in vivo, a specific 
drug stimulus known to act on Elk1 and CHOP pathways was administered directly into a 
developed tumor. An increase in the bioluminescence signal was observed, demonstrating 
cellular responsiveness of the signaling cascade within the tumor to external stimulation.   
CONCLUSIONS/SIGNIFICANCE 
To reveal the behavior of major signal transduction pathways within the growing tumor in this 
study, we combined out robust lentiviral reporter system with a noninvasive longitudinal in vivo 
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imaging technique to reveal the behavior of major signal transduction pathways within the 
growing tumor. For the cascades examined, no significant temporal variations in signaling 
beyond those provoked by tumor size were observed. Nevertheless, we believe that this 
technology might help to shed more light into the action of various therapeutic compounds as 
well as improve the development of drug targeted technologies.  
3.3.1 INTRODUCTION 
The origin of cancer is a huge subject area with still too many unanswered questions. 
Although several lines of evidence suggest that human tumorigenesis is a multistep process in 
which different genetic and epigenetic alterations drive the progressive transformation of normal 
human cells into highly malignant derivatives, rapidly increasing evidence of human inter - 
individual variation in the cancer development and progression as well as differential responses 
of patients to the cancer treatment propose a rather more complicated picture of the cancer 
pathogenesis and therapy. 
At the core of many regulatory systems of each living cell, signal transduction pathways play 
a dominant role. In general, these transductions encompass a multitude of interacting and cross-
talking molecular cascades regulating the process of conversion of the external signals such as 
growth factors, neurotransmitters, cytokines or hormones to a specific cellular response such as 
gene expression, cell division or even cell death. It is also very well recognized that appropriate 
regulation of signaling pathways is essential for the maintenance of the overall cellular 
homeostasis, while on the other hand various alterations in this information flow can cause 
abnormal signal activation or inactivation that ultimately leads to the disease status such as 
cancer. Therefore, it is crucial to systematically analyze and understand gene expression 
signatures in the context of signaling pathways and uncover the mechanisms underlying 
pathogenic cellular phenotypes.  
Many model systems, ranging from a simple in vitro cell culture to whole body in vivo 
molecular imaging have been established to decipher the crucial signaling components that play 
a role in human tumorigenesis. Although in vitro cell culture techniques are in principle valuable 
systems that complement more complex in vivo studies of signaling mechanisms underlying 
cancer development, molecular imaging is a particularly useful approach that allows the 
visualization of critical molecular signaling events in action in living subjects, in a noninvasive 
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and longitudinal manner. A variety of small animal imaging technologies like microcomputed 
tomography (CT), micropositron emission tomography (PET), single photon emission computed 
tomography (SPECT), magnetic resonance imaging (MRI) as well as optical bioluminescence 
and fluorescence have been developed to monitor the cell biology of tumor development and 
progression [588]. Up to date, bioluminescence is the favorite technology for whole body optical 
imaging. Exceptionally high signal to noise levels, absence of background activity and a rapid 
turnover of the firefly luciferase protein with a relatively short half-life of  3h [589], predicts this 
system to be ideal to study kinetics and dynamics of gene expression within short time frames.  
In the last few years of research, whole body imaging technology has become extremely 
useful for noninvasive and longitudinal monitoring of cell fate in vivo. This whole body 
bioluminescence imaging studies was not only successfully applied in studies of cancer cells has 
after their injection into living mice, but also for the monitoring of stem cells, to study the 
response of immune cells as well as tracking the rejection of allografts [590-594]. Moreover, this 
approach has been widely utilized to study oncogene regulation, genes involved in circadian 
clock rhythms, viral gene expression or genes involved in inflammation and various disease 
states [595-601]. In addition to the monitoring of endogenous gene expression, bioluminescence 
imaging (BI) approaches also found application in the visualization of efficacy of the transgene 
delivery and expression in vivo [602-604]. Besides gene expression studies at the transcriptional 
level, bioluminescence approaches also facilitate imaging of biological processes at the level of 
protein function and interaction. For example, Lehman et al. developed a fusion protein 
containing HIF-1α and firefly luciferase to study the stabilization of HIF-1α in the developing 
tumor [598]. Murine colon cancer cell line was transfected with this fusion reporter and 
subcutaneously injected into nude mice to form a C51 allograft model. In vivo bioluminescence 
measurement revealed an interesting initial increase in HIF-1α level that was followed by the 
dramatic decrease when the tumor volume reached 1cm
3
. Apart from the detecting stability of 
given proteins, researchers also used BI to assess the activities in the degradation protein 
machinery. One example of such a work was published by Luker et al.in 2003. These authors 
generated a ubiquitin-luciferase reporter to determine the in vivo activity of 26S proteosome by 
assessing the degradation of the reporter [605].  
Since many biological processes involve protein-protein interactions that are important for 
homeostasis of the overall cellular system, bioluminescence imaging found an application also in 
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this field of science. In this type of imaging, luciferase gene is split into two non-functional 
fragments, each of which is fused to one of the two studied proteins. Interacting proteins bring 
two fragments of luciferase close enough to re-form a fully functional luciferase. By using this 
approach, Luker et al. successfully imaged the activation and inhibition of chemokine receptor 
signaling in breast cancer in vivo, by detecting interactions between CXCR4 and β-arrestin. This 
study revealed a new imaging model to test CXCR signaling pathways and suggested the 
possibility to perform the screen for inhibitors in living animals [606].  
Inspired by all these findings, a similar approach based on the whole animal bioluminescence 
imaging could be applied to study temporal changes in the activities of the major signal 
transduction pathways within the tumor microenvironment in vivo. Therefore, we utilized our 
robust lentiviral cell-based reporter system previously used in the study of human inter-
individual differences, to trace the behavior profiles of eight signal transduction pathways in a 
mouse C51 allograft model. As cancer is an extremely complex and heterogeneous disease 
affecting  many people over the world, better understanding of the molecular mechanisms that 
underlie the human cancer pathogenesis is necessary for the development of more efficient anti-
cancer treatment, in which signaling pathways seems to play an attractive role.   
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3.3.2 RESULTS 
3.3.2.1 Use of lentiviral reporters revealed pathway specific transcriptional 
activation in mouse colon carcinoma cell line  
To determine the cellular transcriptional activity of eight different signal transduction 
pathways (CREB, Elk1, c-jun, CHOP, NFAT, NFκB, GAS and p53), we performed a lentiviral 
transduction of C51 cells. These cells have been incubated in the presence of lentiviral 
supernatant for at least twelve hours. For four days after the transduction, cells have been kept in 
the normal growth medium and puromycin / hygromycin selection scheme has been done to 
isolate positive transformants that stably express lentiviral construct coding particular signal 
transduction pathways. Subsequently, a real-time bioluminometry of drug induced signaling 
pathway activation was done in the presence of luciferin. Since some of our signal transduction 
pathway reporters are components of the MAP Kinase pathway (such as CREB and Elk1) that 
are easily inducible by various growth factors, cytokines etc., we needed to assure that the 
activation peaks for the respective signaling pathways obtained from our reporter assays are due 
to a response to the specific stimulus and not due to factors that might be present in the growth 
medium. Hence, to minimize an interfering effect, a protein rich fetal bovine serum was 
substituted for the defined serum replacement that was used for the following experiment. As 
shown in Figure 1A, even different concentrations of the serum replacement showed slight 
effects on the basal levels of some tested pathways. Therefore, rather lower (1-5%) but still 
sufficient concentrations have been used for all in vitro experiments. The overall raw profiles of 
the signaling pathways activation measurement are shown in Figure 1B. Beside the GAS and p53 
signaling that seemed to be constitutively expressed within the C51 cell line, all other signaling 
pathways (CREB, Elk1, c-jun, CHOP, NFAT and NFkB) showed a robust drug induced 
activation with a specific kinetic pattern.  
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Figure 1A Effect of different concentrations of the serum replacement on the basal levels of tested signal 
transduction pathways. Black bars represent the basal levelsof pathways activation measured in the C51 cell line 
without the addition of the activator stimulus. Red bars represent pathway specific transcriptional activation in a 
response to a specific stimulus. For each set of measurement 1%, 5% and 10% serum replacement content was 
tested over 24-48hours. Reading time: 1min intervals.  Drugs used for induction: CREB – Forskolin (5μM); Elk1 - 
phorbol 12-myristate 13-acetate (PMA, 100ng/ml)); c-JUN – Dexamethasone (5μM); CHOP - methyl 
methanesulfonate (MMS, 10ng/ml); NFAT - phorbol 12-myristate 13-acetate (PMA)/calcimycin (0.5µM); NFκB - 
human tumor necrosis factor α (hTNFα, 50ng/ml), GAS - human tumor necrosis factor α (hTNFα, 50ng/ml);.p53 - 
Actinomycin D (5nM). 
1.      2.         3.            4. 
 
 
 
5.      6.           7.           8.   
 
 
 
Figure 1B Pathway specific transcriptional activation in mouse colon adenocarcinoma cell line responds to 
specific drug stimulus. Raw bioluminescence profiles of the C51 cell line transduced with pathway specific 
reporters and then treated at time 0 with pathway specific activating compounds. Drugs used for induction: 1.CREB 
– Forskolin (5μM); 2.Elk1 - phorbol 12-myristate 13-acetate (PMA, 100ng/ml)); 3.c-JUN – Dexamethasone (5μM); 
4.CHOP - methyl methanesulfonate (MMS, 10ng/ml); 5.NFAT - phorbol 12-myristate 13-acetate (PMA)/ 
calcimycin (0.5µM); 6. NFkB - human tumor necrosis factor α (hTNFα, 50ng/ml), 7.GAS - human tumor necrosis 
factor α (hTNFα, 50ng/ml); 8.p53 - Actinomycin D (5nM). 
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3.3.2.2 Longitudinal in vivo imaging of signaling pathways showed a monotonic 
increase of the signal within a growing tumor 
To gain further insight into the complex and dynamic of signaling events, we performed in 
vivo real time bioluminescence imaging of chosen signaling pathways (Elk1, CHOP, NFAT and 
p53) in the growing C51 allograft tumors. The C51 cell line that has been stably transfected with 
lentiviral reporters and previously used for in vitro profiling of signaling pathways behavior, has 
been used for tumor inoculation in 8 to10 weeks’ old BALB/C female nude mice. Five days after 
the inoculation, mice were anesthetized and intra peritoneal injection of luciferin was followed 
by a bioluminescence measurement performed in the light-tight chamber with a charge-coupled 
device imaging camera; IVIS 100, Xenogen. As showed in Figure 2 representing raw data of an 
actual measurement, CHOP, NFAT and p53 signaling pathways revealed only a monotonic 
increase of the signal within the growing tumor what could suggest that the tested pathways 
seem to be constitutively active within the in vivo environment of the tumor.  
 
Figure 2 In vivo bioluminescence imaging of signaling pathway kinetics in C51 allograft tumors. In vivo 
bioluminescence imaging began on day 5 after the tumor inoculation. Altogether 5 data points for each pathway 
were measured. The black curve represents the average total photon counts/min; the red curve represents the average 
tumor volume; Error bars represent standard deviations of measurements in three mice per pathway (N=3).   
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3.3.2.3 Elk1 and CHOP pathways showed increase in their transcriptional 
activity upon a drug specific stimulation  
Since many studies showed the involvement of Elk1 and CHOP transcription factor in the 
tumorigenesis and these two pathways also showed the robust in vitro induction pattern (Figure 
1B) by using our lentiviral reporter system, in out further studies we decided to focus on these 
two signaling pathways. The C51 cell line that has been transduced with Elk1 and CHOP 
reporters was used for inoculation and in vivo monitoring of the transcriptional activity of these 
signaling pathways within a developing tumor. As shown in Figure 3, both signaling pathways 
revealed a monotonic increase in their expression pattern during nine days of the tumor growth. 
To test if these signal transduction pathways can respond to the specific drug stimulus also in in 
vivo environment, PMA (2.5µg of phorbol 12-myristate 13-acetate per mouse) and MMS 
(13.7µg of Methyl methanesulphonate per mouse) drug compounds, known to be acting on these 
pathways have been administered directly into the mouse tumor at the terminal ninth day of the 
measurement. An ultimate result revealed an interesting increase of the bioluminescence levels 
upon the drug stimulation what might suggest that the usage of longitudinal real-time 
bioluminescence measurement might in future reflect the drug evoked behavior of signal 
transduction pathways within the growing tumor in living mice.  
 
Day 5     7       9.0.      9.3.      9.7. Day 5    7       9.0.     9.3.      9.7.                 Figure 3 Monitoring the behavior of 
signaling pathways within the growing 
tumors. Upper panels: In vivo 
bioluminescence imaging of a) Elk1 
signaling and b) CHOP signaling measured 
on a fifth, seventh and ninth day post 
injection. Three different time points were 
measured during the last ninth day. The 9.0. 
point refers to the time of the measurement 
before the injection of a specific pathway 
activator; the point 9.3. refers to the time of 
the measurement 3 hours after the injection 
of the activators and the point 9.7 refer to the 
time of the measurement 7 hours after the 
injection of the activators directly into the mouse tumors. Activators used for injection: Elk1 – PMA (2.5µg/mouse); 
CHOP – MMS (13.7µg/mouse). Lower panels: Charts representing bioluminescence measurement of both A) Elk1 
and B)CHOP signaling. Red coloured points on the chart correspond to the time point measurements 9.0, 9.3 and9.7. 
Error bars represent the standard deviation (N=4 animals per pathway)   
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3.3.3 DISCUSSION 
The induction of signaling pathways within cancer is often a result of genomic alterations 
such as mutations, translocation and copy number gains or losses, in crucial components of these 
pathways. Therefore, genomic technologies that are able to detect these aberrations represent 
important tools for identifying the so called "drug response biomarkers" of pathway specific 
signaling that are urgently needed for the rational selection of patient’s cancer therapy. The 
activation of signaling pathways in cancer causes alterations in gene expression that are highly 
specific for the involved signaling pathway. Many studies have already demonstrated the 
potential of gene expression profiles for the analysis of oncogenic pathways as well as they 
helped to define the cancer subtypes, recurrence of disease and response to specific therapies 
[607-609]. However these DNA microarray-based gene expression signatures suffer by the fact 
that most of them reflect only a single point situation. Therefore, many various reporter systems 
and optical imaging technologies became more often used to reveal the underlying mechanisms 
of human tumorigenesis. 
In this study, we combined the robust lentiviral cell-based reporter system with a long - term 
in vivo imaging technique with the aim to reveal the behavior of main signal transduction 
pathways within the developing tumor. A big advantage of this noninvasive imaging technique 
arises from a longitudinal and dynamic monitoring of cellular and molecular processes in the 
same subject. In our initial in vitro screen we determined which signaling pathways from the set 
of eight tested are able to respond to a specific drug stimulus. Apart from GAS and p53 signaling 
that seem to be insensitive to our drug stimulus and therefore they are constitutively active in 
C51 cell line, we obtained a pathway-specific kinetic pattern for all other tested signaling events. 
To reveal the kinetics and behavior of signaling pathways within the microenvironment of tumor 
in vivo, we injected a C51 reporter cell line into BALB/C nude mice. While five time point 
measurement didn’t reveal any significant pattern for the majority of signal transduction 
pathways, in vivo administration of a specific drug compounds directly into the tumors 
modulated the transcriptional activity of Elk1 and CHOP pathway.  
Although the longitudinal monitoring of the signal transduction pathways activity directly in 
the developing tumors seems to be a powerful tool that might bring more insights into the human 
cancer pathogenesis, we experienced significant variability of the signal distribution within the 
tested group of animals, during our measurements. To compensate for this variation in the signal 
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intensity that could be associated with changes in a tumor volume, blood absorption or tumor 
necrosis, the development of a normalizing system is required. Recent publication by Lehmann 
and her colleagues was focused on the role of tumor hypoxia and the hypoxia inducible factors in 
the growing cancer. In this study, the authors estimated the luciferase activity by a normalizing 
measurement of both HIF-1 luciferase and luciferase control tumors to the theoretical counts 
calculated for luciferase control tumors [598]. We attempted to apply this type of normalization 
on our existing dataset; however enormous discrepancy between the raw and normalized data 
was obtained (data not shown). Therefore, other kind of normalizing system, such as dual marker 
strategy possessing for example two distinguishable luciferase constructs, could be more suitable 
for the correction of possible inter-tumor variances [610]. 
Many recent studies revealed the relationship between cancer pathogenesis, signaling 
pathways and circadian clocks. As it is generally known, circadian rhythms rule many aspects of 
human physiology and therefore it is not so surprising that any genetic or epigenetic alterations 
might lead to the development of various disease states as for example cancer. For instance, from 
all known core clock genes, Per2 has been shown to have an important role in tumor progression 
[611, 612] and its deregulation has been found in many types of human cancers [411, 412]. 
Moreover, genetic studies revealed that mice with dysfunctional circadian rhythms are more 
susceptible to many kinds of cancer development [613, 614]. In addition to this discovery, 
overexpression studies done on mPer2 gene showed an inhibition pattern of cancer cell growth in 
both cellular in vitro systems and a xenograft mouse model. Further studies of this phenomenon 
exhibited possible mechanism where C-erB-2 and p53 were suggested to act as downstream 
players for hPer2 in the course of tumor progression [402, 615-617]. Taken together, all these 
studies suggest a crucial role of circadian clocks in tumorigenesis. Therefore, it would be worth 
in the future to look at the kinetics of tumor’s signal transduction pathways within a more dense 
time window, than is offered by current long-term optical technologies.  
Determining the principal mechanisms that underlie cancer pathogenesis might offer the 
possibility for novel therapies. One of the therapeutic concepts that appear to have a big potential 
in the current cancer treatment is chronotherapy. Cancer chronotherapy - the timed use of 
chemotherapy that is based on circadian rhythms of individuals, certify the importance of 
understanding cellular dynamics to optimize therapy using the physiological drug doses as well 
as uses the differences among the cellular rhythms of normal and tumor cells [618-620]. 
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Although it is still not completely employed in the clinical practice, modeling of cellular 
dynamics such as drug absorption, distribution and metabolism might be important in the 
identification of optimal, temporal windows for drug therapy. Thus, the specific timed drug 
administration seems to play an important role in various treatment strategies. So far, our initial 
results suggested only monotonic increase in the transcriptional activity of tested signaling 
pathways.  At this point, we can only speculate what this result might mean for the therapy. 
Since, we didn’t look closer at the circadian function of the C51 cell line within the context of 
tested signaling pathways; the obtained results might simply suggest that there is no importance 
of specific time for the treatment in the case of the pathways that we tested and the physiological 
doses of the drug compounds would have to be kept in the constant level.  Nevertheless, it would 
be needed to determine the activity status of signal transduction pathways within denser time 
frame such as 24hours as well as we should consider the impact of circadian clock function, 
since some signaling pathways showed diurnal variation in their activity [621]. Moreover, it 
would be interesting to compare the kinetics of signaling events across different cancer cell lines. 
Although signal transduction pathways are highly conserved among various cell types, it is 
possible that we would find differences in the signaling behavior. As cellular behavior is 
regulated by the gene activity it would be logical to assume that differences in invasiveness or 
aggressiveness of tumor cells could be inferred from differences in gene expression.  
Lastly, comparison of the expression profiles of tumor activated / inactivated signaling 
pathways obtained from different patients as well as a detailed screen of possibly differential 
treatment responses among these human individuals would also add some more light into the 
therapeutic approaches of cancer. Our in vivo activation experiment suggests that activities of 
signal transduction pathways traced within the developing tumor can be modulated by drug 
compounds known to be acting upon these pathways. Therefore, we can imagine that various 
drug toxicity and efficacy experiments could be initially performed in a simple in vitro screen 
and then followed by a more sophisticated in vivo longitudinal imaging of the target signaling 
pathways directly in the developing cancer.  
  
                          Chapter 3: Imaging of Signal Transduction Pathways within the Growing Tumor 
109 
 
3.3.4 MATERIAL AND METHODS 
Vector production 
The cell-based reporter system used for the measurement of the transcriptional activation of 
all eight signaling pathways is based on the Stratagene In Vitro Path Detect system. This system 
is described in detail in chapter 3.4 Materials and Methods.  
In vitro Bioluminescence measurement of the transcriptional activation of 
different signaling pathways 
Semiconfluent plates (2.5 -5 x10
5
 cells in 35mm Petri dish) of C51mouse colon 
adenocarconoma cells which were initially transduced and selected for the lentiviral luciferase 
reporter construct carrying puromycin resistance (pLDEST-FRLuc-Puro) were additionally 
cotransfected with the activator (pLDEST-CREB-Hygro, pLDEST-Elk-1-Hygro or pLDEST-c-
Jun-Hygro, pLDEST-CHOP-Hygro, pLDEST-NFAT Luc-Hygro, pLDEST-NF-κB Luc-Hygro 
pLDEST-GAS Luc-Hygro pLDEST-p53 Luc-Hygro) and selected. Ultimately, DMEM medium  
high glucose, w/o phenol red, 5% KnockOut™ Serum Replacement, 1%penicilin/streptomycin, 
1% Gentamycin, 0,1mM luciferin was used to measure basal levels of the light emission during 
20 - 30 min. Consequently, pathway specific drug stimulus was added to the tested samples: 
CREB – Forskolin (5μM); Elk1 - phorbol 12-myristate 13-acetate (PMA, 100ng/ml)); c-JUN – 
Dexamethasone (5μM); CHOP - methyl methanesulfonate (MMS, 10ng/ml); NFAT - phorbol 
12-myristate 13-acetate (PMA)/ calcimycin (0.5µM); NFkB - human tumor necrosis factor α 
(hTNFα, 50ng/ml), GAS - human tumor necrosis factor α (hTNFα, 50ng/ml); p53 - Actinomycin 
D (5nM). The signal was recorded over the 24-48 hours. 
Tumor inoculation  
All the experiments were carried out according to the laws and regulations of the Canton of 
Zurich (Licence 16/ 2011 Steven Brown). 8 ~ 10 weeks old BALB/C female nude mice (Janvier, 
France) were gas anesthetized by 1.5 ~ 2% isoflurane. 1 × 10
6 
C51 cells stably transduced with 
the lentiviral reporters were injected subcutaneously on the left flank of the mouse. We 
transferred the mice back to the cage after injection, waited till them totally recovered from 
isoflurane and made sure they did not suffer from the injection. The mice were sacrificed after 15 
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days of tumor inoculation, when the tumor sizes reached about 2 cm
3
. The tumor volume was 
calculated by the formula: tumor volume= (length×width
2
)/2. 
Bioluminescence imaging of signaling pathways behavior in growing tumors 
The imaging of the transcriptional activity of Elk1 and CHOP signaling pathways has been 
done as previously described by Lehman et al., 2009. Briefly, mice were anesthetized by using 
3% isoflurane and oxygen as a carrer gas. Each mouse was i.p. injected with 100µl of luciferin in 
PBS (15 mg/mL; Caliper Life Sciences). 10 minutes later, the animals were placed in a light –
tight chamber consisting charge-coupled device imaging camera, IVIS 100; Xenogen. 
Bioluminescence measurement was done in 5 and 300 seconds intervals. Collected images have 
been analyzed with Living Image software (Xenogen) and IGOR image analysis software 
(Xenogen). Total photon counts were determined by drawing a region of interest ROI around the 
peak of photon emission. The border of a ROI was formed by those pixels whose signal intensity 
was 5% of the maximal signal in the ROI. To correct for the loss of signal associated with bigger 
tumor volumes we normalized total counts from those tumors to pcDNA3.1-luciferase control 
tumor counts. 
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CHAPTER 4  
General Discussion and Perspectives 
The regulation of gene expression is one of the most essential cellular functions that defines 
and maintains cell type specificity, shapes very complex profiles in health and disease and it is 
likely that a significant portion of the genetic signal is associated with the phenotypic variation. 
While the dissection of these genetic signatures at the level of whole organism might be quite 
demanding, genetic variants at the cellular level can be easily interpretable. In the last decade, a 
significant portion of the scientific community has been attracted by the genetic diversity that 
explains variation of gene expression and many studies have been devoted to characterize its 
genetic architecture [472, 473, 622]. Throughout my PhD studies I have been exploring aspects 
of natural gene expression variation in circadian as well as other major non-circadian signal 
transduction pathways. To decipher the extent of human signaling variation, I have developed a 
novel high-throughput viral system that is capable of measuring differences in the output of these 
transduction cascades among primary fibroblasts derived from different human individuals. 
Furthermore, I showed that this robust system can be utilized to trace the behavior of signaling 
pathways within the developing cancer. The following sections summarize the findings of these 
three studies and discuss other relevant advances and pressing issues in the field.  
4.1 Individuality of human circadian behavior 
Circadian clocks are biological signaling networks that exhibit a period of ~24 hours under 
constant environmental condition. They have been identified in a wide range of organisms, from 
cyanobacteria to mammals and it is widely believed that many aspects of human physiology, 
mood and cognition are regulated by this highly conserved signaling phenomenon [623]. 
Multiple studies focused on circadian biology revealed that in addition to a “master circadian 
oscillator” located in the suprachiasmatic nucleus (SCN) of the brain, nearly all mammalian 
peripheral tissues possess circadian clocks [149, 167, 624]. Moreover, peripheral clocks appear 
to have a similar molecular set up as the clocks orchestrating in SCN neurons. Thus, in both SCN 
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and peripheral cells, the circadian rhythms are thought to be based on delayed 
transcriptional/translational feedback loops [625]. In addition to the various tissues explant 
studies, Balsalobre et al. in 1998 demonstrated that even immortalized Rat-1 fibroblasts that had 
been kept in the culture for decades possess functional and robust circadian oscillators. Since 
then, circadian gene expression has been demonstrated in a broad range of cultured cell lines 
such as primary fibroblasts, murine NIH-3T3 fibroblasts, human U2OS osteosarcoma cells and 
various types of peripheral mononuclear blood cells [149, 287, 392, 527, 626].   
The interest in the genetic basis of individual differences via the research of the human 
circadian clock formed the initial phase of my PhD studies. Humans show large inter-individual 
differences in organizing their behavior within the 24-hours day and several studies showed that 
this diurnal preference is highly heritable [512-515]. Diurnal preferences or so called 
chronotypes are associated with the differences in the circadian clock and the genetic basis of 
this phenotype has been well established in animals. However, the genetic architecture that 
underlies the distinct circadian organization in humans still remains unknown. Although several 
genetic approaches based upon the linkage and association studies have been used to define a 
causative single nucleotide polymorphism of various human pathological chronotypes [516, 518, 
519, 522], only a few reports about the genetic basis of human natural diurnal variation have 
been published [339, 517].  
Both because measuring human circadian function via behavior is a laborious process, and in 
order to gain mechanistic insight into human circadian variations, I set out to develop a high-
throughput way to measure circadian clock properties (such as period length, phase and 
amplitude) in human peripheral tissues. Recent technological advances in the molecular biology 
have afforded the opportunity to monitor eukaryotic gene expression selectively and in real-time 
in living cells. Among a variety of available “reporter genes”, high sensitivity, excellent dynamic 
range, and low toxicity has made luciferase the most commonly used bioluminescent reporter in 
the analysis of eukaryotic transcriptional regulation [627-629]. To deliver such reporters, several 
chemical, physical as well as viral technologies have been developed to study gene functions and 
protein expression in the context of a cell.  Although both, chemical and physical transfection 
technologies have been used in various studies [630-635], extensive optimization is very often 
required to balance transfection efficiency and cell viability. Moreover, these methods allow only 
short-term studies of transient gene expression and therefore would be unsuitable for my studies. 
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Due to these obstacles, the use of viruses as delivery vectors has been explored as an alternative 
method. Virus based vectors have several remarkable advantages. Apart from the fact that they 
can rapidly infect a broad range of human cells and can achieve high levels of gene transfer, they 
can also accommodate relatively large segments of DNA. For example, Adenovirus based 
vectors have impressive packaging capacity up to 7.5kb, can transduce nonproliferating cell and 
are relatively easy to manipulate using recombinant DNA techniques. Other vectors of interest 
include adeno-associated virus, herpes simplex virus, retroviruses and lentiviruses. Lentiviruses 
(e.g. HIV-1) are of particular interest because they can integrate into the host cell genome to 
allow stable and long-term transgene expression as well as they can infect quiescent cell [636]. 
In my study devoted to "Inter-individual differences in human circadian rhythmicity", I 
employed various transient as well as viral technologies to deliver circadian reporter construct 
into human umbilical cord fibroblasts (UCFs) and lymphoblastoid cell lines (LCLs). Since the 
cultures of human primary cell as well as LCLs are quite refractory to transient transfection 
technologies, lentiviral delivery system seemed a logical choice [535]. Furthermore, this reporter 
system already proved to be useful in several studies of human circadian properties [287-289]. 
As described in Chapter 3.1., to my big surprise, lentivirus mediated gene delivery revealed only 
circadian rhythms of low amplitude in UCFs and very poor transfectability with no circadian 
gene expression in LCLs. Moreover, Adenoviral, Herpes Simplex Virus amplicon vector-
mediated gene transfer as well as electroporation of an Epstein-Barr Virus-based vector 
containing the circadian reporter construct also showed no circadian gene expression in LCLs. 
To verify these unexpected results, the levels of mRNA for all circadian core clock genes in an 
around a clock experiment were determined. However, as mentioned previously, the result of 
qPCR showed only random, inconsistent circadian gene expression of low amplitude in both 
UCFs and LCLs (Chapter 3.1.). Since all tested viral based technologies are currently used as the 
most powerful approaches to the study the gene expression in various mammalian cells, it is 
unlikely that other packaging and delivery methods (e.g. adeno-associated viral based system), 
would improve the transfection rates of LCLs. Moreover, the levels of mRNA of the circadian 
clock genes revealed also only irregular pattern, suggesting more and more suggest a hypothesis 
of strong down-regulation or even complete abolishment of core clock gene expression in LCLs. 
Lymphoblastoid cell lines are generated by Epstein - Barr virus (EBV) transformation of the 
B-lymphocytes from the peripheral blood lymphocyte population [637, 638]. Although several 
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previous studies showed that primary B-lymphocytes as well as other mononuclear blood cells 
possess circadian gene expression [529, 534], until now there is no evidence of robust circadian 
gene oscillations in LCLs. Epstein-Barr virus is a member of the herpesvirus family that has been 
associated with various human tumors such as Burkitt and Hodgkin lymphomas, B- and T-cell 
lymphomas, as well as with nasopharyngeal and gastric carcinomas. In LCLs, EBV expresses six 
nuclear antigen proteins, two latent infection membrane proteins, two small RNAs and BamHI A 
rightward transcripts that interact with or exhibit homology to wide variety of antiapoptotic 
molecules, cytokines and signal transducers and therefore promote EBV infection, 
immortalization and transformation [639]. From all, two Epstein Barr nuclear antigen proteins, 
EBNA3A and EBNA3C have been found to have essential roles in EBV immortalization of B 
cells. Although the complete mechanism is not yet fully understood, it was demonstrated that 
these two factors are important for maintaining LCLs growth by repressing CDKN2A p16
INK4A
 
and p14
ARF
 expression [640]. CDKN2A p16
INK4A
, cyclin dependent kinase inhibitor 2A is a 
tumor suppressor protein that is encoded by the CDKN2A gene. p14
ARF
 is an alternate reading 
frame product of the CDKN2A locus. Both p16INK4A and p14ARF are involved in the 
regulation of cell cycle and their disruption lead to elevation of mdm2 and therefore loss of p53 
function and cell cycle control. My initial hypothesis was that immortalization of human B cells 
might lead to the disruption of circadian clock gene expression in LCLs. Although 
immortalization of LCLs is not exactly a ‘cancer type transformation’, one might only speculate 
about the impact of accelerated proliferation of B cells [537] on circadian clock gene function.  
For example, it was demonstrated that circadian clocks regulate the expression of many genes 
involved in cell cycle. However this interaction appears to be reciprocal. In breast cancer the 
expression of Per genes is deregulated and many tumor cells have lost circadian rhythmicity as 
well as daytime dependent cell cycle proliferation [114, 613, 641]. One can imagine that by an 
EBV transformation, suppression of important cell cycle genes might lead to deregulation of 
circadian clock gene expression in LCLs. However, a set of several experiments would have to 
be done to prove this hypothesis.  
Other possibility that might explain the lack of circadian clock gene expression in LCLs could 
be built on the knowledge that mitogen-activated protein kinase (MAPK) pathway is 
constitutively phosphorylated in most LCLs [642]. As it is generally known, that circadian 
synchronization involves photic stimulation of the SCN via the retinohypothalamic tract and 
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glutamatergic dependent signaling pathway through which immediate-early genes and clock 
genes are expressed in the SCN [643-645]. Circadian photic signaling also involves MAPK 
family [117, 391, 646, 647] from which phospho-ERK1/2 exhibit rhythmicity in the SCN. Other 
than light, variety of signals such as PACAP, NGF or GRP modulate ERK activity that in turn 
controls various downstream pathways [17, 648-650]. Studies done in the SCN showed that 
constitutive activation of MAPKinase completely blocked the responses of the SCN to phase 
shifting light pulses in vivo [651]. Moreover, MAPK pathway phosphorylates a basic helix-loop-
helix-PAS transcription factor BMAL1 at multiple sites and BMAL1-CLOCK induced 
transcription is also inhibited by expression of a constitutive active form of MAPK in HEK293 
cells [652]. Altogether, these findings suggest that constitutive expression of MAPK pathway 
might be responsible for a disrupted synchronization or can directly inhibit transcriptional 
machinery of circadian core clock genes. MAPK kinase in LCLs has been shown to be 
constitutively active. This constitutive activation might be responsible for the ineffective 
synchronization of circadian phases among the lymphoblastoid cell, which in turn result in 
inability to determine circadian rhythms via real time bioluminescence measurement as well as at 
the level of mRNA. On the other hand as discussed previously, constitutive phosphorylation of 
MAPK can completely abolish the circadian rhythms of LCLs that are based on the coordinated 
function of transcriptional/translational feedback loops. To distinguish between these two 
possibilities, I would suggest to initially screen for the MAPK activation status in LCLs. If 
constitutive activation would be confirmed, inhibition experiments that according to my 
hypothesis and published literature should restore the circadian rhythmicity in LCLs would be 
done.  
Since I wasn’t able to see the robust circadian clock gene expression in LCLs, this cell line 
became completely unsuitable for my studies of the genetic origin that underlies variation in the 
human circadian behavior. Moreover, none of the umbilical cord fibroblasts that have been tested 
along with the LCLs showed circadian gene oscillations. Although in this case, weak circadian 
oscillations during the in vitro measurement have been observed, only irregular circadian gene 
expression was found at the level of mRNA. Dampening or low amplitude of circadian rhythms 
might be explained by loss of synchrony among these cells. Other synchronizing agents beside 
dexamethasone and serum would maybe help to improve the circadian rhythmicity in UCFs, if 
any exist within these cell lines.  
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Although lymphoblastoid cell lines as well as umbilical cord fibroblasts are available as 
reasonably large cellular libraries, they failed to be utilized for my study due to their lack of 
robust circadian rhythmicity. To accomplish this goal, other cell types, e.g. human primary skin 
fibroblasts could have been taken as an alternative. These cells possess autonomous and self-
sustained circadian rhythms and it has been already shown that the lentiviral based reporter 
system is efficient to deliver circadian reporter construct into these cells. The Coriell Institute for 
Medical Research is one of the few providers of human cell repositories from which I attempt to 
order several primary fibroblast cell lines. The idea was to screen founders from existing human 
pedigrees which are commercially available. For promising pedigrees, resulting period lengths 
would be used as quantitative traits in standard linkage analyses in order to identify human loci 
whose polymorphism influences circadian period length. However, the detection of the circadian 
gene expression in these cell lines was equally unsuccessful because only one cell line of eight 
survived the shipment. Senescent cell lines came either with poor density or with a fungus or 
mycoplasma contamination. Due to these incredible problems, the only way to perform planned 
expression quantitative trait mapping studies would be to establish our own reasonably large 
library of human skin fibroblasts derived from independent young healthy individuals or from 
multiple generation human pedigrees.  In addition, the genome-wide transcription information 
would have to be determined as well.  
In spite of my unsuccess, I still believe that signaling outputs obtained from the human 
primary fibroblasts could in future serve as an excellent system to determine the genetic basis of 
human inter-individual differences not only in the circadian but also in other major signal 
transduction pathways. 
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4.2 Inter-individual variations in human cellular signaling 
Several studies evolved efforts to map and characterize differences in human gene expression 
patterns associated with differences in cell and tissue type, physiological processes as well as 
disease. In vitro experiments explored many aspects of physiological control of human gene 
expression, including the identification of genes periodically expressed within the cell cycle 
[653], the dissection of signaling pathways [654] and response of human cell to various 
compounds [655]. Moreover, gene expression profiles began to help to understand the complex 
biological programs associated with health and diseases also in vivo. However, the nature and 
extent of variation in gene expression among healthy individuals is still a largely unexplored 
aspect of human biology. Novel approaches and investigations of human gene expression 
programs linked to a disease and their impact on the detection and diagnosis will depend on an 
understanding of their normal variation within and between individuals.  
The system that I have developed provides a quantitative readout of signaling pathway 
function. Because it utilizes an ideal synthetic promoter and activator at the endpoint of each 
cascade to report this activity, it provides low-background, high-amplitude signals that detect 
inter-individual differences in signaling proportional to, but greater than those provided by 
microarray-measured gene expression in the same cells. As discussed in chapter 3.2., by using 
this system, I discovered notably large inter-individual differences in the peak expression of the 
three studied pathways: CREB, ELK1 and CHOP. Moreover, the existence of these variations 
was confirmed by genome-wide differences in transcription from promoters known to be 
activated by these pathways, as well as by differences in cellular toxicity and efficacy of 
pathway-specific drugs. Finally, to demonstrate the broader physiological relevance of these 
findings, I was able to relate reporter-detected inter-individual differences in human fibroblast 
CREB signaling with actual suppression of the hormone melatonin by light in the same human 
subjects, a process known to be CREB-dependent from rodent studies [60-62]. Thus, I 
demonstrated that my non-invasive cellular signaling profiling technology could be relevant to 
various complex responses in other tissues that are impossible to access. Taken together our data 
suggests that highly conserved inherent signal transduction pathways might allow simple 
fibroblasts to predict complex behavior responses and that large inter-individual differences in 
signaling function in these cells could be highly useful to for example personalized medicine. 
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Beside utilization of primary skin fibroblasts for my research, many recent studies revealed that 
easily accessible peripheral cells could be a valuable tool to study not only alterations in 
signaling pathways connected to various aspects of diseases but can also serve as a model in the 
drug development technologies [580, 581]. Moreover, several very recent papers also highlighted 
that skin fibroblasts can even be de-and re-differentiated into different cell types such as neurons, 
muscle cells or cardiomyocytes to predict and study various human disease phenotypes [583-
585, 656, 657].  
In addition to all of these interesting applications, I believe that with a suitably genotyped 
library of cell lines, one would be able to use our technology to identify genetic modifier loci 
responsible for the large inter-individual differences in the expression pattern of signal 
transduction pathways that we observed. Possible cellular library that certainly meet the 
requirements of genetic studies comprises umbilical cord fibroblasts. The power of this library 
was already determined by Dimas et al., who identified unique and shared expression 
quantitative trail loci (eQTLs) among three different cell types derived from the umbilical cord 
[658]. Moreover, Borel et al. employed primary umbilical cord fibroblasts to reveal regulatory 
polymorphic variants strongly associated with miRNA expression levels [577]. Although these 
cell lines have been unsuitable for the determination of genetic modifiers that underlie variations 
in human circadian behavior (Chapter3.1.), the preliminary screen performed in this cell line has 
already shown a feasibility of this idea. Thus, eQTLs mapping strategies applied to this library 
have already allowed to identify individual regulatory elements implicated in gene expression 
variation. Coupling this method with the reporter gene technology that I have developed should 
offer considerable further contributions to our understanding of variations in human gene 
regulation.  
4.2.1 Promise of in vitro gene expression profiling and eQTLs studies  
Given the wide variations in the human genome, it is not surprising that for any individual 
tissue, variations have also been observed in the transcriptome (the sum of all RNAs transcribed 
from cellular DNA), the proteome (the sum of all proteins made from the RNAs), and the 
metabolome (the sum of all small molecules catalytically created by the proteins). Investigators 
have used the same quantitative approaches upon these substrates, for example correlating the 
abundance of a particular transcript with a particular cancer outcome [574], or a particular 
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metabolite with risk of diabetes or coronary disease [659], often in unexpected ways. For 
example, while trait-based approaches were certainly not required to link the abundance of 
saturated fats to risk of infarctus, the link between branched-chain amino acids and diabetes 
[660] only became apparent through diabetic metabolome analyses. 
Recently, investigators have taken such analyses one step farther, treating the expression 
levels of transcripts, proteins, and metabolites among various individuals as quantitative traits in 
themselves, and relating them to particular genetic polymorphisms. Such “eQTLs” (expression 
quantitative trait loci) have been heralded to hold great promise for the elucidation of the causes 
of disease, based upon the assumption that polymorphisms in regulatory proteins, binding sites 
or genes are likely to be responsible for heritable variation in gene expression [661, 662]. eQTLs 
mapping has been already applied to a number of species ranging from yeast to humans as a 
powerful tool for determining various regulatory associations [663-671].  Nevertheless, due to 
limitations in sample size coupled with often very small effects, such studies have been 
notoriously variable and often yield quite large eQTL regions (up to several centimorgans) [672], 
leading some prominent investigators even to question their diagnostic potential [673]. For this 
reason, several strategies have been used to improve accuracy and narrow down the candidate 
causal gene regions, including traditional but frequently infeasible "fine mapping" [674-676], 
likelihood-based selection [677], and pathway-based approaches founded on the assumption that 
target gene expression correlates with the activity of other genes in the same pathway [678]. 
Such pathway-based approaches have been particularly useful for eQTL-based pharmacology, 
where drugs applied to cells are known to elicit responses in particular signaling cascades[679]. 
eQTL approaches in humans, though promising, are subject to a serious limitation that only a 
few tissues are readily available, such as blood and skin, except in certain clinical situations 
where biopsy is routine (in cancer, for example). Nevertheless, several recent eQTL studies 
revealed that the gene expression levels generated from various human samples including 
lymphoblastoid cell lines (LCLs) [473, 670], liver tissues [680] or primary lymphocytes [681] 
could be vigorously associated with cis-acting genetic variants. However, usage of immortalized 
versus primary cell lines for eQTL mapping has raised significant contradictions. While some 
studies highlighted cell type-specific effect, others found a significant amount of shared eQTLs 
across tissues [576, 577]. Other studies comparing the overlap of eQTLs found in LCLs and 
primary tissues revealed that some [682-684] but not all [685] eQTLs detected in LCLs can be 
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detected in even the same primary tissue. Hence, even though the same signaling pathways are 
widely conserved in all tissues, application of eQTL technologies to human populations 
effectively remains an important challenge. 
4.2.2 Signaling pathway profiling vs. eQTL studies 
So far, mapping of expression quantitative traits has focused upon determining genetic 
modifier loci for the expression of individual genes, as the word implies [686].  In these studies, 
we have rather taken the novel approach of focusing upon methodologies for determining 
quantitative assays for entire signal transduction pathways as functional units.  This methodology 
has both advantages and disadvantages, as discussed above.  Because the reporters that we have 
developed contain optimal synthetic transcription factor binding sites, fold-differences in 
transcription are typically higher in amplitude compared to effects at individual genes.  Most 
importantly, however, inherent crosstalk is minimized.  Treatment of cells with even the most 
specific pharmacological agents results in broad-scale transcriptional changes of enormous 
complexity.  Our results showed that application of a pharmacological reagent specific for a 
given pathway – for example, forskolin to activate cAMP/CREB signaling, or dexamethasone to 
activate glucocorticoid signaling – activates first the expected pathway, and then multiple others.  
As a result, single-time point genome-wide measures of transcription fail to indicate which 
pathway was the primary target of the compound.  In reverse, for a given tissue or cell line, only 
a small number of possible target genes is activated.  For example, chromatin 
immunoprecipitation (ChIP) studies identified  10,447 promoters bound by the CREB protein 
upon activation of this pathway – already only a small subset of the 4,084 promoters with 
consensus binding sites.  However, only 100 or ˂2%  genes were actually detected as 
transcriptionally activated [565]. Thus, looking at the whole transcriptome, not only are many 
more genes activated by a single pathway than would be predicted directly, but also far fewer of 
the genes that could be predicted directly.  Therefore, in looking broadly at signaling differences 
as quantitative traits, choice of different genes could yield hugely different outcomes.  By using a 
simple optimized virally delivered promoter that is integrated into thousands of different sites in 
thousands of different cells, the methods that we have developed essentially bypasses some of 
this variability, providing a clear signal of high amplitude. 
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Even if signaling pathway profiling allows higher-amplitude quantitative traits which would 
translate directly into improved mapping of modifier loci, such analyses have one obvious 
drawback:  pathways are composed of many components, and the reporter readouts that we use 
are essentially summed effects of modifications of each step.  Therefore, while the method is 
diagnostic of defects or variations in a pathway, it provides no indication of where that variation 
occurs.   For example, the most studied cAMP responsive element binding protein, CREB, is a 
transcription factor that is both a positive and a negative regulator of gene transcription that 
influences the expression of multiple genes. Activation of adenylyl cyclases, i.e. by forskolin, 
elevates the intracellular level of the cAMP, which in turns activates cAMP-dependent protein 
kinase A (PKA). Ultimately, PKA phosphorylates and therefore activates CREB and exactly this 
endpoint of cAMP signaling pathway we are able to measure. However, besides the adenylyl 
cyclases induction, membrane depolarization or calcium ion pore opening signals that elevate 
intracellular levels of calcium, activate calcium/calmodulin kinase, which also phosphorylate 
CREB. Moreover, the p90 ribosomal S6 kinases, RSK1 and RSK2, components of a growth and 
anti-growth signaling pathway, can also activate CREB. Additionally, CREB is phosphorylated 
by MSK1 and MSK2 that are kinases of the MEKK/MKK/p38 cellular stress pathway [687]. 
Thus, several signal transduction cascades converge at CREB. Therefore, it would be highly 
interesting to determine the distribution of human inter-individual variation based upon the 
activation of distinct signaling branches.  
There are two principal repercussions of this complexity.  First, since pathway profiling 
measures the summed activity of a given pathway, the results obtained are not necessarily 
applicable to any given gene regulated by that pathway.  Transcriptome analyses have shown 
particular gene sets activated or repressed by each of the branched pathways above that regulates 
CREB signaling, and which are distinct or overlapping with the set of CREB-regulated genes.  
Thus, inter-individual variation in a particular branch might be better analyzed by survey of a 
known set of target genes, rather than an amalgamated index of pathway status.  Secondly, the 
breadth of regulation of a single pathway means by definition that overall variation will be 
polygenic in nature.  Until actual mapping studies are performed, it will remain unclear whether 
particular regulatory variants will be strong enough to rise above this genetic “noise”, 
particularly when mapping variation in healthy individuals.     
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4.2.3 Pathway profiling as a phenotyping tool 
In the preceding pages, I have outlined advantages and disadvantages of the methodologies 
that I have developed, mostly in view of gene discovery strategies.  However, the system 
possesses great practical utility in a variety of ways.  For example, our experiments revealed that 
inter-individual differences in pathway profiling directly correlate with cellular drug toxicity for 
the CHOP pathway.  Therefore, the system possesses considerable versatility for drug screening.  
Indeed, such approaches have been used previously in many pharmacological studies. General 
toxicity tests have been carried out on many cell types such as fibroblasts, HeLa or hepatoma 
cells and parameters including viability, cytosolic enzyme release and cell growth are commonly 
used as end-points to measure toxicity [688-691].  Besides these cell types, very recent studies 
revealed that iPSCs also present interesting avenues of exploration for the drug discovery [581].   
To fully realize the potential of this system, it would be useful to establish banks of fibroblasts 
from healthy and diseased subjects for a given disorder, or for patients responding to a particular 
drug vs. non-responders.  In this way, it would be possible to estimate the utility of pathway 
profiling for endophenotyping of individual patient populations, as opposed to using it as a 
strictly cellular screening tool.  For example, many mood disorders remain broadly classified on 
a symptomatic basis described over a century ago.  Within these classifications, however, 
significant variations exist.  For example, schizophrenia is marked by both so-called “positive” 
symptoms (psychosis, disordered thinking, etc.) and “negative” ones (social withdrawal, reduced 
motivation).  Different patients are marked by different combinations of these symptoms.  
Moreover, the two sets of symptoms appear to have completely different functional correlates: 
whereas positive symptoms are in some way associated with brain dopamine levels, negative 
symptoms are correlated with actual structural changes in the brain [692]. Genetically, 
polymorphisms at the Disc1 locus have been identified in a number of studies of schizophrenia 
as a possible source of risk.  The DISC1 protein, in turn, participates in a number of signaling 
cascades, including the WNT pathway and the PI3/Akt pathway, which are conserved across all 
cell types [693].  Hence, specific dysfunction in signaling could conceivably be identified by 
pathway profiling at a cellular level, even in peripheral cell types.  Such information could in 
turn suggest particular treatment options; currently a wide range of medications are prescribed on 
a symptomatic basis, with mixed success.  
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4.2.4 Pathway profiling for systemic differences 
In my studies, I have focused upon inter-individual genetic differences in signaling pathway 
expression.  However, the same system can be used in multiple different fashions.  For example, 
one aspect of inter-individual genetics is the sum of genetic and epigenetic changes induced in 
cancer.  Much as one can look at signal transduction signatures from cells from different 
individuals, one can look at similar properties in different tumor cells, both in culture and in 
xenograft models.  This subject is treated separately as Section 4.3 below.  Equally, however, 
cellular gene expression is influenced by external paracrine or endocrine signals, and differences 
in these can also be profiled.  Our laboratory is currently using the technologies presented in this 
thesis in multiple pilot studies in this direction.  For example, circadian reporters in primary 
fibroblasts were used to screen serum from older and younger individuals in order to identify 
serum factors contributing to circadian disturbances in elderly individuals [694].  More 
generally, it would be interesting to know how cellular signaling in general is affected in these 
individuals, both as a result of intrinsic genetic factors and circulating endocrine ones.  For 
example, recently the chemokine CCL11 was identified as a circulating factor inhibiting 
neurogenesis in older mice [695].  In another project, our laboratory is using an array of primary 
fibroblast signaling pathway reporters to look at signaling pathways induced by endocrine factors 
in chronic fatigue syndrome.  Since acute infection produces sickness behavior that is dependent 
upon the cytokine TNF-α [696], it might be expected that chronic fatigue – even if TNF-α-
independent – might result from circulating cytokines that activate similar pathways, like NFκB.     
4.3 Signal transduction pathways in cancer pathogenesis 
Various signaling pathways regulate cell growth, differentiation, proliferation and death. 
Many common genetic aberrations in cancer involve various signaling components, either as 
activating mutations or loss of function of tumor suppressors. Since signals along the signal 
transduction cascades are typically propagated by different protein kinases many specific kinase 
inhibitors have already proven to be clinically successful. However, complete mechanisms 
underlying different cellular signaling pathways involved in human cancer pathogenesis still 
remain unclear.  
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Although high throughput ‘omics’ analysis of cancer patient gene expression resulted in the 
identification of key genes and signaling pathways that drive cancer progression [697] most of 
these studies reflect only single points of a multilevel and very complex process of cancer 
pathogenesis. Therefore various real-time and longitudinal approaches have been developed to 
crack the nature of cancers. Beside macroscopic imaging systems that provide physiological and 
anatomic information (e.g. CT/computed tomography, MRI/magnetic resonance imaging, 
US/ultrasound), molecular imaging technologies have found an application in clinical 
(PER/positron emission tomography, SPECT/single-photon emission computed tomography) or 
experimental (BLI/bioluminescence imaging, FRI/fluorescence-mediated tomography, 
MPM/multiphoton microscopy) use. In my study, I utilized long-term in vivo bioluminescence 
imaging technology coupled with the robust lentiviral cell-based system to uncover the signaling 
pathways behavior directly in a developing tumor. As discussed in detail in Chapter 3.3., in vivo 
bioluminescence measurement revealed only constitutively active profiles for the majority of 
tested signal transduction pathways although in vitro detection suggested that only two (GAS 
and p53 signaling) are constantly active and therefore insensitive to the pathway specific drug 
stimulus in C51 murine cancer line. This result is maybe not so surprising when one considers 
that the cell-cell and cell-environment interactions play important roles. One refreshing result of 
this study came in a form of modulation of signal transduction outputs upon in vivo drug 
application. Elk1 as well as CHOP pathway showed an increase in the transcriptional activity 
when pathway specific drug stimuli were administrated directly into the tumor.  
The last few years of intense research has been focused on the development of the targeted 
therapies. In this approach specific drugs are directed at genetic defects in cellular signaling 
events that might occur in only small subpopulation of patients, thus proposing the concept and 
promise of personalized medicine. In oncology, distinct biomarkers are helping to characterize 
the signaling defects in selected patient subsets. Although identification of biomarkers is a key 
step for the targeted treatment, the so called pharmacodynamic biomarkers are important 
predictors of drug efficacy and toxicity that is very often altered by the presence of genetic 
polymorphisms in drug-metabolizing enzymes among human individuals [698]. Many of these 
biomarkers could be used to distinguish mechanistically distinct drug classes or can provide 
information about the expression activity of molecular targets in a response to a therapy. 
Undeniably, the methodology that I have used in my cancer study needs further optimizations 
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(such as development of the reporter system) as well as the measurements should be repeated to 
get higher impact of significance. Nevertheless, I believe that the two powerful technologies 
coupled in this study (characterization of the signaling pathways behavior was based upon the 
molecular imaging) will allow the development of biomarkers for signaling pathways and will 
provide better and importantly noninvasive measurement of drug effects. Consequently, they 
could be useful in preclinical and early clinical phases of the drug development. For instance, 
such biomarkers could serve to determine drug dose and identify the best duration and timing of 
a treatment or could identify possible toxicities and compare potencies of several drug 
candidates.  
Oncogenesis is a complex process where not only accumulating genomic (e.g. gene dosage, 
allelic status, mutation in sequence) but also epigenomic defects (e.g. DNA methylation, histone 
modification, microRNA) significantly alters the cellular transcriptional programs. Various 
signaling pathways responsible for tumor progression lead to the upregulation of polycomb 
group protein, components of DNA methylation machinery. For example, overexpression 
experiments done in the context of Ras pathways demonstrated a requirement of these proteins in 
abnormal gene promoter DNA methylation [699]. Furthermore, it was revealed that 
overexpression of c-myc gene creates a signature of CpG island hypermethylation in culture and 
in vivo T-cell lymphoma models [700]. Similar observations have been published for Wnt/β-
catenin signaling [701], ERK and NFκB as well as Notch signaling [702]. The fact that 
epigenetic changes are so extensive in different types of cancers, many therapeutic approaches 
directed to reverse gene silencing are under development. These compounds usually function as 
inhibitors of the DNA methyltransferase enzymes [703-705]. 
Although various drugs have already been developed, the majority of cell-line information about 
the abolishment of signaling pathways in cancer are based on molecular profiles of untreated 
cells. Real-time longitudinal imaging of signal transduction pathways within the developing 
tumors also offers a possibility to test different cancerostatic compounds directly in vivo. 
Moreover, since the rising amount of reports indicate the existence of not only natural inter-
individual differences but also inter-individual variations in the therapy responses, it would be 
highly interesting to employ our system and look at the expression profiles of tumor associated 
pathways among the different patients suffering with the same type of cancer and to test different 
drug compounds. Last but not least, the dynamic variation of these signal transduction pathways 
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would have to be determined within a certain time frame such as 24 hours, since the circadian 
clocks and therefore specific time points of the drug administration seem to play an important 
role in many treatment strategies.  
 
In conclusion, the principal achievement of my work is the development of a high-throughput 
technology for profiling of signaling pathways, both circadian and otherwise, in primary cells 
from different individuals.  This technology provides a powerful tool for basic gene discovery 
using genome-wide mapping approaches in a variety of experimental contexts.  It provides a way 
to analyze directly how signaling pathway function is influenced at a cellular level on the one 
hand by genetic factors, and on the other hand by circulating cytokines that could be genetically 
or environmentally regulated.  The resulting information should be applicable to the study of 
many physiological disorders.  Moreover, the same technologies could be directly applied to the 
phenotyping of human disease or drug response, providing a direct way to validate particular 
diagnoses or therapeutic approaches.  For all of these applications, my contribution represents a 
promising beginning.  In the years to come, future studies both in our laboratory and that of 
others will prove instrumental in translating these methodologies for purposes of clinical practice 
and scientific discovery. 
4.4 Perspectives 
The importance of natural gene expression variation to differences in human behavior and 
physiology is by now undisputed, and eQTL studies have shown not only that gene expression 
levels differ among individuals, but have also revealed unexpected and interesting aspects of 
gene regulation [670, 706]. The profiling technique that I have developed for the analysis of 
cellular signal transduction pathways could have a significant impact not only for basic research 
but as well for its application to medicine. In the area of basic research, identification of genetic 
modifier loci that might correlate with a variety of difficult-to-access behavioral phenotypes 
(daily behavior, memory consolidation, or mood) will bring more insights into the knowledge of 
natural human variability regulated by the complex operation of these pathways.  
Apart from basic research, however, I believe that my methodology could be directly 
applicable to the fields of pharmacology and medicine.  The last century has been devoted to 
discovery of new medical treatments of scores of human diseases.   Nevertheless, most drugs do 
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not act equally upon all people. Increasing evidence of inter-individual differences in 
pharmaceutical drug treatment has greatly increased interest in the field of so-called 
"personalized medicine". Until now, two main factors are thought to be responsible for 
variability in drug toxicity and treatment efficacy:  first is a matter of timing (e.g. 
chronopharmacology; timed treatment) and a second is the actual existence of inter-individual 
variation in human physiology (e.g.  inherited metabolic differences, genetic polymorphism in 
drug metabolizing enzymes or target receptors, etc.) [456]. 
My initial results suggest that we are indeed able to see trait-like behavior (inter individual 
differences) in signal transduction pathways in peripheral cells. Since the behavior or expression 
pattern of these pathways is in fact a response to various pharmacological stimuli, I suppose that 
the signals obtained from our assay could be used equally as valuable biomarkers for individual 
therapeutic response. Thus, my method can possibly be used as a noninvasive and potentially 
high-throughput screening technology for many pharmaceutical compounds directly in human 
peripheral cells. Therefore, it would be highly interesting to look at possible differences in case 
and control individuals for many complex disorders, as well as on “in vitro drug treatment”. For 
instance, many affective disorders, including depression, bipolar disorder, schizophrenia etc. are 
thought to be a result of various signal transduction pathways alterations. Identification of 
biomarkers for mood disorders that are capable to predict the response to the treatment is a 
highly challenging task. Until recently, different levels of neurotransmitters have been used as 
primary biological markers found in mood disorders. However, the discovery of various players 
within signal transduction pathways in neurotransmission has begun to redirect the focus of 
many scientists in a hunt for new biomarkers. Differences in for example signal transduction 
pathways endpoints as well as differential activation of target genes could play a crucial role in 
providing new treatment targets for a variety of diseases. 
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Abbreviations  
AANAT   Arylalkylamine N-acetyl transferase 
AC    Adenylyl cyclase 
AMP   Adenosine monophosphate  
AMPA   α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid  
APC   β-catenin-Adenomatous Polyposis Coli  
ATP   Adenosine-5'-triphosphate 
AVP  Arginine vasopressin 
BI   Bioluminescence imaging 
BMAL1   Brain and muscle ARNT-like protein 1 
BMP   Bone Morphogenic Protein  
cAMP   Cyclic 3’5’-adenosine monophosphate 
CaMK   Ca
2+
/calmodulin – dependent protein kinase  
CLOCK   Circadian locomoter output cycles protein kaput 
CREB  cAMP response – element – binding protein 
CRE   cAMP responsive element 
CRY  Cryptochrome 
cGK  Cyclic guanosine monophosphate dependent protein kinase 
CKIε  Casein kinase epsilon 
DRN  Dorsal raphe nucleus 
EEG   Electroencephalography  
ERK1/2  Extracellular signal- related kinase  
FRD   Free-running disorder  
FRQ  Frequency locus  
GABA  γ-aminobutyric acid 
GC    Gyanylyl cyclase  
GHT   Geniculohypothalamic tract  
Glu   Glutamate   
GR    Glucocorticoid receptor 
GRP   Gastrin releasing peptide 
GSK-3  Glycogen-Activated Kinase-3  
GWA   Genome-wide association studies 
HER2   Human Epidermal Growth Factor Receptor 2 
HIOMT   Hydroxyindole O-methyltransferase  
HMG-CoA  3-hydroxy-3-methylglutaryl-coenzyme A 
ICER   Inducible cyclic AMP early repressor  
IGL   Intergeniculate leaflet  
IP3   Inositol triphosphate receptors 
ISWR   Irregular sleep wake rhythm 
JNK/ SAPK Terminal kinase/Stress activated protein kinase 
Kir3   Inwardly rectifying potassium channel 
LCL  Lymphoblastoid cell line 
MAPK    Mitogen –activated protein kinase cascades  
MRN  Median raphe nucleus 
MSK1  Stress-activated protein Kinase 1 
Abbreviations 
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MT1 and MT2 High affinity G – protein coupled melatonin receptors 
NF1  Neurofibromin 1  
NMDA   N-methyl-D-aspartate 
NPAS2   Neuronal PAS domain-containing protein 2 
NPY  Neuropeptide Y 
nNOS   Nitric oxide synthase  
NO    Nitric oxide  
OPM   Olivary pretectal nucleus  
P    Phosphate groups  
PACAP  Pituitary adenylate cyclase-activating peptide 
PCK2  Phosphoenolpyruvate carboxykinase 2  
PER  Period 
PI3K/AKT   Phosphatidylinositol 3-kinase / protein kinase B  
PKA   cAMP dependent protein kinase A  
PKAII   Cyclic AMP-dependent protein kinase type II 
PKC  Protein kinase C 
PKG   Protein kinaseG 
PLC   Phospholipase C 
PRC  Phase Response Curve  
PTEN   Phosphatase and tensin homologue  
QTLs  Expression quantitative trait loci 
RGC   Retinal ganglion cells  
RHT   Retinohypothalamic tract  
ROS   Reactive oxygen species  
RSK   p90 Ribosomal S6 Kinases  
RTKs   Receptor tyrosine kinases 
SCN   Suprachiasmatic nucleus 
SIRT1   Sirtuin 
SNP  Single nucleotide polymorphism 
SOS   Son Of Sevenless  
SP   Substance P 
STATs   Signal Transducers and Activators of Transcription  
SWD   Shift work disorder  
TGF-β   Transforming Growth Factor-β  
UCFs   Umbilical cord fibroblasts  
VIP   Vasoactive intestinal polypeptide 
vLGN   Ventral lateral geniculate nucleus  
VPAC2   Vasoactive intestinal peptide receptor 2 
5HT   Serotonin 
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